---
document_datetime: 2023-09-21 20:47:40
document_pages: 90
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/noxafil-h-c-610-ii-0062-epar-assessment-report-variation_en.pdf
document_name: noxafil-h-c-610-ii-0062-epar-assessment-report-variation_en.pdf
version: success
processing_time: 114.6594901
conversion_datetime: 2025-12-18 11:15:24.414184
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

16 September 2021 EMA/590500/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Noxafil

International non-proprietary name: posaconazole

Procedure No. EMEA/H/C/000610/II/0062

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   | Status of this report and steps taken for the assessment   |
|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|
| Current step¹                                              | Description                                                | Planned date                                               | Actual Date                                                | Need for discussion²                                       |
|                                                            | Start of procedure                                         | 26 Dec 2020                                                | 26 Dec 2020                                                |                                                            |
|                                                            | CHMP Rapporteur Assessment Report                          | 19 Feb 2021                                                | 19 Feb 2021                                                |                                                            |
|                                                            | PRAC Rapporteur Assessment Report                          | 26 Feb 2021                                                | 19 Feb 2021                                                |                                                            |
|                                                            | PRAC members comments                                      | 03 Mar 2021                                                | 03 Mar 2021                                                |                                                            |
|                                                            | Updated PRAC Rapporteur Assessment Report                  | 04 Mar 2021                                                | n/a                                                        |                                                            |
|                                                            | PRAC endorsed relevant sections of the assessment report³  | 11 Mar 2021                                                | 11 Mar 2021                                                |                                                            |
|                                                            | CHMP members comments                                      | 15 Mar 2021                                                | n/a                                                        |                                                            |
|                                                            | Updated CHMP Rapporteur(s) (Joint) Assessment Report       | 18 Mar 2021                                                | n/a                                                        |                                                            |
|                                                            | Request for supplementary information                      | 25 Mar 2021                                                | 25 Mar 2021                                                |                                                            |
|                                                            | Submission of responses                                    | 21 May 2021                                                | 21 May 2021                                                |                                                            |
|                                                            | Start of procedure                                         | 24 May 2021                                                | 24 May 2021                                                |                                                            |
|                                                            | CHMP Rapporteur Assessment Report                          | 22 Jun 2021                                                | 23 Jun 2021                                                |                                                            |
|                                                            | PRAC Rapporteur Assessment Report                          | 25 Jun 2021                                                | 23 Jun 2021                                                |                                                            |
|                                                            | PRAC members comments                                      | 30 Jun 2021                                                | n/a                                                        |                                                            |
|                                                            | Updated PRAC Rapporteur Assessment Report                  | 01 Jul 2021                                                | n/a                                                        |                                                            |
|                                                            | PRAC endorsed relevant sections of the assessment report³  | 08 Jul 2021                                                | 08 Jul 2021                                                |                                                            |
|                                                            | CHMP members comments                                      | 12 Jul 2021                                                | 12 Jul 2021                                                |                                                            |
|                                                            | Updated CHMP Rapporteur(s) (Joint) Assessment Report       | 15 Jul 2021                                                | 15 Jul 2021                                                |                                                            |
|                                                            | 2 nd Request of supplementary information                  | 22 Jul 2021                                                | 22 Jul 2021                                                |                                                            |
|                                                            | Submission of responses                                    | 17 Aug 2021                                                | 17 Aug 2021                                                |                                                            |
|                                                            | Start of procedure                                         | 18 Aug 2021                                                | 18 Aug 2021                                                |                                                            |
|                                                            | CHMP Rapporteur Assessment Report                          | 01 Sep 2021                                                | 01 Sep 2021                                                |                                                            |
|                                                            | CHMP members comments                                      | 06 Sep 2021                                                | n/a                                                        |                                                            |
|                                                            | Updated CHMP Rapporteur(s) (Joint) Assessment Report       | 09 Sep 2021                                                | 07 Sep 2021                                                |                                                            |
|                                                            | Opinion                                                    | 16 Sep 2021                                                | 16 Sep 2021                                                |                                                            |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................5                               |                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 2. Scientific discussion ................................................................................6               |                                                                                                        |
| 2.1. Introduction ...................................................................................................... | 6                                                                                                      |
| 2.1.1. Problem statement                                                                                                 | .......................................................................................... 6           |
| 2.1.2. About the product                                                                                                 | ........................................................................................... 7          |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                         | ....... 7                                                                                              |
| 2.1.4. General comments on compliance with GCP                                                                           | ........................................................ 8                                             |
| 2.2. Non-clinical aspects............................................................................................    | 8                                                                                                      |
| 2.3. Clinical aspects                                                                                                    | ................................................................................................ 10    |
| 2.3.1. Introduction                                                                                                      | ................................................................................................. 10   |
| 2.3.2. Pharmacokinetics                                                                                                  | .......................................................................................... 10          |
| 2.3.3. Pharmacodynamics........................................................................................          | 35                                                                                                     |
| 2.3.4. PK/PD modelling............................................................................................       | 37                                                                                                     |
| 2.3.5. Discussion on clinical pharmacology                                                                               | ................................................................. 39                                   |
| 2.3.6. Conclusions on clinical pharmacology ...............................................................              | 40                                                                                                     |
| 2.4. Clinical efficacy                                                                                                   | ................................................................................................ 40    |
| 2.4.1. Discussion on clinical efficacy ..........................................................................        | 67                                                                                                     |
| 2.4.2. Conclusions on the clinical efficacy...................................................................           | 69                                                                                                     |
| 2.5. Clinical safety                                                                                                     | .................................................................................................. 69  |
| 2.5.1. Discussion on clinical safety ............................................................................        | 77                                                                                                     |
| 2.5.2. Conclusions on clinical safety ..........................................................................         | 78                                                                                                     |
| 2.5.3. PSUR cycle ...................................................................................................    | 78                                                                                                     |
| 3. Risk management plan                                                                                                  | ..........................................................................78                           |
| 3.1. Overall conclusion on the RMP............................................................................           | 86                                                                                                     |
| 4. Changes to the Product Information......................................................86                            |                                                                                                        |
| 5. Benefit-Risk Balance..............................................................................86                  |                                                                                                        |
| 5.1. Therapeutic Context .........................................................................................       | 86                                                                                                     |
| 5.1.1. Disease or condition.......................................................................................       | 86                                                                                                     |
| 5.1.2. Available therapies and unmet medical need .....................................................                  | 87                                                                                                     |
| 5.1.3. Main clinical studies                                                                                             | ....................................................................................... 87             |
| 5.2. Favourable effects............................................................................................      | 87                                                                                                     |
| 5.3. Uncertainties and limitations about favourable effects                                                              | ........................................... 87                                                         |
| 5.4. Unfavourable effects.........................................................................................       | 87                                                                                                     |
| 5.5. Uncertainties and limitations about unfavourable effects                                                            | ........................................ 88                                                            |
| 5.6. Effects Table                                                                                                       | ................................................................................................... 88 |
| 5.7. Benefit-risk assessment and discussion ...............................................................              | 89                                                                                                     |
| 5.7.1. Importance of favourable and unfavourable effects                                                                 | ............................................ 89                                                        |
| 5.7.2. Balance of benefits and risks...........................................................................          | 89                                                                                                     |
| 5.8. Conclusions.....................................................................................................    | 89                                                                                                     |
| 6. Recommendations.................................................................................89                    |                                                                                                        |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AE     | adverse event                                                                    |
|--------|----------------------------------------------------------------------------------|
| ALT    | alanine aminotransferase                                                         |
| AML    | acute myelogenous leukemia                                                       |
| AST    | aspartate aminotransferase                                                       |
| BID    | twice a day                                                                      |
| CAC    | Clinical Adjudication Committee                                                  |
| CHMP   | Committee for Medicinal Products for Human Use (of the EMA)                      |
| CLSI   | Clinical and Laboratory Standards Institute                                      |
| CNS    | central nervous system                                                           |
| EMA    | European Medicines Agency                                                        |
| EUCAST | European Committee on Antimicrobial Susceptibility Testing                       |
| EU     | European Union                                                                   |
| FDA    | Food and Drug Administration (US)                                                |
| FLU    | fluconazole                                                                      |
| GOF    | goodness-of-fit                                                                  |
| GVHD   | graft-versus-host disease                                                        |
| HSCT   | hematopoietic stem cell transplant                                               |
| IA     | invasive aspergillosis                                                           |
| IFI    | invasive fungal infection(s)                                                     |
| ISA    | isavuconazole                                                                    |
| ITR    | itraconazole                                                                     |
| IV     | intravenous                                                                      |
| MIC90  | minimum drug concentration at which organism growth is inhibited by at least 90% |
| NWT    | non-wild-type                                                                    |
| OS     | oral suspension                                                                  |
| PK     | pharmacokinetic(s)                                                               |
| POS    | posaconazole                                                                     |
| QD     | once a day                                                                       |
| rIFI   | refractory invasive fungal infection                                             |
| SAE    | serious adverse event                                                            |
| SOC    | system organ class                                                               |
| US     | United States                                                                    |
| VOR    | voriconazole                                                                     |
| WT     | wild-type                                                                        |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 26 August 2020 an application for a variation.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include primary treatment of invasive aspergillosis in adults for Noxafil gastroresistant tablet and concentrate for solution for infusion as result of conclusion of Study P069 (a Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 16.2 of the RMP has also been submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

N/A.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH has requested scientific advice at the CHMP on January 2007 and February 2016 concerning clinical development of posaconazole in first-line aspergillosis treatment.

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

This variation, supported by the results of a single Phase 3 study, MK-5592-069 (hereafter referred to as P069), proposed to extend the use of posaconazole (POS) to include first-line treatment of invasive aspergillosis (IA). The formulations of POS proposed to be used for this indication are the tablets and the solution for infusion.

## 2.1.1. Problem statement

## Disease or condition

Aspergillus species are filamentous fungi, commonly found in the environment that cause a wide spectrum of infections in humans; these infections can be acute and life-threatening, primarily in immunocompromised individuals. Among over 250 species of Aspergillus , fewer than 40 are known to cause human infection; of these, Aspergillus fumigatus is the most common cause of infections in humans and the most common cause of serious, invasive disease.

Invasive aspergillosis (IA) is a serious, life-threatening disease among patients with prolonged and/or severe impairment of the immune system. Without the initiation of antifungal therapy, the acute mortality rate has been shown to exceed 85%. Despite the use of mold-active antifungal prophylaxis, breakthrough infections caused by Aspergillus species remain a serious threat in the immunocompromised population. Breakthrough IA is difficult to diagnose due to low sensitivities of mycological tests for IA. Nonetheless, early diagnosis and prompt initiation of antifungal treatment is the most important predictive factor for a successful outcome in immunocompromised individuals.

A meta-analysis conducted by the MAH of all-cause mortality in patients with IA, after 6 weeks of antifungal treatment, estimated a mortality rate of 23% based on historical data of 3 prospective comparative trials of voriconazole (VOR) given for IA treatment. In 2015, a prospective clinical study of isavuconazole (ISA) vs VOR in patients with IA reported Day 42 (Week 6) all-cause mortality rates of 18.6% and 20.2% in the ISA and VOR treatment arms, respectively. In the same clinical study, a successful clinical response at the end of therapy was noted to be 35.0% (ISA) and 38.9% (VOR).

## Management

Current guidelines for the primary treatment of IA recommend early initiation of antifungal therapy while definitive diagnostic evaluation is in progress. Only 2 medications, the triazoles VOR and ISA, have been approved for the primary treatment of IA in the past 20 years (initial approvals in 2002 and 2015, respectively). Recent guidelines (ECIL-6, 2017, ESCMID 2017, IDSA 2016) recommend VOR and/or ISA for the primary treatment of IA, with liposomal amphotericin B being the first alternative and POS, as well as echinocandins, mainly recommended for salvage treatment.

VOR is efficacious but has significant safety concerns that limit its clinical use. These include adverse effects that are more pronounced than observed with other triazoles (i.e., transient visual disturbances, skin rash, erythroderma, photosensitivity, perioral excoriations, visual or auditory hallucinations, and cardiovascular events including tachyarrhythmias). Higher VOR plasma concentrations are associated with higher rates of visual disturbances and hepatic toxicity. Additionally, VOR is primarily metabolized by the hepatic cytochrome P450 enzyme CYP2C19, which exhibits genetic polymorphism and can result in marked variability in the PK of VOR.

<div style=\"page-break-after: always\"></div>

ISA has also been approved and recommended for the treatment of IA since 2015. Safety information for the use of ISA post approval is limited. Adverse effects that may limit ISA use include shortening of the QT interval, hepatic toxicity, and anemia. Infusion reactions including hypotension, dyspnea, chills, dizziness, and paresthesias have been reported during infusion and may require discontinuation of the infusion. ISA product labeling cautions against coadministration of ISA with CYP3A4/5 inducers such as aprepitant, prednisone, and pioglitazone, as these may result in mild to moderate decreases of ISA plasma levels, thereby reducing its efficacy.

Given the noted limitations of VOR and ISA and the high underlying mortality of IA, a need exists for additional therapies that can overcome the limitations of currently approved IA therapies while providing at least similar levels of efficacy in the primary treatment setting.

## 2.1.2. About the product

POS is a broad-spectrum antifungal compound in the triazole class and blocks the synthesis of ergosterol, a key component of the fungal membrane, through inhibition of lanosterol 14 αdemethylase (CYP51). The antifungal activity of POS against clinically relevant molds includes most strains of Aspergillus , as well as other mold fungal pathogens such as the Zygomycetes (e.g., species of Absidia , Mucor , Rhizopus , and Rhizomucor ).

POS is currently available as oral suspension, tablets and solution for injection formulations, and indicated only in adults. Of note, a paediatric extension for children between 2 to 18 years old, with a new formulation (Noxafil gastro-resistant powder and solvent for oral suspension), is ongoing in parallel of this procedure.

Currently, POS (oral suspension, tablets and solution for injection) is indicated in EU notably for the treatment of invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products. With this application, an indication for the treatment of invasive aspergillosis, whatever the line of treatment, is being proposed for the tablets and solution for injection formulations.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

The clinical development program for the treatment of IA consisted of a single Phase 3, multicenter, randomized, double-blind, active-comparator study of the efficacy and safety of POS versus VOR for the treatment of IA in adults and adolescents (P069). The pivotal P069 study was designed to support the use of POS IV and POS tablet for the primary treatment of IA and to fulfil post-marketing commitments to the CHMP. An open-label Phase 3 study of POS versus VOR in the treatment of deepseated fungal infection was also conducted at multiple sites in Japan, and used as the basis for licensure in Japan; data from that study are not included in this application with the exception of the population PK analysis.

During the clinical development program of POS for primary treatment of IA, discussions were held with the US and EU health authorities with regard to study design, dose selection, and data endpoints for study P069. The dosing regimens of POS IV and tablet that were approved for prophylaxis and salvage treatment of IFI (salvage treatment approved in the EU) were selected for evaluation. Consistent with regulatory guidance, POS was compared with the approved dosing regimens of VOR IV and oral formulations, which are the standard of care for the treatment of IA. A single study with a double-dummy design was considered acceptable. While study P069 was ongoing, additional regulatory guidance was sought in 2016 in order to switch the original primary study endpoint of global clinical response at Week 6 in the FAS population, based on a non-inferiority margin of 15%, with the key

<div style=\"page-break-after: always\"></div>

secondary endpoint of all-cause mortality through Day 42 in the ITT population. Following regulatory discussions with the EMA and the FDA, a non-inferiority study design using a 10% non-inferiority margin for the proposed primary endpoint (all-cause mortality through Day 42 in the ITT population) was considered acceptable by the FDA. In the EU, despite global clinical response being preferred as the primary endpoint, the new proposed primary endpoint was also considered acceptable provided that the original primary endpoint (global clinical response at Week 6 in the FAS population) was also achieved.

## 2.1.4. General comments on compliance with GCP

The MAH confirmed that study P069 was conducted in accordance with GCP.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which is considered acceptable.

The EPAR table should be updated as this extension application contains new environmental data.

Updated prevalence data:

|                  | Indication                         | Estimated Size of Population (N) in 2013                                       |
|------------------|------------------------------------|--------------------------------------------------------------------------------|
| Treatment        | Invasive Aspergillosis             | 64 000 a                                                                       |
|                  | Fusariosis                         | 246 b [Incidence: 6/1000 for HSCT (41,000 allogenic and autologous)]           |
|                  | Chromoblastomycosis and mycetoma c | Rare d                                                                         |
|                  | Coccidioidomycosis c               | Rare d                                                                         |
|                  | Oropharyngeal candidiasise e       | Estimated 148,000 oral candidiasis and 96,200 oesophageal candidiasis f        |
|                  | Acute Myeloid Leukemia [8]         | 55,000 a (prevalence; 19,000 incidence)                                        |
|                  | Myelodyspastic Syndrome [8]        | 25,000 a (prevalence; 8,000 incidence)                                         |
|                  | HSCT (Allogenic) [4]               | 41,000 allogenic and autologous HSCTs per year (approximately 43% allogeneic)* |
| Total Population |                                    | 429,200                                                                        |

a Rounded to the nearest thousand.

b This number is not included in the total because it is already included in the row below for total HSCT.

c Chromoblastomycosis, mycetoma, and coccidioidomycosis are rarely observed in Europe. These infections are usually imported to

Europe from endemic regions. There are no published incidence estimates of these infections in Europe.

d Per the European Commission, rare is defined as a disease affecting fewer than 5 people in 10,000.

e The majority of patients with oropharayngeal candidiasis will be treated with and respond to topical antifungals.

Patients who are

immunosuppressed are more likely to require treatment with a systemic antifungal such as an azole (including possible use of posaconazole) [25] [26].

f This is based on estimated 2 million and 1.3 million global incidence of oral candidiasis and oesophageal candidiasis and prorated to

EU28 2020, Norway, Iceland and Liechtenstein.

<div style=\"page-break-after: always\"></div>

## Summary of main study results

| Substance (INN/Invented Name): Noxafil (Posaconazole) CAS-number (if available): 171228-49-2   | Substance (INN/Invented Name): Noxafil (Posaconazole) CAS-number (if available): 171228-49-2   | Substance (INN/Invented Name): Noxafil (Posaconazole) CAS-number (if available): 171228-49-2                             | Substance (INN/Invented Name): Noxafil (Posaconazole) CAS-number (if available): 171228-49-2   | Substance (INN/Invented Name): Noxafil (Posaconazole) CAS-number (if available): 171228-49-2   |
|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| PBT screening                                                                                  |                                                                                                | Result                                                                                                                   |                                                                                                | Conclusion                                                                                     |
| Bioaccumulation potential- log D ow                                                            | OPPTS 830.7560                                                                                 | pH 7 = 4.15                                                                                                              | pH 7 = 4.15                                                                                    | Potential PBT (N)                                                                              |
| PBT-assessment                                                                                 |                                                                                                |                                                                                                                          |                                                                                                |                                                                                                |
| Parameter                                                                                      | Result relevant for conclusion                                                                 |                                                                                                                          |                                                                                                | Conclusion                                                                                     |
| Bioaccumulation                                                                                | log K ow                                                                                       | pH 5 = 4.06 pH 7 = 4.15                                                                                                  | pH 5 = 4.06 pH 7 = 4.15                                                                        | not B                                                                                          |
|                                                                                                | BCF                                                                                            | 29-36 L/kg (fish)                                                                                                        | 29-36 L/kg (fish)                                                                              | not B                                                                                          |
| Persistence                                                                                    | DT50                                                                                           | Transformation Products in                                                                                               | Transformation Products in                                                                     | vP                                                                                             |
| Toxicity                                                                                       | NOEC                                                                                           | 0.041 mg/l (algae)                                                                                                       | 0.041 mg/l (algae)                                                                             | not T                                                                                          |
| PBT-statement :                                                                                | The compound is not                                                                            | considered as PBT nor vPvB                                                                                               | considered as PBT nor vPvB                                                                     |                                                                                                |
| Phase I                                                                                        |                                                                                                |                                                                                                                          |                                                                                                |                                                                                                |
| Calculation                                                                                    | Value                                                                                          | Unit                                                                                                                     |                                                                                                | Conclusion                                                                                     |
| PEC surfacewater , refined (prevalence data) Fpen = 0.0829%                                    | 0.33                                                                                           |  g/L                                                                                                                    |  g/L                                                                                          | > 0.01 threshold (Y)                                                                           |
| Phase II Physical-chemical properties and fate                                                 | Phase II Physical-chemical properties and fate                                                 | Phase II Physical-chemical properties and fate                                                                           | Phase II Physical-chemical properties and fate                                                 | Phase II Physical-chemical properties and fate                                                 |
| Study type                                                                                     | Test protocol                                                                                  | Results                                                                                                                  |                                                                                                | Remarks                                                                                        |
| Adsorption-Desorption                                                                          | OECD 106                                                                                       | Soil: Log Koc = 5.12 to 5.52 Kd = 1875 to 5820 Sludge: Log Koc = 3.6 Kd = 1607                                           | Soil: Log Koc = 5.12 to 5.52 Kd = 1875 to 5820 Sludge: Log Koc = 3.6 Kd = 1607                 |                                                                                                |
| Ready Biodegradability Test                                                                    | OECD 301                                                                                       | 0% (28d), not readily biodegradable k (0 h-1)                                                                            | 0% (28d), not readily biodegradable k (0 h-1)                                                  |                                                                                                |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems                               | OECD 308                                                                                       | STP DT 50, water = 0.5-4.5d DT 50, sediment = 8.7-11.9d DT 50, whole system =0.7-13.3d %shifting to sediment = 29.3 (day | 28)                                                                                            | DT 50 sediment Transformation products: M1: stable M2: 215.9 d M3: 358.1 d                     |
| Phase IIa Effect studies                                                                       | Phase IIa Effect studies                                                                       | Phase IIa Effect studies                                                                                                 | Phase IIa Effect studies                                                                       | Phase IIa Effect studies                                                                       |
| Study type                                                                                     | Test protocol                                                                                  | Endpoint                                                                                                                 | value Unit                                                                                     | Remarks                                                                                        |
| Algae, Growth Inhibition Test/ Species                                                         | OECD 201                                                                                       | NOEC                                                                                                                     | 41 µg/L                                                                                        | Pseudo- kirchneriella subcapitata                                                              |
| Daphnia sp . Reproduction Test                                                                 | OECD 211                                                                                       | NOEC                                                                                                                     | 244 µg/L                                                                                       | Daphnia magna                                                                                  |
| Fish, Early Life Stage Toxicity Test/ Species                                                  | OECD 210                                                                                       | NOEC                                                                                                                     | 206 µg/L                                                                                       | Pimephales promelas                                                                            |
| Activated Sludge, Respiration Inhibition Test                                                  | OECD 209                                                                                       | NOEC                                                                                                                     | 10 6 µg/L                                                                                      | Sewage sludge mixed population                                                                 |
| Phase IIb                                                                                      | Phase IIb                                                                                      | Phase IIb                                                                                                                | Phase IIb                                                                                      | Phase IIb                                                                                      |
| Calculation                                                                                    | Value                                                                                          | Unit                                                                                                                     |                                                                                                | Remarks                                                                                        |
| PEC surfacewater , refined                                                                     | 0.073                                                                                          |  g/L                                                                                                                    |                                                                                                | Fpen = 0.0829%                                                                                 |

<div style=\"page-break-after: always\"></div>

|                            |          |          |       |       | Koc soil (geomean) = 182602.16   |
|----------------------------|----------|----------|-------|-------|----------------------------------|
| PEC sediment               | 230      | µg/kgdwt |       |       | Kd soil (geomean) = 3151         |
| Phase IIb Studies          |          |          |       |       |                                  |
| Bioaccumulation            | OECD 305 | BCF      | 29-36 | L/kg  | Lepomis macrochirus              |
| Sediment dwelling organism | OECD 218 | NOEC     | 76    | mg/kg | Chironomus riparius              |

## 2.3. Clinical aspects

## 2.3.1. Introduction

Tabular overview of clinical studies:

| Study Number (Status) [CTD Location] Number of Study Sites (Regions)                                           | Design (Indication)                                                                                                                                                                          | Number of Participants by Intervention Group                                                                                                                                                                                                                                                                           | StudyPopulation (2)                                                                               | Primary Endpoint(s)                                      |
|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| Phase 3 Studies                                                                                                | Phase 3 Studies                                                                                                                                                                              | Phase 3 Studies                                                                                                                                                                                                                                                                                                        | Phase 3 Studies                                                                                   | Phase 3 Studies                                          |
| P069 (completed) [Ref.5.3.5.1: P069MK5592] 91 sites (Asia/Pacific region, Europe, and North and South America) | Randomized, double- blind study Duration:12 weeks (84 days; maximum allowed duration up to 98 days) (Treatment of invasive aspergillosis in adults and adolescents at least 13 years of age) | POS (IV or oral)a: Day 1b:300 mgBID Day 2-84: 300 mg QDc 288treated/184completedstudy 139 completed study treatment VOR IV: Day 1b:  6 mg/kg administered BID Day 2-84: 4 mg/kg administered BID VOR oral: Day 1b:300 mg BID Day 2-84: 200 mg BID VOR Total: 287treated/177completed study/ 142completedstudytreatment | Gender:344 M/231 F Median age: 57.0 yrs Range: 14 to 91 yrs <18 yrs: 5(0.9%) ≥65 yrs: 160 (27.8%) | All-cause mortality through Day 42 in the ITT population |

a Subjects were to begin IV study drug and then transition to oral study drug. If clinically indicated, subjects could begin study drug with oral therapy instead of IV therapy.

b Day 1 refers to the first day of subject taking either IV or oral therapy. Subjects were to take a single formulation at a time, either IV or oral.

c To maintain the blind, POs (whether IV or oral) was to be administered as the first daily dose and placebo as the second daily dose.

This extension of indication of posaconazole (POS) in the first-line treatment of invasive aspergillosis (IA) is based on a Phase 3 non-inferiority study.

## 2.3.2. Pharmacokinetics

## 2.3.2.1. Introduction

Posaconazole (POS, MK-5992, NOXAFIL) is a broad spectrum systemic triazole antifungal that inhibits lanosterol 14 α -demethylase (also known as CYP51), an enzyme essential for the biosynthesis of ergosterol comprising the cell membrane microorganisms.

The currently marketed formulations of POS are an OS (oral suspension), an IV and an oral delayedrelease tablet (also as referred to as a gastro-resistant tablet, hereafter referred as tablet).

POS IV solution and tablet are currently approved for use as prophylaxis and salvage treatment (in some regions) of IFI including IA in adults with a dosing regimen of 300 mg QD (BID the first day).

The POS tablet is supplied at a dosage strength of 100 mg and the IV formulation as a solution containing 300 mg POS per 16.7 mL solution (18 mg/mL).

<div style=\"page-break-after: always\"></div>

The key PK properties obtained from adults' data are briefly summarized below:

- POS tablets are absorbed with a median Tmax of 4 to 5 hours and exhibit dose proportional PK after single and multiple dosing up to 300 mg. F is 54%.
- POS has a distribution volume of 261 L, indicating extravascular distribution and is highly protein bound (&gt; 98%).
- POS primarily circulates as the parent compound in plasma and does not have any major circulating metabolites. Of the circulating metabolites, the majority are glucuronide conjugates of POS with only minor amounts of oxidative (CYP40 mediated) metabolites. POS is primarily metabolized via UDP glucuronidation and is a substrate of P-gp efflux.
- POS after administration of 300 mg POS IV is slowly eliminated with a mean half-life of 27 hours and CL of 7.3 L/h. Following tablet administration, POS is eliminated with mean half-life of 26 to 31 hours and CL of 7.5 to 11 L/h. Steady-state is reached by Day 6 for both formulations.

According to these past approvals, a wealth of PK information of POS in adults is available. Hence PK properties are considered as well known in adults. Consequently, this assessment report will focus on specific and relevant PK (and PD aspects) in association with the current submission: extension of the indications of POS IV and tablet for use in the primary treatment of IA.

The POS clinical development program for primary treatment of IA consists of a pivotal Phase 3 study (Study P069) where both formulations were investigated in patients aged ≥ 13 years with IA.

A summary of the PK profile of POS following both formulation in the intended population is presented thereafter. In addition, a population PK analysis (PPK) was performed to characterize POS PK in subjects being treated for IA.

## 2.3.2.2. Methods

- Analytical methods

A HPLC/MS/MS assay procedure was used to quantify POS plasma concentration and was validated by PPD® (Middleton, WI and Richmond, VA). The plasma assay isolated POS and its internal standard from plasma using solid phase extraction followed by liquid chromatographic separations. This assay was used to support the clinical study P069. The analytical range from 5 to 5000 ng/mL as presented in Table 1 below.

<div style=\"page-break-after: always\"></div>

Table 1: Summary of the validated method for the quantification of POS in plasma

| Method Description                                          | PPD Method LCMSC 549 Version 1.00                                                                                                                                                     |
|-------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analytes                                                    | MK-5592 (formerly known as SCH-56592)                                                                                                                                                 |
| Method Validation Report                                    | PPD Validation Report, Project LPW2, MK-5592: Validation of a Liquid Chromatographic-Tandem Mass Spectrometric Method for the Determination of MK-5592 Concentrations in Human Plasma |
| Reference Standard(s)                                       | Posac0nazole (MK-5592), Lot: 12874 [15N2, 13C]-MK-5592, Lots: L-003669433- 000M023,L-003669433-004W003                                                                                |
| Matrix                                                      | Human Plasma                                                                                                                                                                          |
| Anticoagulant                                               | Dipotassium EDTA                                                                                                                                                                      |
| Method of Detection                                         | UPLC with MS/MS Detection                                                                                                                                                             |
| Sample Aliquot Volume                                       | 50.0-μL                                                                                                                                                                               |
| Calibration Range                                           | 5.00 to 5000 ng/mL                                                                                                                                                                    |
| Quality Control (QC) Concentrations                         | 15.0, 150, 400, and 4000 ng/mL                                                                                                                                                        |
| Highest Dilution QC Concentration                           | 25000 ng/mL                                                                                                                                                                           |
| Regression, Weighting                                       | Quadratic, 1/conc.2                                                                                                                                                                   |
| Demonstrated Storage Stability                              | 2268 days at -25°℃                                                                                                                                                                    |
| Maximum Sample Storage Duration From Collection to Analysis | 2247 days at -25°C (within Stability Limits)                                                                                                                                          |
| Analysis Start Date                                         | 14-FEB-2014                                                                                                                                                                           |
| Analysis Completion Date                                    | 20-FEB-2020                                                                                                                                                                           |

In addition, plasma VOR (voriconazole) were determined using an HPLC/MS/MS assay procedure, validated at Syneos Health Clinic Inc (Quebec). The analytical range for VOR was 5 to 200 ng/mL

## · Pharmacokinetic data analysis

No NCA analysis were performed since only trough PK samples (Cmin or Ctrough) per subjects were available.

POS PK data following both IV and tablet formulation from study P069 and all available clinical studies where these formulations were administered (Healthy volunteers or Prophylaxis) were pooled to develop a PPK model using NONMEM, version 7.2 (Globomax, 7250 Parkway Drive, Suite 430, Hanover, MD 21076 USA). The applied estimation method was FOCE with an additive model for RUV on log-transformed data. From this analysis predicted PK metrics (Cavg and Cmin) were derived. Exploratory ER analysis (efficacy and safety) have been also performed.

## 2.3.2.3. Absorption

## · Absolute bioavailability

Based on the prescribing information (PI) of the tablet formulation an absolute bioavailability of 54% is reported (PI US 056Q9W, Revised 3/2019).

Based on the final parameter estimates from the PopPK analysis (please refer to section 5.3.2.8), the absolute bioavailability for the tablet formulation has been estimated at 82% (95% CI: 79-85).

<div style=\"page-break-after: always\"></div>

## · Food effect

Based on the prescribing information of the tablet formulation, the food effect as a fed/fasted GMR (90% CI) was 1.51 (1.33-1.72) for AUCinf based on a single-dose comparisons in Phase 1 studies.

## Study P069 (Descriptive statistics)

Food effect was also investigated during study P069 on a subset of 179 patients with IA. Comparison of mean trough plasma concentrations across subjects who received POS with a meal of any type compared to fasting subjects showed an overall modestly higher exposure, from 15% at week 1 to approximately 33% to 39% from weeks 2 to through 12 (Table 2). There was no discernible trend in POS exposure with the type of meal consumed (light, medium, heavy) in subjects who took POS with a meal. The trend towards higher POS trough plasma concentrations when POS tablets were administered with a meal versus fasting, regardless of meal type, is evident from both Week 1 data (where subjects received tablet only) and data pooled across Weeks 2 through 12 (where subjects may have been switched from IV solution to tablet). These results demonstrate administration of POS tablet with a meal had a moderate effect (15% to 39%) on POS trough plasma concentrations.

Table 2: Summary statistics for POS trough plasma concentrations by fed or fasted status in subjects receiving POS tablet 200 mg QD

| Fed/ Fasted   | Week   |   N |   Mean (ng/mL) |   SD (ng/mL) |   Min (ng/mL) |   Median (ng/mL) |   Max (ng/mL) |   CV (%) |   GM (ng/mL) |   GMCV (%) |
|---------------|--------|-----|----------------|--------------|---------------|------------------|---------------|----------|--------------|------------|
| Fed           | 1      |  58 |           1625 |        902.9 |         295   |             1450 |          4210 |    55.57 |         1374 |      67.96 |
| Fed           | 2      |  64 |           1992 |       1190   |         422   |             1640 |          5230 |    59.76 |         1668 |      67.55 |
| Fed           | 4      |  67 |           1994 |        956.3 |         347   |             1760 |          4520 |    47.96 |         1740 |      61.86 |
| Fed           | 6      |  65 |           2005 |       1333   |          26.4 |             1570 |          6290 |    66.47 |         1568 |      97.27 |
| Fed           | 12/EOT |  49 |           2169 |       1255   |         158   |             1820 |          4960 |    57.85 |         1776 |      79.77 |
| Fasted        | 1      |  24 |           1411 |       1185   |         344   |              997 |          5040 |    83.99 |         1075 |      84.88 |
| Fasted        | 2      |  33 |           1494 |        881.2 |         285   |             1350 |          3960 |    58.99 |         1232 |      74.9  |
| Fasted        | 4      |  43 |           1480 |       1078   |         335   |             1080 |          4760 |    72.81 |         1184 |      75.17 |
| Fasted        | 6      |  34 |           1439 |        682.5 |         443   |             1375 |          3130 |    47.42 |         1277 |      55.25 |
| Fasted        | 12/EOT |  35 |           1691 |       1083   |          39.1 |             1550 |          4340 |    64.06 |         1285 |     111.96 |
| Unknowin      | 1      |  11 |           1600 |        791.8 |         464   |             1640 |          3010 |    49.48 |         1385 |      66.95 |
| Unknowin      | 2      |   9 |           1739 |        657.8 |         784   |             1790 |          2550 |    37.83 |         1612 |      45.37 |
| Unknowin      | 4      |  12 |           1915 |       1470   |         184   |             1735 |          4920 |    76.78 |         1346 |     126.81 |
| Unknowin      | 6      |   8 |           2087 |       1561   |         588   |             1725 |          4830 |    74.78 |         1619 |      90.71 |
| Unknowin      | 12/EOT |  10 |           1864 |       1160   |         661   |             1410 |          3810 |    62.22 |         1567 |      68.62 |

## All Studies (PPK analysis and simulations)

Based on the final parameter estimates from the PPK analysis (please refer to section 5.3.2.8), food was found to increase by 20% (95% CI: 16-23) POS F1, indicating that POS tablet administered with food (given the estimated F of 82%) is close to being completely bioavailable.

Following simulations, POS exposure parameters (Cmin and Cavg) comparing IV and oral administration in fasted and fed conditions for each disease status are shown in the Figure below. Similar distribution of Cavg in fed state vs IV is observed for all disease status. Also, Cavg in IA patients are slightly increased compared to subject in prophylaxis (effect of the disease status on CL).

<div style=\"page-break-after: always\"></div>

Source Rscript 15.2.PK-Results-posthocs-sim-food-vs-nofood-vs-IV; Figure\\_Posthocs\\_Boxplot\\_Disease-Cavg-Fasted-vsFed-vs-IV, Figure\\_Posthocs\\_Boxplot\\_Disease-Cmin-Fasted-vs-Fed-vs-IV

<!-- image -->

Figure  1:  Boxplot  of  predicted  Day  42  Cavg  and  Cmin  according  to  disease  status,  formulation  and fast/fed conditions

Similar results are observed when the regional ethnicity was accounted for.  Nevertheless, Chinese subject Cavg were particularly increased compared to global or Japanese subjects as shown in Figure 2.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Disease Status

Source Rscript 15.2.PK-Results-posthocs-sim-food-vs-nofood-vs-IV; Figure\\_Posthocs\\_Boxplot\\_Ethinicity-Disease-CavgFasted-vs-Fed-vs-IV Figure\\_Posthocs\\_Boxplot\\_Ethinicity-Disease-Cmin-Fasted-vs-Fed-vs-IV.png

Figure 2: Boxplot of predicted Day 42 Cavg and Cmin according to ethnicity, disease status, formulation and fast/fed conditions

The CHMP noted that administration of food increased Cmin by 15% at week 1 and by 33 to 39% from week 2 to 12. Overall mean Cmin in fast and fed states ranged from 1411 to 1691 ng/mL and 1625 to 2169 ng/mL, respectively, in IA patients.

Following the PPK analysis, food effect was found to increase by 19.5% POS F1, however given the high eta-shrinkage of F1, the magnitude of the food effect on F1 should be viewed with caution. This is particularly highlighted in the Figure  where both simulated Cmin and Cavg following administration of tablet in the fed state approximately equal Cmin and Cavg following IV infusion suggesting (as stated by the MAH), that POS tablet administered with food is close to being completely bioavailable (bearing in mind an estimated F1 of 82%).

Indeed, based on formal clinical studies in HV absolute bioavailability has been estimated at 54% (here 82%) and food effect was associated to a 50% increase of AUCinf.

The CHMP considered that the recommendation that tablets may be taken with or without food as already stated in the SmPC is supported.

## 2.3.2.4. Distribution

N/A

<div style=\"page-break-after: always\"></div>

## 2.3.2.5. Elimination

N/A

## 2.3.2.6. Dose proportionality and time dependencies

N/A

## 2.3.2.7. Intra- and inter-individual variability

N/A

## 2.3.2.8. Pharmacokinetic in target population

The current Type II variation of extension of the indications of POS in adult patients with IA  includes one PPK analysis. This analysis was performed following the results from Study P069.

## Study P069

Design

This was a Phase 3, randomized, double blind, double-dummy study to evaluate the efficacy and safety of POS vs voriconazole (VOR) in subject's ≥ 13 years with proven, probable, or possible IA. Study treatments are outlined in Table 3.

Table 3: Treatment arms and study treatments for P069

| Treatment Arms   | IV Therapya                                                          | Oral Therapy                             |
|------------------|----------------------------------------------------------------------|------------------------------------------|
| POS              | Day 1b: 300 mg BID Day 2-84%: 300 mg QDd                             | Day 1b: 300 mg BID Day 2-84c: 300 mg QDd |
| VOR              | Day 1b: 6 mg/kg administered BID Day 2-84c: 4 mg/kg administered BID | Day 1b: 300 mg BID Day 2-84: 200 mg BID  |

Subjects were to begin IV study drug and then step down/transition to oral study drug. If clinically indicated, subjects could begin study diug with oral therapy instead of IV therapy.

Day 1 refers to the first day of subject taking either IV or oral therapy. Subjects were to take only one formulation at a time, either IV or oral.

c The planned duration of study therapy was 12 weeks (84 days) with a maximum allowable duration of up to 98 days.

d To maintain the blind, POS (whether IV or oral) was to be administered as the first daily dose and placebo as the second daily dose.

Subjects were allowed to begin treatment with the IV formulation then step/down transition to oral therapy or to begin with oral therapy. The duration of treatment was 84 days with a maximal duration of 96 days.

## Rationale of the POS dosing regimen

The dosing regimen selected for P069, POS 300 mg QD (BID on Day 1) IV solution or tablet, is the same as the dosing regimen approved for prophylaxis and salvage treatment (in some regions) of IFI.

This past -approval was based on a PK bridging strategy which was designed in consultation with the FDA and EMA supporting extrapolation of the indications supported by OS to tablet and IV. In these

<div style=\"page-break-after: always\"></div>

bridging studies, the predefined exposure target ( ≥ 90% of subjects achieving 500 ng/mL) was met following administration of either tablet or IV solution with acceptable safety and tolerability profiles.

## PK sampling

POS and VOR plasma concentration were to be determined in all subjects prior to the first dose of study treatment and pre-dose on week 1, 2, 4, 6, 12/EOT.

For adult subjects in IV therapy, at week 1, an additional POS plasma concentration at the end of the infusion was performed (Cmax)

For adolescents in IV therapy, Cmax were determined in Week 1, 2, 4, 6, 12/EOT.

## Results

The overall POS PK population analysis in P069 consisted of 264 subjects (of 288 in the ITT population) who had ≥ 1 reported plasma concentration at any time point during the treatment period. PK data were further used for the PPK analysis. A limited number (N=3) of adolescents received POS in P069 and there is insufficient data to support any conclusion regarding POS plasma concentration in this age group.

Mean POS trough plasma concentrations, pooled across both IV and oral routes of administration, appear to have been approaching SS by the end of week 1. GM trough POS concentration was approximately 1500 ng/mL at all time points through to Week 12 as show in Figure 3 and Table 4.

Figure 3: POS Ctrough pooled across subjects receiving either POS IV solution or tablet 300 mg QD

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 4: Summary statistics for POS Ctrough pooled across subjects receiving IV or tablet

<!-- image -->

| Week                                                                                       | N                                                                                          | Mean (ng/mL)                                                                               | SD (ng/mL)                                                                                 | Min (ng/mL)                                                                                | Medlian (ng/mL)                                                                            | Max (ng/mL)                                                                                | CV (%)                                                                                     | GM (ng/mL)                                                                                 | GMCV (%)                                                                                   |
|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| 1                                                                                          | 183                                                                                        | 1658                                                                                       | 980.6                                                                                      | 280.0                                                                                      | 1460                                                                                       | 5040                                                                                       | 59.16                                                                                      | 1386                                                                                       | 68.76                                                                                      |
| 2                                                                                          | 160                                                                                        | 1867                                                                                       | 1221                                                                                       | 228.0                                                                                      | 1545                                                                                       | 7030                                                                                       | 65.39                                                                                      | 1521                                                                                       | 73.98                                                                                      |
| 4                                                                                          | 146                                                                                        | 1843                                                                                       | 1190                                                                                       | 184.0                                                                                      | 1570                                                                                       | 7310                                                                                       | 64.54                                                                                      | 1494                                                                                       | 77.12                                                                                      |
| 6                                                                                          | 123                                                                                        | 1859                                                                                       | 1195                                                                                       | 26.40                                                                                      | 1570                                                                                       | 6290                                                                                       | 64.27                                                                                      | 1502                                                                                       | 82.66                                                                                      |
| 12/E0T                                                                                     | 111                                                                                        | 2007                                                                                       | 1263                                                                                       | 39.10                                                                                      | 1770                                                                                       | 6230                                                                                       | 62.92                                                                                      | 1577                                                                                       | 93.12                                                                                      |
| Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean | Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean | Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean | Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean | Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean | Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean | Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean | Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean | Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean | Abbreviations: SD = standard deviation; CV = coefficient of variation; GM = geometric mean |

## Population Pharmacokinetic analysis

## Model development

The analysis was conducted using all available PK data from clinical trial where POS was administered as IV or tablet formulations. The concentration-time data for POS were modelled using a compartmental approach. Log transform PK data was considered.

Pre-dose POS concentration above the LOQ were excluded. All PK observations which were not associated with a dosing event, were regarded as unevaluable and therefore excluded. BLQ were excluded from the analysis, however in case of the proportion was larger than 5%, the impact of this exclusion approach was investigated by exploring alternative methods to account for these missing data. In addition, a search for outliers as abs CWRES &gt;6 was also performed and effects of these PK outliers were evaluated.

Food, age, body weight, CRCL, sex, disease state (categorized as healthy subjects/prophylaxis of IFI/treatment IA/Other Disease), race and regional ethnicity were assessed as potential covariates for POS pharmacokinetic model parameters. Of these covariates, the impact of race, regional ethnicity and disease state was assessed according different levels for each parameter of interest, in order to prevent identification of these covariates as proxy for any confounded but more mechanistic covariates such as age and CRCL.

The PopPK model was built using nonlinear mixed effects model with the first order conditional estimation method (FOCE) in Nonmem (version 7.4.3, Globomax, 7250 Parkway Drive, Suite 430, Hanover, MD 21076 USA).

Covariates selection was performed using a stepwise/backward procedure. Then the PopPK model was checked using standard goodness-of-fit (GOF) and evaluated using a pcVPC. Finally, a bootstrap analysis was performed.

Then the final PPK model was used to predict the distribution of POS exposure in all subjects included in the analysis on order to derive the POS summary statistics of Cavg and Cmin. Three scenarios have been investigated and Cavg and Cmin were computed accordingly:

- Tablet/fast following 300 mg BID (Day 1), then 300 mg QD up to Day 42, Cavg and Cmin at Day 42
- Tablet/fed following 300 mg BID (Day 1), then 300 mg QD up to Day 42, Cavg and Cmin at Day 42
- IV formulation following 300 mg BID (Day 1), then 300 mg QD up to Day 42, Cavg and Cmin at Day 42

The goals of this analysis was to assess a) the distribution of POS exposures of subjects according their disease status, regional ethnicity, food status, b) the impact of age and BW on the PK exposure

<div style=\"page-break-after: always\"></div>

metrics and c) to evaluate the distribution of POS exposures in a Japanese regional treatment of IA patient population.

## Results

The analysis dataset included 1092 subjects with a total observations of 11466 evaluable PK samples as presented in Table 5.

A total of 1400 concentrations were not included in the analysis because they were BLQ. Among them 818 reflected a pre-dose sample collected before the first administration and 582 reflected a sample after the first dose of administration (4.8% of the total of observations).

Table 5: Summary of included study data

| Study number                  | Iype    | Subject No Active Population   | Dose regimen and dose                           | PK sampling scheme   |   Number of samples evaluable | Number of excluded samples   |
|-------------------------------|---------|--------------------------------|-------------------------------------------------|----------------------|-------------------------------|------------------------------|
| P04975 (Global)               | Phase 1 | Healthy N=16                   | SD 100 mg                                       | rich                 |                           848 | 4                            |
| P05637 (Global)               | Phase 1 | Healthy N=19                   | SD 200 mg SD 400 mg MD 200 mg MD 400 mg         | rich                 |                           675 | 0                            |
| P07764 (Global)               | Phase 1 | Healthy N=21                   | SD 400 mg                                       | rich                 |                          1253 | 0                            |
| P07783 (Global)               | Phase 1 | Healthy N=25                   | SD 300 mg MD 300 mg                             | rich                 |                           526 | 0                            |
| P05615 (Global)               | Phase 3 | Prophylaxis N=231              | MD 200 mg MD 300 mg                             | rich/ sparse         |                          2140 | 13                           |
| P07691 (Global)               | Phase 1 | Healthy N=23                   | SD 100 mg                                       | rich                 |                           505 | 0                            |
| PN111/P111 (Chinese)          | Phase 1 | Healthy N=18                   | SD 300 mg                                       | rich                 |                           665 | 2                            |
| PN117/P117 (Chinese)          | Phase 3 | Prophylaxis N=65               | MD 300 mg                                       | rich/ sparse         |                           498 |                              |
| PN067/P067 (Japanese)         | Phase 1 | Healthy N=28                   | SD&MD 200 mg MD 300 mg SD & MD 400 mg MD 600 mg | rich                 |                           670 | 0                            |
| PN101/P101 (Japanese)         | Phase 3 | Treatment Other Disease* N=76  | MD 300 mg                                       | rich/ sparse         |                           835 | 2                            |
| PN120/P120 (Chinese)          | Phase 1 | Prophylaxis N=70               | MD 300 mg                                       | rich/ sparse         |                           433 | 0                            |
| P05520 (Global)               | Phase 1 | Prophylaxis N=239              | SD 200 mg SD 300 mg MD 200 mg MD 300 mg         | rich/ sparse         |                          1395 | 30                           |
| PN069/P069 (G1oba1 + Chinese) | Phase 3 | Treatment ofIA N=290           | MD 300 mg                                       | rich/ sparse         |                          1098 | 23                           |
| Total                         |         | 1121                           |                                                 |                      |                         11541 | 75                           |
| Evaluable                     |         | 1092                           |                                                 |                      |                         11466 |                              |

<div style=\"page-break-after: always\"></div>

Table 6 presents a summary of categorical covariates and Table 6, a summary of continuous covariates. A  higher  proportion  of  male  subjects  is  included  in  the  analysis  (60%  versus  40%).  Comparable proportions  of  male  and  female  subjects  were  observed  in  the  Prophylaxis  of  IFI  and  Treatment-IA populations whereas male subjects represented more than 2/3 of the population of Healthy subjects and more than 90% of the population in Treatment-Other Disease patients. White and Asian subjects (62% versus 29%) represented nearly all of the subjects. Chinese and Japanese regional subjects represented 17% and 10% of the population, respectively. Patients treated in prophylaxis of IFI reflected the majority of the analysis population (55%) whereas patient for IA represented 25%.

Table 6: Summary of categorical covariates at baseline for all subjects

<!-- image -->

| Covariate          | Category                                    |   Nlevel |   Ntotal | Percentage   |
|--------------------|---------------------------------------------|----------|----------|--------------|
| Sex                | Male                                        |      651 |     1092 | 59.6         |
| Sex                | Female                                      |      441 |     1092 | 40.4         |
| Race               | White                                       |      675 |     1092 | 61.8         |
| Race               | Black or African American                   |       55 |     1092 |              |
| Race               | Asian                                       |      316 |     1092 | 28.9         |
| Race               | Multiracial                                 |       38 |     1092 | 3.5          |
| Race               | American Indian                             |        4 |     1092 | 0.4          |
| Race               | Native Hawaii                               |        4 |     1092 | 0.4          |
| Formulation        | Tablet A                                    |        8 |     1092 | 0.7          |
| Formulation        | Tablet B                                    |        8 |     1092 | 0.7          |
| Formulation        | Tablet C                                    |       51 |     1092 | 4.7          |
| Formulation        | Tablet D                                    |      544 |     1092 | 49.8         |
| Formulation        | IV                                          |      481 |     1092 | 44           |
| Food condition     | Fasted                                      |      953 |     1092 | 87.3         |
| Food condition     | Fed                                         |      139 |     1092 | 12.7         |
| Disease status     | Healthy Subjects                            |      150 |     1092 | 13.7         |
| Disease status     | Prophylaxis of IFI (AML/MDS/ HSTC)          |      602 |     1092 | 55.1         |
| Disease status     | Invasive-Aspergillosis                      |      273 |     1092 | 25           |
| Disease status     | Other Disease (CPA/Fusariosis/ Zygomycosis) |       67 |     1092 | 6.1          |
| Chinese ethnicity  | Global and Japanese                         |      911 |     1092 | 83.4         |
| Chinese ethnicity  | Chinese                                     |      181 |     1092 | 16.6         |
| Japanese ethnicity | Global and Chinese                          |      988 |     1092 | 90.5         |
| Japanese ethnicity | Japanese                                    |      104 |     1092 | 9.5          |
| Global ethnicity   | Global                                      |      807 |     1092 | 73.9         |
| Global ethnicity   | Chinese and Japanese                        |      285 |     1092 | 26.1         |

Based on the complete dataset, median (range: min-max) age was 51 years (14-90), median BW was 70 kg (31.8-172.4 kg).

<div style=\"page-break-after: always\"></div>

Key steps of the base PK structural model building are provided in Table 7. Base structural PK model consisted of a 2 compartment PK model with sequential zero and first-order absorption model and linear elimination parameterized by Ka, CL, Vc, Q, Vd, D1 and F1. BW allometric scaling was considered with estimated exponents. IIV was estimated on all PK parameters except Q.

All model parameters were well estimated, with RSE% values &lt; 13% for the fixed effect parameters and &lt;20%  for  the  random  effect  parameters.  Estimates  of  the  shrinkage  for  the  different  parameters suggested that the individual estimates for CL were reasonably robust (shrinkage 14%), whereas the individual estimates of the Vc, Vp, bioavailability (F1) and absorption parameters (KA and D1) were subject to shrinkage and were therefore less reliable (shrinkage values varying from 42% up to 63%). This  implies  that  evaluations  of  individual  post-hoc  estimates  for  these  parameters,  for  example  in relation to covariates, should be interpreted with caution.

Table 7: Summary of key models for the structural model

<!-- image -->

| Model          | Model Ref   | Description                                                                                   |      OFV | △OFV      | Comments                                                                                      |
|----------------|-------------|-----------------------------------------------------------------------------------------------|----------|-----------|-----------------------------------------------------------------------------------------------|
| Run01          |             | 1 compartment sequential zero- first order absorption- No IV- dependent additive error model  |  4599.14 |           |                                                                                               |
| Rum10          | Run01       | 2 compartment sequential zero- first order absorption- No IIV- dependent additive error model |  4055.36 | -543.785  | Significant                                                                                   |
| Runl1          | Run10       | Addition lag time on run10                                                                    |  3950.13 | -105.227  | Significant                                                                                   |
| Run12          | Runl1       | Allometric scaling added on CL, V. Vp and Q1 with estimated exponents                         |  2901.2  | -1048.932 | Significant                                                                                   |
| Run12bis       | Run12       | Allometric scaling added on CL Ve, Vp and Q1 with fixed exponents                             |  2964.42 | +63.22    | Not-Significant to fix exponent of allometric scaling                                         |
| Run13          | Run12       | Addition IV on CL Ve Q Vp                                                                     | -4004.82 |           | Significant                                                                                   |
| Run13bis1      | Run13       | Addition IIV on D1                                                                            | -4540.71 | -535.889  | Most Significant decreases of OFV vs IIV on KA or IIV on F1                                   |
| Rum13bis5      | Ruml3bisl   | Addition IIV on F1                                                                            | -4820.61 | -279.902  | Most Significant decreases of OFV vs IIV on KA                                                |
| Rum13bis6      | Run13bis5   | Addition IV on KA                                                                             | -4836.42 | -15.806   | Significant                                                                                   |
| Rum13bis7      | Run13bis6   | Deletion IIV on Q1                                                                            | -4834.77 | +1.645    | Not Significant to keep IV on Q1                                                              |
| Rum14          |             | Correlation KA-D1                                                                             | -4881.23 | -46.46    | Significant but correlation prediction very high and problems occurred with the minimization. |
| Run_Base-Model | Run13bis7   | Same model than Run13bis7                                                                     | -4834.77 | 0         | Base Model                                                                                    |

An SCM covariate analysis was performed with the covariates as defined in Table 8 below. Following covariates selection, IOV was investigated on Ka, F1 and D1, however no IOV was retained.

<div style=\"page-break-after: always\"></div>

Table 8: Categorical covariates included in SCM

| Categorical covariate      | Category definition            | Number' of subcategories   |
|----------------------------|--------------------------------|----------------------------|
| SUB2 for CL,Ve, Vp, D1, F1 | Prophylaxis+IA vs HV vs Others | 3                          |
| HV for CL, Vc, Vp. D1, F1  | HV vs Others                   | 2                          |
| FOOD for CL, F1            | Fed vs Fasted                  |                            |
| RACE for CL                | Asian vs Others                | 2                          |

Final PK parameter estimates are provided in Table 9. Overall all PK parameters were estimated with a good precision (RSE &lt;20% for fixed and RSE &lt;30% for random effects).

Table 9: Final PK parameter estimates with bootstrap results

| Parameter         | Estimate   | CI95             | RSE (%)   | Shrinkage   | Bootstrap median   | Bootstrap CI     |
|-------------------|------------|------------------|-----------|-------------|--------------------|------------------|
| Fixed effects     |            |                  |           |             |                    |                  |
| CL (L/h)          | 6.8        | [6.49-7.12]      | 2.3       |             | 6.79               | [6.45;7.09]      |
| Vc(L)             | 123        | [105-141]        | 7.5       |             | 121                | [99.8;142]       |
| Q(L/h)            | 52.7       | [46.9-58.5]      | 5.6       |             | 53.1               | [44.6;81.2]      |
| Vp (L)            | 250        | [235-265]        | 3         |             | 251                | [223;274]        |
| KA (1/h)          | 0.264      | [0.227-0.301]    | 7.2       |             | 0.268              | [0.221;0.349]    |
| D1 (L)            | 1.99       | [1.62-2.36]      | 9.5       |             | 2                  | [1.59;2.34]      |
| F1                | 0.819      | [0.791-0.848]    | 1.8       |             | 0.818              | [0.78;0.855]     |
| Lag time (h)      | 0.419      | [0.412-0.425]    | 0.7       |             | 0.417              | [0.367;0.778]    |
| WT for CL and Q   | 0.531      | [0.387-0.676]    | 13.9      |             | 0.539              | [0.383;0.691]    |
| WT for Ve and Vp  | 1.41       | [1.27-1.56]      | 5.3       |             | 1.41               | [1.3;1.54]       |
| Covariate effects |            |                  |           |             |                    |                  |
| Food on F1        | 0.195      | [0.159-0.231]    | 9.4       |             | 0.195              | [0.141;0.251]    |
| HV~Vp             | -0.2       | [-0.283--0.116]  | 21.3      |             | -0.195             | [-0.265;-0.103]  |
| Other Disease~CL  | -0.437     | [-0.514--0.359]  | 9.1       |             | -0.436             | [-0.502;-0.361]  |
| IA~CL             | -0.11      | [-0.171--0.0495] | 28.2      |             | -0.112             | [-0.176;-0.0385] |
| HV ~Vc            | -0.543     | [-0.677--0.41]   | 12.5      |             | -0.547             | [-0.737;-0.439]  |
| HV~D1             | 0.63       | [0.198-1.06]     | 35        |             | 0.632              | [0.392;0.96]     |
| Age ~CL           | -0.234     | [-0.327--0.141]  | 20.3      |             | -0.237             | [-0.318;-0.147]  |
| Race-Chinese ~CL  | -0.248     | [-0.316--0.18]   | 14        |             | -0.248             | [-0.307;-0.178]  |
| Random effects    |            |                  |           |             |                    |                  |
| IV CL (%CV)       | 45.5       | [43-47.8]        | 2.45      | 13.9        | 44.9               | [41.5;48.6]      |
| IIVVc(%CV)        | 109        | [97.2-121]       | 3.8       | 40.3        | 111                | [81.1;146]       |
| IVV, (%CV)        | 22.4       | [18.6-25.7]      | 7.8       | 63.7        | 21.6               | [11.9;31.3]      |
| IIV KA (%CV)      | 42.7       | [26.9-55.2]      | 14.9      | 61.8        | 43                 | [20;63.1]        |
| IIV D1 (%CV)      | 71.9       | [54.9-87.6]      | 9.35      | 54.0        | 70.7               | [60.5;86]        |
| IV F1 (%CV)       | 179        | [143-221]        | 5.85      | 42.7        | 179                | [135;260]        |
| Residual error    |            |                  |           |             |                    |                  |
| SD (Ph1)          | 31.3       | [30.9-31.6]      | 0.55      | 12.2        | 31.2               | [29.2;33.4]      |
| SD (Ph3)          | 45.5       | [43-47.8]        | 2.45      | 13.9        | 44.9               | [41.5;48.6]      |

<div style=\"page-break-after: always\"></div>

Food effect was found to have an effect on F1 with an increase of 19.5% in fed conditions suggesting that tablet administration with food results in similar PK levels to IV.

An exponential effect of age on CL was found resulting in an approximately 10% and 5% decrease in CL (corresponding to an 11% and 5% decrease in Cavg) for an 80- year old subject as compared to the median 51-year-old or a 65-year old subject, respectively.

The exponential effect of weight on CL caused a 33% increase for a 120-kg subject (corresponding to a 25% decrease in Cavg) and a 16% decrease for a 50-kg subject (corresponding to a 19% increase in Cavg) compared to the median 70 kg subject.

The disease status effect on CL in the subpopulation treated for IA and Other Disease was predicted with an 11% and 44% reduction (corresponding to 12% and 79% increase in Cavg), respectively. Decreases of 20% and 54% were found in Vc and Vp, respectively, in healthy subjects as compared to the general study population. Healthy subjects also showed a 63% higher D1.

Finally, it was identified that CL in the Chinese regional subjects in the study population was 25% lower (corresponding to a 33% increase in Cavg) compared to the general population.

Standard GOF are provided in Figure 4 and pcVPC in Figure 5. In the IA subpopulation, N=4 concentrations were quantifiable more than 300 h after the last administration driving the trend observed in the plot whereas those concentrations appeared to be more consistent with those obtained before 100 hours. Altogether these plots provide further confirmation that the final model adequately described the observed concentrations and can be used prospectively for predictive purposes.

<!-- image -->

Note: Dots are individual data; solid blue lines are trend lines. In the two plots of the first row, solid grey lines are lines of identity, while for the plot in the second row this represents a reference (zero) line.

Figure 4: Standard GOF for the integrated IV and tablet model without outliers

<div style=\"page-break-after: always\"></div>

Figure 5: pcVPC of final model describing POS concentration time data in subjects according to disease status

<!-- image -->

## PPK model

The CHMP noted that the PPK model presented by the MAH was based on PK data from N=1092 subjects from which n=11457 PK samples were available. PK data were retrieved from 13 clinical studies where POS was administered as IV or tablet formulation. Whereas PK data from patients with IA represent 290 patients with 1098 PK samples, the proposed analysis is only descriptive and supportive. Nevertheless, for the entire population, results from this analysis (and mainly the simulation exercise) were highlighted in the special populations section in the SmPC.

The PPK model consisted of a 2 cpt PK model parameterized in terms of D1, F1, CL, Q, Vc, Vp and ka. BW allometric scaling with estimated exponents (0.531 for CL and Q, 1.41 for Vc and Vp) were considered. All PK parameters were estimated with a good precision (RSE&lt;30% for both fixed and random effects). CL was estimated at 6.8 L/h and F1 at 0.812. IIV was particularly high for F1 and Vc (&lt; 100%). Eta-shrinkage is acceptable for CL only (&lt;15%), whereas for other PK parameters shrinkage range from 40.3 to 63.7%. Therefore, any output for the covariate screening procedure investigation on these parameters should be interpreted with cautions (Food effect on F1, healthy volunteer status on Vc, Vp and D1). IA or other disease status, age and race were found to have an effect on POS CL.

GOF does not show a particular bias and pcVPC shows good predictive performance (except for the IA population at later time points). Overall, the PPK analysis was considered acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## Simulation

Based on the final population PK model, a series of model predictions was performed for all subjects (N=1092) after IV or oral administration (fasted and fed conditions) of a dose regimen of 300 mg of POS BID at Day 1 and QD up to Day 42 (last day of dosing in P069).

A full PK profile was predicted with the individual POP PK parameters for all subjects in the current analysis in order to calculate the individual exposure parameters Cavg, Cmin. Then, the predictions were compared to explore the impact of food effect by comparing all subjects in fasted and fed conditions, and then per subpopulation of interest, disease status and regional ethnicity levels.

In addition, the effect of weight with three level of stratification (&lt;71 kg and over 71 kg; &lt; 29 kg, 29&lt;69 kg and over 69 kg; and a band every 10 kg from &lt; 50 and up to ≥ 120 kg). Similarly , the effect of age was also explored with four level of stratification (&lt; 65 y, 65-&lt;75 years and over 75 years; &lt;29 years, 29-&lt;69 years and over 69 years; and a band every 10 years from &lt; 20 years and up to ≥ 80 kg).

Finally, the effect of race (Japanese) was also explored. In order to support the use of POS in Japanese subjects with IA, simulations were performed to create a virtual Japanese IA population. For the purpose of simulations and in order to apply a distribution of age and weight that would optimally reflect a true patient population, the distribution of individual age/weight combinations was obtained from the Global+Chinese regional patients in the current analysis (N=264).

A scaling of age and weight distributions was performed, based on published literature in Japanese IA subjects, to obtain a Japanese IA population. For the scaling, the mean age applied was 55.5 years, comparable to that in Global+Chinese regional IA (53.3 years) and mean weight of 56.5 kg, lower than the mean observed in the Global+Chinese regional IA (68.3 kg).

Therefore, results from three sets of simulation (Table 10) are presented thereafter.

Table 10: Summary of model prediction and simulation with the number of subjects per boxplot

| Type of comparison                                                    | Methodology       |   N total |
|-----------------------------------------------------------------------|-------------------|-----------|
| Food Condition; Disease status; Disease status and regional ethmicity | Model Predictions |      1092 |
| Age and Weight Impact                                                 | Model Predictions |       875 |
| Virtual LA JapanesePopulation                                         | Simulations       |       264 |

Results of the different scenarios with age, weight and race will be presented in the Section  Special Populations. Results of the different scenarios with fed/fast status are presented in the Section Absorption, food effect.

## 2.3.2.9. Special Populations

## · Gender

Results from the PPK analysis indicated that gender was not a significant covariate of any of the available PK parameters.

<div style=\"page-break-after: always\"></div>

## · Race

The PK dataset consisted of 62% of White, 29% of Asian, 17% of Chinese and 10% of Japanese subjects.

Results from the PPK analysis indicated that Chinese status has a significant effect on POS CL. POS clearance in subjects enrolled in clinical studies in China was decreased 25% (corresponding to a 33% increase in Cavg) compared to the global population (ex-China) when all other covariates are held constant. There was no significant effect of race or Japanese regional ethnicity when Chinese regional ethnicity was included in the model.

Figure 2 (section food effect) presents the distribution of the model predicted steady-state POS Cavg in Chinese, Japanese and other races.

Overall the effect of Chinese race is not considered to be clinically meaningful.

## Japanese IA population

Based on a simulation exercise, a slight increase of both exposure parameters was observed for Japanese-IA patients in the three scenarios as shown in

Table 11, presumably due to the influence of weight which appears to be slightly lower based upon the virtual population.

Table 11: Summary statistics of model simulated Day 42 Cavg and Cmin between Virtual Japanese IA patients and others following IV or oral administration, in fed/fast state

<!-- image -->

The CHMP noted that Chinese race was found to have a significant effect on POS CL (increase of Cavg by 33%). However, the effect does not appear to be clinically meaningful.

## · Weight

Results from the PPK analysis indicated that weight have a significant effect on POS PK parameters, as BW allometric scaling was considered using estimated allometric exponents.

Following a simulation exercise, after administration of tablet under fast conditions, POS exposure parameters taking account for weight level stratification is presented in Figure 6 and summary

<div style=\"page-break-after: always\"></div>

statistics in Table 12. The model prediction results show that subjects with a lower body weight have higher exposures. Subjects with a body weight higher than 80kg generally have overlapping distributions of Cmin and Cavg whereas below 80kg, the distributions of Cmin and Cavg are shifted higher with decreasing bodyweight, particularly for subjects with bodyweight &lt;50kg.

Figure 6: Boxplot of predicted Day 42 Cavg and Cmin for all subjects according to Weight bands following administration of tablet in fast state

| Parameter    | Population       |   Min |   P10 |   Q1 |   Median |   Mean |   Q3 |   P90 |   Max |   N |
|--------------|------------------|-------|-------|------|----------|--------|------|-------|-------|-----|
| Cavg (ng/mL) | <50 kg           |   714 |  1230 | 1770 |     2140 |   2380 | 2700 |  3880 |  6350 |  54 |
| Cavg (ng/mL) | ≥ 50 -< 60 kg    |   598 |  1010 | 1310 |     1830 |   2020 | 2440 |  3380 |  5170 | 156 |
| Cavg (ng/mL) | ≥ 60 -< 70 kg    |   341 |   922 | 1340 |     1750 |   1990 | 2360 |  3220 |  8640 | 206 |
| Cavg (ng/mL) | ≥ 70 -< 80 kg    |   451 |   809 | 1090 |     1540 |   1650 | 1990 |  2670 |  5680 | 197 |
| Cavg (ng/mL) | ≥80 -< 90 kg     |   181 |   793 | 1080 |     1420 |   1550 | 1890 |  2430 |  3800 | 145 |
| Cavg (ng/mL) | ≥ 90 -<100 kg    |   489 |   768 |  988 |     1370 |   1440 | 1850 |  2220 |  2990 |  58 |
| Cavg (ng/mL) | ≥100 -<110 kg    |   472 |  1010 | 1210 |     1330 |   1580 | 2000 |  2280 |  4100 |  33 |
| Cavg (ng/mL) | ≥ 110 - < 120 kg |   543 |   711 | 1090 |     1210 |   1250 | 1450 |  1520 |  2560 |  14 |
| Cavg (ng/mL) | ≥ 120 kg         |   958 |   971 | 1050 |     1400 |   1330 | 1480 |  1680 |  1850 |  12 |
| Cmin (ng/mL) | <50 kg           |   444 |   907 | 1400 |     1770 |   2000 | 2370 |  3430 |  5740 |  54 |
| Cmin (ng/mL) | ≥ 50 -< 60 kg    |   399 |   730 |  990 |     1490 |   1710 | 2130 |  3010 |  4890 | 156 |
| Cmin (ng/mL) | ≥60 -< 70 kg     |   150 |   675 | 1070 |     1480 |   1710 | 2030 |  2830 |  8100 | 206 |
| Cmin (ng/mL) | ≥ 70 -< 80 kg    |   252 |   587 |  859 |     1290 |   1410 | 1750 |  2360 |  5280 | 197 |
| Cmin (ng/mL) | ≥ 80 -< 90 kg    |   127 |   627 |  880 |     1220 |   1340 | 1660 |  2180 |  3540 | 145 |
| Cmin (ng/mL) | ≥90 -<100 kg     |   340 |   567 |  776 |     1200 |   1250 | 1610 |  1980 |  2780 |  58 |
| Cmin (ng/mL) | ≥ 100 - < 110 kg |   354 |   843 | 1050 |     1170 |   1390 | 1770 |  2020 |  3360 |  33 |
| Cmin (ng/mL) | ≥ 110 -< 120 kg  |   414 |   541 |  906 |     1060 |   1090 | 1280 |  1350 |  2350 |  14 |
| Cmin (ng/mL) | ≥ 120 kg         |   761 |   856 |  883 |     1270 |   1180 | 1330 |  1520 |  1710 |  12 |

Table 12: Summary statistics of predicted Day 42 Cavg and Cmin for all subjects according to Weight bands following administration of tablet in fast state

<!-- image -->

<div style=\"page-break-after: always\"></div>

In fed state similar trends were observed and are presented in Table 13 below.

Table 13: Summary statistics of predicted Day 42 Cavg and Cmin for all subjects according to Weight bands following administration of tablet in fed state

<!-- image -->

| Parameter    | Population     |   Min |   P10 |   Q1 |   Median |   Mean |   Q3 |   P90 |      |   N |
|--------------|----------------|-------|-------|------|----------|--------|------|-------|------|-----|
| Cavg (ng/mL) | <50kg          |  1110 |  1600 | 2150 |     2520 |   2860 | 3360 |  4460 | 6350 |  54 |
|              | ≥50-<60 kg     |   899 |  1380 | 1580 |     2190 |   2410 | 2870 |  3980 | 6180 | 156 |
|              | ≥60-<70 kg     |   341 |  1200 | 1620 |     2130 |   2330 | 2680 |  3560 | 8640 | 206 |
|              | ≥ 70 -<80 kg   |   680 |  1040 | 1370 |     1790 |   1950 | 2310 |  3140 | 5680 | 197 |
|              | ≥80-<90kg      |   181 |  1070 | 1310 |     1680 |   1830 | 2250 |  2860 | 4220 | 145 |
|              | ≥90-<100 kg    |   661 |   935 | 1190 |     1630 |   1680 | 2070 |  2590 | 3500 |  58 |
|              | ≥100 -<110 kg  |   565 |  1220 | 1420 |     1590 |   1830 | 2210 |  2450 | 4600 |  33 |
|              | ≥110-<120 kg   |   543 |   759 | 1290 |     1450 |   1490 | 1680 |  2130 | 2810 |  14 |
|              | ≥120 kg        |  1100 |  1160 | 1240 |     1540 |   1540 | 1770 |  1880 | 2220 |  12 |
| Cmin (ng/mL) | <50kg          |   630 |  1180 | 1740 |     2090 |   2400 | 2830 |  3960 | 5740 |  54 |
|              | ≥50-<60kg      |   652 |   991 | 1230 |     1800 |   2030 | 2510 |  3570 | 5840 | 156 |
|              | ≥60 -<70 kg    |   150 |   884 | 1310 |     1770 |   1990 | 2330 |  3200 | 8100 | 206 |
|              | ≥70 -<80 kg    |   380 |   741 | 1090 |     1540 |   1680 | 2010 |  2850 | 5280 | 197 |
|              | ≥80 -<90 kg    |   127 |   819 | 1080 |     1430 |   1580 | 1960 |  2620 | 3990 | 145 |
|              | ≥90-<100 kg    |   451 |   734 |  966 |     1440 |   1450 | 1820 |  2290 | 3280 |  58 |
|              | ≥100 -< 110 kg |   423 |  1110 | 1220 |     1400 |   1600 | 2070 |  2230 | 3770 |  33 |
|              | ≥110-<120 kg   |   414 |   582 | 1060 |     1280 |   1300 | 1460 |  1940 | 2580 |  14 |
|              | ≥120 kg        |   876 |  1020 | 1050 |     1370 |   1370 | 1590 |  1700 | 2050 |  12 |

For the IV formulation, overall similar results as those obtained for tablet and fed states are observed. Table 14 presents the simulation results for weight bands.

<div style=\"page-break-after: always\"></div>

Table 14: Summary statistics of predicted Day 42 Cavg and Cmin for all subjects according to Weight bands following administration of the IV formulation

<!-- image -->

| Parameter     | Population    |    Min |   P10 |   Q1 |   Median |   Mean |   Q3 |   P90 |   Max |   N |
|---------------|---------------|--------|-------|------|----------|--------|------|-------|-------|-----|
| Cave. (ng/mL) | <50 kg        | 1160   |  1660 | 2240 |     2590 |   2940 | 3440 |  4610 |  6460 |  54 |
| Cave. (ng/mL) | ≥50-<60kg     |  918   |  1420 | 1620 |     2240 |   2470 | 2930 |  4060 |  6320 | 156 |
| Cave. (ng/mL) | ≥60-<70 kg    |  353   |  1230 | 1660 |     2180 |   2380 | 2730 |  3630 |  8780 | 206 |
| Cave. (ng/mL) | ≥70-<80kg     |  704   |  1070 | 1410 |     1890 |   2000 | 2370 |  3190 |  5780 | 197 |
| Cave. (ng/mL) | ≥80-<90 kg    |  487   |  1110 | 1360 |     1720 |   1870 | 2280 |  2910 |  4280 | 145 |
| Cave. (ng/mL) | ≥90-<100 kg   |  678   |   962 | 1210 |     1670 |   1720 | 2130 |  2630 |  3570 |  58 |
| Cave. (ng/mL) | ≥100-<110 kg  |  577   |  1250 | 1460 |     1620 |   1860 | 2260 |  2490 |  4660 |  33 |
| Cave. (ng/mL) | ≥110 -≤120 kg |  559   |   776 | 1310 |     1490 |   1520 | 1700 |  2250 |  2840 |  14 |
| Cave. (ng/mL) | ≥120 kg       | 1120   |  1180 | 1260 |     1560 |   1570 | 1800 |  1910 |  2260 |  12 |
| Cmin (ng/mL)  | <50kg         |  513   |  1100 | 1630 |     2020 |   2260 | 2690 |  3970 |  5550 |  54 |
| Cmin (ng/mL)  | ≥50-<60kg     |  563   |   895 | 1120 |     1690 |   1930 | 2390 |  3440 |  5800 | 156 |
| Cmin (ng/mL)  | ≥ 60-<70 kg   |   94.8 |   804 | 1210 |     1700 |   1910 | 2240 |  3100 |  7970 | 206 |
| Cmin (ng/mL)  | ≥70-<80kg     |  322   |   667 | 1040 |     1480 |   1610 | 1960 |  2770 |  5180 | 197 |
| Cmin (ng/mL)  | ≥80 -<90kg    |  194   |   767 | 1030 |     1360 |   1520 | 1920 |  2550 |  3980 | 145 |
| Cmin (ng/mL)  | ≥90-<100 kg   |  409   |   671 |  909 |     1400 |   1410 | 1770 |  2240 |  3260 |  58 |
| Cmin (ng/mL)  | ≥100 -≤110 kg |  386   |  1080 | 1180 |     1360 |   1560 | 2050 |  2200 |  3790 |  33 |
| Cmin (ng/mL)  | ≥110 -≤120 kg |  385   |   540 | 1020 |     1260 |   1270 | 1400 |  1980 |  2520 |  14 |
| Cmin (ng/mL)  | ≥120 kg       |  856   |   993 | 1020 |     1340 |   1340 | 1570 |  1660 |  2030 |  12 |

The CHMP noted that subjects with low body weight &lt; 50 kg or high bodyweight ≥ 120 kg have increased POS Cavg by 19% and decreased POS Cavg by 25% respectively, when all PK parameters from the PPK model are held constant.

Median Cavg or Cmin following administration of tablet under fed/fast state or the IV formulation, remain in all the situations above 500 ng/mL.

The Committee considered that for tablet/fed vs IV, Cavg appears similar.

## · Elderly

Results from the PopPK analysis indicated that age was a significant covariate on CL.

Following a simulation exercise, after administration of tablet under fast conditions taking account for age level stratification, POS exposure parameters is presented in Figure 7 and summary statistics in

<div style=\"page-break-after: always\"></div>

Table 15 . The model prediction results show that subject with an age ≥ 75 years generally have a slight increase in Cavg and Cmin, this is particularly driven by subjects older than 80 years old.

<div style=\"page-break-after: always\"></div>

Figure  7:  Predicted  Day  42  Cavg  and  Cmin  for  all  subjects  according  to  Age  bands  following administration of tablet in fast state

| Parameter    | Population       |   Min |   P10 |   Q1 |   Median |   Mean |   Q3 |   P90 |   Max |   N |
|--------------|------------------|-------|-------|------|----------|--------|------|-------|-------|-----|
| (ng/mL)      | < 20 years       |   667 |   894 | 1160 |     1410 |   1600 | 2050 |  2150 |  3630 |  15 |
| (ng/mL)      | ≥20 -< 30 years  |   608 |   789 | 1060 |     1490 |   1580 | 1900 |  2460 |  3910 |  91 |
| (ng/mL)      | ≥30 -< 40 years  |   540 |   784 | 1090 |     1570 |   1740 | 2070 |  2540 |  8640 | 121 |
| (ng/mL)      | ≥ 40 -< 50 years |   598 |   940 | 1170 |     1540 |   1810 | 2220 |  3130 |  6350 | 147 |
| (ng/mL)      | ≥50 -< 60 years  |   181 |   883 | 1180 |     1600 |   1800 | 2250 |  2930 |  7120 | 209 |
| (ng/mL)      | ≥ 60 -< 70 years |   341 |   927 | 1270 |     1680 |   1850 | 2200 |  2820 |  5170 | 208 |
| (ng/mL)      | ≥ 70 -< 80 years |   655 |   930 | 1280 |     1740 |   1880 | 2220 |  3310 |  4850 |  74 |
| (ng/mL)      | ≥ 80 years       |  1930 |  2030 | 2090 |     2640 |   2750 | 3060 |  3780 |  4390 |  10 |
| Cmin (ng/mL) | < 20 years       |   583 |   732 |  907 |     1060 |   1330 | 1690 |  1850 |  3230 |  15 |
| Cmin (ng/mL) | ≥20 -<30 years   |   339 |   565 |  848 |     1230 |   1310 | 1570 |  2040 |  3510 |  91 |
| Cmin (ng/mL) | ≥30 -< 40 years  |   351 |   583 |  879 |     1300 |   1470 | 1770 |  2280 |  8100 | 121 |
| Cmin (ng/mL) | ≥ 40 -< 50 years |   399 |   688 |  913 |     1290 |   1550 | 1930 |  2810 |  5740 | 147 |
| Cmin (ng/mL) | ≥ 50 -< 60 years |   127 |   648 |  971 |     1330 |   1540 | 1950 |  2620 |  6370 | 209 |
| Cmin (ng/mL) | ≥ 60 -< 70 years |   150 |   726 | 1050 |     1440 |   1600 | 1930 |  2540 |  4890 | 208 |
| Cmin (ng/mL) | ≥ 70 -< 80 years |   484 |   702 | 1060 |     1470 |   1630 | 1930 |  3020 |  4430 |  74 |
| Cmin (ng/mL) | ≥ 80 years       |  1700 |  1760 | 1840 |     2210 |   2470 | 2760 |  3570 |  4100 |  10 |

Table 15: Summary statistics of predicted Day 42 Cavg and Cmin for all subjects according to Age bands following administration of tablet in fast state

<!-- image -->

In fed state, similar trends were observed and are presented in

<div style=\"page-break-after: always\"></div>

Table 16 below.

<div style=\"page-break-after: always\"></div>

Table 16: Summary statistics of predicted Day 42 Cavg and Cmin for all subjects according to Age bands following administration of tablet in fed state

<!-- image -->

For the IV formulation, overall similar results as those obtained for tablet and fed states are observed. Table 17 presents the simulation results for age band.

Table 17: Summary statistics of predicted Day 42 Cavg and Cmin for all subjects according to Age bands following administration of the IV formulation

<!-- image -->

<div style=\"page-break-after: always\"></div>

The CHMP considered that age was found to have a significant effect on POS CL. Median Cavg approximately increased by 13.8% from 1880 ng/mL (20-&lt;30 years) to 2140 ng/mL (70-&lt; 80 years).

Elderly subjects (≥ 80 years) have an i ncreased POS Cavg by 11% compared to a typical subject of 50 years, when all PK parameters from the PPK model are held constant.

However, based on the simulation exercise when administered POS tablet under fast /fed conditions or following the IV formulation, it is predicted that more than 50% (tablet fast, median Cavg of 2640 ng/mL) and 75% of the subjects (tablet fed and IV with Q1 of 2510 and 2570 ng/mL) have a Cavg above 2500 ng/mL, a threshold which have been used previously for PK bridging studies (from OS to IV and tablet). In the SmPC, it is recommended to closely monitor the older patients (&gt; 80 years old) for adverse events, which was agreed by the Committee.

## · Children

Only five adolescents aged 14-17 years were enrolled in study P069 and treated with either formulation (three of whom in the POS arm).

The CHMP noted that just five adolescent patients were included in Study P069. The MAH statement ' A limited number (N=3) of adolescents received POS in P069 and there is insufficient data to support any conclusion regarding POS plasma concentration in this age group' was agreed to by the Committee.

With this procedure, the IA indication is claimed for adults only, which is supported by the Committee.

## · Disease status

The effect of disease status was more formally assessed in the population PK analysis and was identified as having a significant effect on clearance. The effect was estimated to result in an 11% reduction in clearance (corresponding to a 12% increase in Cavg) in the subpopulation treated for IA and a 44% reduction in clearance (corresponding to a 79% increase in Cavg) in the subpopulation being treated for fungal diseases other than IA compared to healthy subjects.

The effect of disease status is illustrated by the distribution of model-predicted steady-state Cavg and Cmin for administration of POS IV solution and tablet (fed and fasted) at the recommended dose of 300 mg QD (BID on Day 1) across all subjects included in the population PK analysis. The results show that the  distributions  of  Cavg  in  the  prophylaxis  and  IA  treatment  groups  were  comparable  and  largely overlapping, although there was more variability in the IA treatment group. Both groups had higher exposure  compared  to  the  healthy  group  although  again  the  distributions  were  largely  overlapping consistent with the small difference in clearance between these groups identified by the model.

<div style=\"page-break-after: always\"></div>

Table 18: Summary statistic of model predicted Cavg and Cmin grouped by disease status

<!-- image -->

The CHMP noted that, in general, median Cavg is similar between the IA and the prophylactic treatment groups, and both have Cavg greater than HV.

## 2.3.3. Pharmacodynamics

## Microbiological data

## In vitro microbiology activity against isolates from study P069

A total of 127 fungal isolates from study P069 were sent to the reference lab. Among them, 119 were identified as Aspergillus spp. ( A. fumigatus [n=76], A. flavus species complex [n=19], A. section Nigri [n=10], A. section Terrei [n=7]; and 7 isolates were Aspergillus spp not further identified). There were also 5 other mold organisms and 3 Candida spp . In vitro susceptibility testing was performed by both CLSI microbroth dilution and EUCAST microbroth dilution methodology.

<div style=\"page-break-after: always\"></div>

Overall, POS (MIC50/90, 0.5/1 mg/L, range 0.12-8 mg/L) displayed similar activity to VOR (MIC50/90, 0.5/1 mg/L, range 0.12-4 mg/L) against these 119 Aspergillus spp. isolates. POS and VOR inhibited 99.2% and 95.8% of Aspergillus spp. isolates, respectively:

-A. fumigatus : POS (MIC50/90, 0.5/0.5 mg/L, range 0.12-1 mg/L) and VOR (MIC50/90, 0.25/0.5 mg/L, range 0.12-1 mg/L) inhibited all 76 isolates at MIC of 1 mg/L. By EUCAST methodology and susceptibility interpretation criteria, POS 93.4% of the isolates (MIC50/90, 0.12/0.12 mg/L, range 0.03-0.25 mg/L) and VOR inhibited 94.7% of isolates (MIC50/90, 0.5/1 mg/L, range 0.12-2 mg/L).

-A. flavus : among 19 isolates recovered from this study, POS (MIC50/90, 0.5/1 mg/L, range 0.25-1 mg/L) and VOR (MIC50/90, 1/1 mg/L, range 0.5-1 mg/L) displayed equivalent activity. Three of 19 isolates (15.8%) were characterized as non-wildtype to POS (MICs, 1 mg/L).

-A. section Nigri : similar activity for POS (MIC50/90, 1/1 mg/L, range 0.5-1 mg/L) and VOR (MIC50/90, 1/1 mg/L, range 0.5-1 mg/L) was observed against 10 isolates. Seven isolates were recovered in this study. All displayed WT phenotypes against the antifungal agents tested.

-A. section Terrei : POS (MIC50, 0.5 mg/L) and VOR (MIC50, 0.5 mg/L) inhibited all isolates at MIC of 0.5 mg/L.

- POS (MIC range, 0.5-1 mg/L) showed similar activity to VOR (MIC range, 0.5-2 mg/L) against other Aspergillus spp., including A. lentulus (n=4), A. nidulans species complex (1) and A. sydowii (1). POS and VOR displayed high MIC values (VOR MIC, 4 mg/L; POS MIC, &gt;8 mg/L) against 1 A. ustus spp. complex isolate.

Five rarely recovered molds were observed in P069 and included the following organisms: Fusarium incarnatum-equiseti species complex (n=1), Mucor circinelloides (1), Rhizomucor pusillus (1), Rhizopus oryzae (1), Lasiodiplodia spp. (1). POS showed activity against 1 Fusarium incarnatum-equiseti species complex (MIC, 2 mg/L), and the 3 Mucorales isolates (MIC range, 0.5-2 mg/L). Limited activity was observed by POS against 1 Lasiodiplodia spp. isolate.

Efficacy endpoints were not analyzed by the type of fungal species isolated or by the MIC as only 24% of subjects overall (140/575) had fungal culture results reported, and the most commonly reported species ( A. fumigatus ) was identified in only 12.3% (71/575) of subjects. Of those subjects infected with A. fumigatus, too few had susceptibility data to evaluate clinical response by MIC value.

The CHMP noted that, overall, the in vitro susceptibility of these fungal agents (mainly A. fumigatus ) to the study drug is similar between POS and VOR groups. However, the clinical consequences of these in vitro susceptibilities were not assessed. Considering the proposed indication in first-line IA, similarly than VOR, these microbiological data are reassuring, but the Committee considered that a higher efficacy of POS on VOR-resistant strains is not expected.

## In vitro microbiology activity against Aspergillu s and rare mold isolates from surveillance studies

Two surveillance study of POS in vitro activities against filamentous fungi were performed:

- -One from 2010 to 2018 with 2,554 isolates of filamentous fungi (2,100 Aspergillus spp . and 454 non-Aspergillus molds) with VOR, ITR, caspofungin, anidulafungin, micafungin, and amphotericin B as comparator agents (Pfaller MA, Castanheira M. Activity of Posaconazole and Comparator Antifungal Agents Tested Against Filamentous Fungi . JMI Laboratories, Feb 2020).
- -One in 2018 with 397 isolates of filamentous fungi (325 Aspergillus spp . and 72 nonAspergillus molds) using the same comparators plus ISA (Carvalhaes C. Activity of Posaconazole and Comparator Antifungal Agents Tested Against Filamentous Fungi collected in 2018 . JMI Laboratories, Apr 2020).

<div style=\"page-break-after: always\"></div>

In the first study, germs were isolated from patients at 75 medical centers in North America (52.2%, Europe (29.6%), the Asia-Pacific (12.5%) region, and Latin America (5.7%).

The most common Aspergillus species was A. fumigatus (1,483 isolates). For A. fumigatus , MIC90 of posaconazole, itraconazole and voriconazole were 0.5 mg/L, 1 mg/L and 0.5 mg/L, respectively.

The MIC90 for POS was ≤ 1 mg/L for Aspergillus fumigatus , Aspergillus section Flavi , Aspergillus section Nidulantes , Aspergillus section Nigri, Aspergillus section Terrei and Aspergillus section Versicolor . VOR and ITR had similar in vitro activity against these species.

All three azoles were less active in vitro (MIC90: &gt;8 mg/L) vs Aspergillu s section Usti .

In Europe, the frequency of non-wild type (NWT) strains of A. fumigatus increased steadily from 2010 to 2018 for POS (0.2 to 4.5%).

In the second study, the distribution of isolates according to the geographical regions was similar to the isolate distribution in the 2010-2018 surveillance report. The most common Aspergillus species was A. fumigatus (220 isolates). POS, VOR, ISA, and ITR had similar in vitro activities against the 266 Aspergillus isolates (POS, ISA, ITR and VOR MIC90 0.5, 1, 2, and 1 mg/L, respectively).

In conclusion, about these two studies:

POS has comparable activity to VOR, ISA, and ITR against Aspergillus spp.

POS was more active in vitro than:

- VOR, ISA, or ITR against Mucorales group
- VOR or ITR against Rhizopus oryzae
- ITR or ISA against Scedosporium apiospermum/Scedosporium boydii

The CHMP considered that these surveillance data are consistent with the known in vitro activity of azole antifungals and the activity of POS against isolates from study P069.

NWT strains of A. fumigatus have increased in Europe during the period 2010-2018 study, steadily and similarly for ITR (0% to 7%), VOR (0% to 4.5%) and POS (1.5% to 4.5%). Of note, there was no consistent trend for an increased frequency of NWT strains in the other geographic areas (North America, Asia-Pacific and Latin America).

## 2.3.4. PK/PD modelling

Exploratory ER (efficacy and safety) analyses were performed for IA based on PK/PD data retrieve from Study P069. The relationship between key efficacy and safety endpoints and POS exposures in P069 was explored by allocating subjects into quartiles based on trough plasma concentration.

## ER-efficacy

For all-case mortality through Day 42 vs quartile of Ctrough, no particular trend is observed as shown in Figure 8. Similarly, no trend was observed in clinical response for Week 6 FAS vs Ctrough as shown in Figure 9.

<div style=\"page-break-after: always\"></div>

Figure 8: All-cause mortality through Day 42 vs Ctrough quartile following administration of POS IV and tablet

<!-- image -->

Figure 9: Global clinical response at week 6 vs Ctrough quartile following administration of POS IV and tablet

<!-- image -->

## ER-safety

Exposure-safety relationships of POS by quartile of exposure were evaluated for drug-related AEs and for all AEs. No difference in incidence for all AEs was observed among the quartiles of exposure and no difference in incidence was observed for the majority of the most commonly reported AEs (those reported by ≥10% of subjects) or for SOCs. Among subjects with available trough plasma POS

<div style=\"page-break-after: always\"></div>

concentrations, there was a trend toward a higher incidence of drug-related AEs in the highest quartile of POS exposure relative to lower exposure quartiles 1 or 2. Specifically, a higher incidence of drug related ALT increased, nausea, and vomiting were noted with higher POS exposures relative to lower trough plasma concentrations. While there is a trend of a higher incidence of drug related AEs in quartile 4 compared with quartile 1 or 2, it is modest and its non-monotonic increase with exposures is not suggestive of a strong PK relationship. Given the variability between specific AE incidence and exposure quartile noted in the P069 exposure-safety analysis and the absence of any exposure-safety relationship noted in prior studies of POS IV and tablet (with similar exposure), there is not considered to be a relationship between POS exposure and safety.

Figure 10: Drug related adverse events vs Ctrough quartile following administration of POS IV and tablet

<!-- image -->

The CHMP considered that, based on the exploratory ER efficacy analysis in IA patients, no trend between Ctrough and efficacy endpoint is obvious, whereas based on the ER safety as long as Ctrough is increased (above 2274 ng/mL, Q4 quartile), a trend of higher incidence of drug-related AE is proven.

## 2.3.5. Discussion on clinical pharmacology

In support of an extension of the indication of posaconazole (POS) as a first line treatment of adult and adolescent IA patients aged ≥ 13 years, a dedicated clinical study (P069) was performed where the currently approved IV and tablet formulations were tested following a dosing regimen of 300 mg BID (Day 1) and 300 mg QD thereafter already approved for prophylaxis and salvage treatment for IFI. A PPK model was developed to characterize the PK of POS IV and tablet across populations, this PPK model is considered only descriptive and supportive.

<div style=\"page-break-after: always\"></div>

Only 5 adolescent patients were included in Study P069, 3 of which in the POS arm. Therefore, any agreement on the extension of indication for subjects ≥ 13 years appears unreasonable. The MAH statement ' A limited number (N=3) of adolescents received POS in P069 and there is insufficient data to support any conclusion regarding POS plasma concentration in this age group' is fully supported. In the SmPC, the IA indication is claimed for adults only, which was supported by the CHMP.

One concern was raised with regar ds to the need for dose adjustment in the patient aged ≥ 80 years. The MAH explained that, based on the PopPK analysis, age was found to have an effect on POS CL with a predicted decreased by 10% (increased of Cavg by 11%) in elderly subjects compared to a typical subject (when all other covariates are kept constant). However, this result does not reflect what is observed presently, since other covariates may increase the observed Cavg in elderly (like BW, which is expected to be low). They also explained that such inflated Cavg cannot be solely linked to extreme body weight, which was agreed by the Committee. In addition, even if the PK dataset in elderly subject is limited, the MAH pointed out that the safety profile remains similar to that of younger subjects.

Therefore, the MAH proposal to indicate in the SmPC that patients who are &gt;80 years of age are more likely to experience higher plasma concentrations of POS and should be closely monitored for adverse events was accepted by the CHMP.

As regards microbiological data, in vitro activity of POS on several strains of Aspergillus is overall similar to VOR. Higher efficacy of POS on VOR-resistant strains is not expected.

## 2.3.6. Conclusions on clinical pharmacology

Exposure to posaconazole in adult patients with IA, receiving the commercial formulations, IV solution for infusion or tablet under fed and fast states, at the recommended dosage regimen of 300 mg QD (BID on Day 1), has been shown to be similar to that of patient following a prophylactic treatment of IFI.

## 2.4. Clinical efficacy

The efficacy was evaluated in a single non-inferiority study P069. This study compared Posaconazole with Voriconazole which is the reference for IA treatment. Isavuconazole is also indicated in first line treatment for IA, supported by a non-inferiority study (study CL-0104). The design of P069 is similar.

## - Study P069

## Methods

This is a Phase 3, randomized, double-blind study of posaconazole (POS) versus voriconazole (VOR) in subjects ≥13 years of age with proven, probable , or possible invasive aspergillosis (IA). The study used IV form and tablet form of POS. The all-cause mortality rate through Day 42 was the main criteria to assess the non-inferiority with VOR.

## Study participants

Subjects with proven or probable IA based 2008 EORTC/MSG definitions (see below). Subjects with possible IA may also be included.

## Inclusion criteria:

Patients were male or female from any ethnicity aged 13 years or older, weighing &gt;40 kg to ≤ 150 kg, with proven, probable or possible IA based on the 2008 revised European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions. Individuals enrolled

<div style=\"page-break-after: always\"></div>

with possible IA were to be further evaluated with mycological diagnosis for proven or probable IA within 7 days post-randomization. The IA was to have been acute (duration of clinical syndrome &lt;30 days). Subjects were required to have a central line in place or planned for placement before beginning IV therapy. Pregnant women were not enrolled and women in age of giving birth had to use an adequate birth control.

<!-- image -->

- Full diagnostic criteria are provided in Appendix 3 of the protocol [16.1.1.6].

b Serum galactomannan criteria may not be used to classify patients as a probable infection if a patient is taking piperacillin/tazobactam within 72 hours of serum sampling.

## Exclusion criteria:

The main exclusion criteria were:

- Chronic (&gt;1 month duration) IA, relapsed/recurrent IA, or refractory IA which has not responded to prior antifungal therapy.
- Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis (ABPA).
-  Known  mixed  invasive  mold  fungal  infection  including  Zygomycetes,  and/or  a  known  invasive Aspergillus fungal infection in which either study drug may not be considered active.
- -Previous antifungal therapy ≥4 days for this infection episode.
- Current mold-active antifungal prophylaxis.
- Known hypersensitivity or other serious adverse reaction to any azole antifungal therapy.
- Known history of Torsade de Pointes, unstable cardiac arrhythmia or proarrhythmic conditions, or a history of recent myocardial infarction within 90 days of study entry.
- QTc in terval ≥ 500 msec on electrocardiogram performed at screening or baseline.
- Significant liver dysfunction, hepatic cirrhosis, severe hepatic impairment.
- Severe renal insufficiency (estimated creatinine clearance &lt;20 mL/min) or on hemodialysis.

<div style=\"page-break-after: always\"></div>

-  Known  hereditary  problem  of  galactose  intolerance,  Lapp  lactase  deficiency,  or  glucose-galactose malabsorption.
- Acute symptomatic pancreatitis (within 6 months of study entry), chronic pancreatitis.
- Artificial ventilation, subject not expected to survive for at least 1 week post-randomization

The CHMP noted that study subjects were adults and adolescents with possible, probable or proven acute invasive aspergillosis (according to standardized diagnostic criteria). Of note, possible IA will be confirmed with an additional diagnostic. In the event that possible IA was not confirmed, the patients may continue to be treated if clinician deems appropriate.

Importantly, subjects should not have history of chronic, recurrent or refractory IA, neither a current antifungal prophylaxis, consistent with the first line treatment of IA proposed within this application. Subjects may have started an antifungal therapy but no more than 3 days.

Exclusion criteria are in accordance to the known safety profiles and SmPC of posaconazole and voriconazole.

## Treatments

Intravenous forms and oral forms were evaluated in this study for POS and VOR. Most subjects began antifungal azole (VOR or POS) therapy via the IV route; however, some began therapy via the solid oral route. Azole therapy was switched from IV route to the solid oral route when the subject is considered clinically stable and able to take oral medication.

Treatment duration was at least 84 days (12 weeks).

| Treatment Arms                         | IV Therapya                                                                                                  | Oral Therapy                                       |
|----------------------------------------|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| Treatment Group 1- Posaconazole (POS)  | POS IV: Day 1b: 300 mg BID Day 2-84: 300 mg QDd                                                              | POS oral: Day 1b: 300 mg BID Day 2-84: 300 mg QDd  |
| Treatment Group 2 - Voriconazole (VOR) | VOR IV: Day 1b: 6 mg/kg per body weight administered BID Day 2-84%: 4 mg/kg per body weight administered BID | VOR oral: Day 1b: 300 mg BID Day 2-84e: 200 mg BID |

a Subjects were to begin VOR or POS study treatment via the IV route, then transition to the oral route, unless the oral route was clinically indicated (ie, subject was clinically stable and able to take oral medication). Study treatment was to be switched from the IV route to the oral route when clinically indicated.

b Day 1 refers to the first day of subject taking either IV or oral therapy. Subjects were to take only one formulation at a time, either IV or oral.

c The planned duration of study therapy was 12 weeks (84 days) with a maximum allowable duration of up to 98 days.

d To maintain the blind, POS (whether IV or oral) was to be administered as the first daily dose and placebo as the second daily dose.

IV=intravenous; POS=posaconazole; VOR=voriconazole

Source: Table 3 of the protocol [16.1.1.6]

The CHMP noted that the dosing regimen of posaconazole and voriconazole are in accordance with their SmPC. Of note, POS was administered as IV or tablet formulations. The oral suspension was not used. As the tablet and oral suspension are not equivalent due to differences between these two

<div style=\"page-break-after: always\"></div>

formulations (in frequency of dosing, administration with food and plasma drug concentration achieved), this extension of indications application did not concern the oral suspension formulation.

## Objectives

## Primary:

To compare all-cause mortality for POS compared to VOR in the first-line treatment of IA through Day 42 in  all  randomized  subjects  who  received  at  least  one  dose  of  study  treatment in  the  ITT population ( all randomized subjects who received at least 1 dose of study drug )

Secondary:

-  To  evaluate  the  all-cause  mortality  for  POS  vs.  VOR  through  Day  42  in  the FAS population ( all randomized subjects who were classified as having proven or probable IA (based upon independent adjudication assessment), and received at least 1 dose of study drug ).

-  To  evaluate  the  all-cause  mortality  for  POS  vs.  VOR  through  Day  84  in  both  the  FAS  and  ITT populations.

- To evaluate mortality due to IA through Day 42 and Day 84 for POS vs. VOR in the FAS population.
- To evaluate the time to death (all causes) for POS vs. VOR in the FAS population.
- -To evaluate the global clinical response for POS vs. VOR at Week 6 in the FAS population .
- To evaluate the global clinical response for POS vs. VOR at Week 12 in the FAS population.

## Outcomes/endpoints

Primary efficacy endpoint:

All-cause mortality through Day 42 in the ITT population.

Secondary efficacy endpoints:

- All-cause mortality through Day 42 in the FAS population, and through Day 84 in the FAS and ITT populations
- Global clinical response for POS vs. VOR at Week 6 and 12 in the FAS population
- Time to death (all causes) in the FAS population
- Mortality due to IA through Day 42 and Day 84 in the FAS population

The CHMP noted that during study P069, the MAH switched the order of the endpoints, whereby the 'all -cause mortality' endpoint would become the primary study endpoint, while the 'global response rate' endpoint would become the secondary study endpoint, in order to be consistent with the design of isavuconazole study CL-104, which formed the basis of registration for isavuconazole for the treatment of IA in the EU.

The EMA (EMA/CHMP/SAWP/264373/2016) considered that the initially proposed endpoint 'global response rate' would be preferred and therefore should be maintained and considered as a key coprimary endpoint. Therefore, the CHMP considered that, in accordance to the EMA scientific advice, both efficacy endpoints ( ' all-cause mortality through day 42 in the ITT population ' and ' global clinical response at 6 week in the FAS population ' ) had to be considered for the non-inferiority assessment of POS vs VOR.

<div style=\"page-break-after: always\"></div>

## Sample size

Approximately 400 evaluable subjects (approximately 600 randomized and treated) were planned to be enrolled in this study and randomly assigned to receive either POS monotherapy or VOR monotherapy. This sample size (200 evaluable FAS ( All randomized subjects who were classified as having proven or probable IA and who received at least one dose of treatment ) subjects in each azole monotherapy arm) was estimated to have &gt;85% power (with 1-sided alpha=0.025) to show noninferiority of POS monotherapy compared to VOR monotherapy using a 15% margin assuming a response rate at 6 weeks of 65% for VOR treated subjects. The response rate for this study was assumed to be slightly higher than previously reported for VOR due to both broader inclusion criteria, an anticipated higher percentage of subjects 'probable' IA to be enrolled in this study, and earlier treatment.

<!-- image -->

| Table 19                                             | Power (%6) Under Various Assumptions of Response (200/arm, 15% Non-inferiority Margin)   | Power (%6) Under Various Assumptions of Response (200/arm, 15% Non-inferiority Margin)   | Power (%6) Under Various Assumptions of Response (200/arm, 15% Non-inferiority Margin)   | Power (%6) Under Various Assumptions of Response (200/arm, 15% Non-inferiority Margin)   | Power (%6) Under Various Assumptions of Response (200/arm, 15% Non-inferiority Margin)   | Power (%6) Under Various Assumptions of Response (200/arm, 15% Non-inferiority Margin)   | Power (%6) Under Various Assumptions of Response (200/arm, 15% Non-inferiority Margin)   |
|------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Underlying Global Clinical Response Rate for VOR (%) |                                                                                          |                                                                                          |                                                                                          | Underlying Difference of Global Clinical Response Rates (POS minusVOR)                   |                                                                                          |                                                                                          |                                                                                          |
|                                                      | -1.5                                                                                     | -1.0                                                                                     | -0.5                                                                                     | 0.0                                                                                      | 0.5                                                                                      | 1.0                                                                                      | 1.5                                                                                      |
| 50                                                   | 77.1                                                                                     | 80.0                                                                                     | 82.6                                                                                     | 85.1                                                                                     | 87.3                                                                                     | 89.3                                                                                     | 91.0                                                                                     |
| 55                                                   | 77.2                                                                                     | 80.2                                                                                     | 82.9                                                                                     | 85.4                                                                                     | 87.7                                                                                     | 89.7                                                                                     | 91.4                                                                                     |
| 60                                                   | 78.2                                                                                     | 81.2                                                                                     | 84.0                                                                                     | 86.5                                                                                     | 88.7                                                                                     | 90.7                                                                                     | 92.4                                                                                     |
| 65                                                   | 80.1                                                                                     | 83.1                                                                                     | 85.8                                                                                     | 88.2                                                                                     | 90.3                                                                                     | 92.2                                                                                     | 93.8                                                                                     |
| 70                                                   | 82.8                                                                                     | 85.7                                                                                     | 88.3                                                                                     | 90.5                                                                                     | 92.5                                                                                     | 94.1                                                                                     | 95.5                                                                                     |
| 75                                                   | 86.4                                                                                     | 89.1                                                                                     | 91.4                                                                                     | 93.4                                                                                     | 95.0                                                                                     | 96.3                                                                                     | 97.3                                                                                     |
| 80                                                   | 90.8                                                                                     | 93.0                                                                                     | 94.9                                                                                     | 96.3                                                                                     | 97.5                                                                                     | 98.3                                                                                     | 98.9                                                                                     |

Note: The power is calculated based on 400 subjects (200/arm and assumes a non-inferiority margin (delta) of 15%

The CHMP noted that the sample size calculation was performed using the initial primary endpoint (global clinical response rate at 6 week). However, this primary endpoint was afterwards switched to the primary endpoint 'all -cause mortality through day 42', but the sample size was not re -calculated, assuming that the upper bound of the 95% CI on the difference (POS-VOR) in the all-cause mortality rates will be compared to 10%, and the pre-specified non-inferiority margin observed response rate for POS could only be at most approximately 3 percentage points worse (more) than VOR and still meet the upper bound of 10% with the current sample size.

Both endpoints were to be treated as co-primary endpoints, but the sample size calculation was performed using the initial primary endpoint and was not recalculated when the primary endpoint was switched. In addition, the size of the study population (n=334) was lower than those initially required for a power &gt;85% (n=400). Therefore, the MAH was asked to discuss the implications for the statistical analysis and the robustness of the results.

The MAH explained the reasons for switching the primary endpoint during study P069 (with Amendment 4) as driven by the change in the regulatory standards with a primary endpoint of allcause mortality at D42 for the treatment of IA.

The MAH also explained why the sample size initially calculated had not been recalculated when the endpoint was switched. The amended study (with the all-cause mortality primary endpoint) for the same sample size (300 ITT population in each arm) has a 80% power to show non-inferiority with a 10% margin and a 6-week mortality rate for voriconazole of 23%.

The study results show that non-inferiority as pre-defined in the protocol was met in both cases.

<div style=\"page-break-after: always\"></div>

The CHMP considered the response to indicate that after the endpoint switch the study retained a sufficient power and sample size to determine and meet pre-defined criteria for non-inferiority.

## Randomisation

This study has randomization with 1:1 ratio.

Subjects were to be stratified prior to treatment assignment by risk status for mortality/poor outcome.

High Risk : Any one of the following are present at Baseline or in the patient's medical history:

- Allogeneic hematopoietic stem cell transplant (HSCT).
- Relapsed leukaemia, undergoing salvage chemotherapy.
- Liver transplant recipients.

Not High Risk: Any other eligible subject (none of the high risk criteria are present at Baseline or in the subject's medical history)

## Blinding (masking)

This is a double blinded study. To maintain the blind in the POS group (whether IV or oral), a placebo is used for the second daily dose.

## Statistical methods

Two populations were considered:

- ITT: all randomized subjects who received at least 1 dose of study drug
- FAS: all randomized subjects who were classified as having proven or probable IA (based upon independent adjudication assessment), and received at least 1 dose of study drug.

For the difference between treatment groups in the all-cause mortality rate (for the ITT and FAS populations), the associated stratified 95% confidence interval (CI) on the difference was calculated. If the upper limit of the CI was &lt;10% (the pre-specified non-inferiority margin), then non-inferiority of POS was declared. Survival rates were assessed using Kaplan-Meier methodology.

For the difference between treatment groups in the proportion of subjects in the FAS population who achieved a global clinical response, the associated stratified 95% CI on the difference was calculated. Responses that were missing or could not be determined were considered as failures. The 6-week and 12-week global clinical response assessments will be performed by the clinical adjudication committee (CAC, composed of independent blinded clinicians) based on the following information: clinical data, radiographic findings of infection, serologic testing and fungal culture and histology. This CAC also defined the diagnosis of IA (proven, probable or possible).

The CHMP noted that the 10% non-inferiority margin is the same used in the isavuconazole vs VOR non-inferiority study CL-0104, and was endorsed by the FDA and EMA.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

A total of 653 individuals were screened, with 585 subjects randomized across 91 study sites in 26 countries in the Asia/Pacific region, Europe, and North and South America. A total of 575 subjects received 1 or more doses of POS (n=288) or VOR (n=287).

All subjects who were randomized and received at least 1 dose of study drug were to be followed for the entire duration of the study (through Day 114) for survival regardless of the duration of study therapy.

<!-- image -->

b: Refers to discontinuation from the study.

<div style=\"page-break-after: always\"></div>

The proportions of subjects who completed the study (62.8% overall) and who completed study treatment (48.9% overall) were comparable in the POS and VOR treatment groups.

The most common reason for discontinuation from the study in each treatment group was death, and the most common reason for discontinuation of study treatment was AE.

The CHMP noted that the participant flow is similar between POS and VOR groups. In both groups, only half of participants have completed study treatment, mainly due to deaths and adverse events, reflecting the difficulties to treat IA.

## Recruitment

The first patient first visit was 25 October 2013. The last patient last visit was 10 September 2019.

All included subjects were treated for 12 weeks (84 days), with a maximum allowable duration up to 98 days. A follow-up visit was required 30 days after completion of treatment.

<div style=\"page-break-after: always\"></div>

## Conduct of the study

There were 5 amendments of the protocol:

| Amendment and Date                                | Primary Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 1 12-DEC-2012                           | Clarified the dosing of study treatments (POS or VOR): Day1referred tothefirst day of subject taking either IVor oral formulation. Subjects were required to take only 1 formulation at a time. ·Loading dose ofPOS oral on Day 1 was 300 mg BID (not 300 mg QD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Amendment 1 04-APR-2013 Applicable onlyto Brazil  | Removed Future Biomedical Research/Pharmacogenetic sample collection and any associated protocollanguage.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Amendment 2 26-JUN-2013                           | Excluded subjects <18 years of age in response to a preliminary, preclinical finding of brainventricular enlargement in5 of 8pre-weaningjuvenile dogs administered POS IV for 6 weeks, but not in pre-weaning juvenile dogs administered placebo or saline.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Amendment 2 24-JUL-2013 Applicable only to Brazil | Implemented the same changes as global Amendment 2, plus the following Brazil- specificchange:Removed the optional pharmacogenetic samplebloodvolume from protocol Appendix 9. (The removal was originally intended for Brazil-specific Amendment 1.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Amendment 3 08-JAN-2015                           | Based on updated preclinical data, the amendment allowed the enrollment of adolescents outside of the EU (ie, in those regions with an approved indication for use of oral POS in the adolescent age population (≥13 years of age).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Amendment4 01-AUG-2016                            | The primary study endpoint of global clinical response at Week 6 (FAS population) of all-cause mortality at Week 6 (ITT population) was changed to the primary study endpoint.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Amendment 5 07-FEB-2019                           | Clarified aspects of the protocol and statistical analyses, including key elements of the analyses for the study including: Approximatesamplesizeandpowercalculationwiththeadditionofthe following statement: This sample (approximately 300 randomized subjects in each azole arm) will have ~82.7% power (with 1-sided alpha=0.025) to show non-inferiority of POS compared to VOR using a 10% margin assuming an all- cause mortality through Day 42 of 23%for both treatment groups. Timewindows allowedfor assessmentof all-causemortality andglobalclinical response with the following statement: Mortality will be evaluated through Day 42 and through Day 84with no time window applied either before or after the target day. Global clinical response at Week 6 and Week 12 will be evaluated to include the completion of the response components within the visit  windows,±2 weeks for Week 6 and ±4 weeks for Week 12. Elimination of the following secondary objectives for which data analyses were no longer planned. To evaluate the time to global clinical response for POS vs.VOR in the FAS population. To evaluate the global clinical response at Weeks 6 and 12 in subjects with a diagnosis of possible, probable, or proven IA receiving POS vs. VOR in the ITT population. |

Important protocol deviations were reported for 62 subjects in this study. See details on the table below. No subject's data were excluded from analyses due to an impor tant protocol deviation.

<div style=\"page-break-after: always\"></div>

Source:[P069MIK5592: adam-adsl] [P069MIK5592: sdhm-dv]

|                                                                                                                                                    | Posaconazole   | Posaconazole   | Voriconazole   | Voriconazole   | Total   | Total   |
|----------------------------------------------------------------------------------------------------------------------------------------------------|----------------|----------------|----------------|----------------|---------|---------|
|                                                                                                                                                    | n              | (%)            | n              | (%)            | n       | (%)     |
| Subjects in population                                                                                                                             | 288            |                | 287            |                | 575     |         |
| With one or more important protocol deviations                                                                                                     | 33             | (11.5)         | 29             | (10.1)         | 62      | (10.8)  |
| With no important protocol deviations                                                                                                              | 255            | (88.5)         | 258            | (668)          | 513     | (89.2)  |
| Inclusion/ExclusionCriteria                                                                                                                        | 3              | (1.0)          | 1              | (0.3)          | 4       | (0.7)   |
| Has torsades de pointes diagnosis or QTe prolongation (either based on Friderica or Bazett's conrection) at screening >500 msec.                   | 3              | (1.0)          | 1              | (0.3)          | 4       | (0.7)   |
| Informed Consent                                                                                                                                   | 1              | (0.3)          | 0              | (0.0)          | 1       | (0.2)   |
| Participants with no documented FBR consent, but FBR sanples Were drawn.                                                                           | 1              | (0.3)          | 0              | (0.0)          | 1       | (0.2)   |
| Prohibited Medications                                                                                                                             | 10             | (3.5)          | 7              | (2.4)          | 17      | (3.0)   |
| Sirolimus                                                                                                                                          | 1              | (0.3)          | 0              | (0.0)          | 1       | (0.2)   |
| Vinca alkaloids (vincristine, vinblastine, or other licensed or investigational members ofthis class).                                             | 9              | (3.1)          | 7              | (2.4)          | 16      | (2.8)   |
| SafetyReporting                                                                                                                                    | 18             | (6.3)          | 14             | (4.9)          | 32      | (5.6)   |
| Participant had a reportable Safety Event and/or followup Safety Event infomation that was not reported per the timelines outlinedin the protocol. | 18             | (6.3)          | 14             | (4.9)          | 32      | (5.6)   |
| Study Interrention                                                                                                                                 | 6              | (2.1)          | 7              | (2.4)          | 13      | (2.3)   |
| Participant was acministered improperly stored study intervention that Was deemed umacceptable for use.                                            | 1              | (0.3)          | 1              | (0.3)          | 2       | (0.3)   |
| assigmed in the allocation schedule, i.e. inconect medication or potential cross-treatment.                                                        | 1              | (0.3)          | 2              | (0.7)          | 3       | (0.5)   |
| Subjects whoreceived inconect study treamment.                                                                                                     | 4              | (1.4)          | 4              | (1.4)          | 8       | (1.4)   |

<!-- image -->

The CHMP noted that the main relevant protocol amendments were the exclusion of subjects &lt;18 years of age in EU and the change of the primary endpoint. Major protocol deviations are balanced between POS and VOR group (11.5% vs 10.5%). All subjects were part of the analyzed database.

## Numbers analysed

The population was classified in two categories for analysis of the different endpoints: ITT (all randomized subjects who received at least 1 dose of study drug) and FAS (all randomized subjects who were classified as having proven or probable IA and received at least 1 dose of study drug population) populations.

| PopulationReasonforexclusion                                                                                                                                                                                                                                                                    | Posaconazole n (%)                                                                 | Voriconazole n (%)                                                                 | Total n (%)                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Randomized IntentiontoTreat NotinIntention toTreat-Randomizedbutnot treated AllSubjectsasTreated NotinAllSubjects asTreated-Randomizedbutnot treated Full Analysis Set Not in Full AnalysisSet RandomizedbutnotinIntentiontoTreat Not classified as having proven or probable IA by adjudicator | 293 288 (98.3) 5 (1.7) 288 (98.3) 5 (1.7) 163 (55.6) 130 (44.4) 5 (1.7) 125 (42.7) | 292 287 (98.3) 5 (1.7) 287 (98.3) 5 (1.7) 171 (58.6) 121 (41.4) 5 (1.7) 116 (39.7) | 585 575 (98.3) 10 (1.7) 575 (98.3) 10 (1.7) 334 (57.1) 251 (42.9) 10 (1.7) 241 (41.2) |

Comparable proportions of subjects (between 55% and 60%) in the POS and VOR treatment groups were included in the FAS population.

<div style=\"page-break-after: always\"></div>

The CHMP noted that the FAS population was 334 subjects. This is below the pre-defined target of 400 FAS subjects (sample size to have power &gt;85%), due to the higher proportion of subjects (41%) for whom their infection was not considered as a proven or probable IA by the CAC.

The MAH explained that the sample size had a 80% power to show non-inferiority with a 10% margin and a 6-week mortality rate for voriconazole of 23%. The study results show that non-inferiority as pre-defined in the protocol has been met in both cases. The response indicates that after the endpoint switch the study retained a sufficient power and sample size to determine and meet pre-defined criteria for non-inferiority.

<div style=\"page-break-after: always\"></div>

## Baseline data

|                                                                     | Posaconazole   | Posaconazole   | Voriconazole   | Voriconazole   | Total         | Total       |
|---------------------------------------------------------------------|----------------|----------------|----------------|----------------|---------------|-------------|
|                                                                     | n              | (%)            | n              | (%)            |               | (%)         |
| Subjects in population                                              | 288            |                | 287            |                | 575           |             |
| Gender                                                              |                |                |                |                |               |             |
| Male                                                                | 172            | (59.7)         | 172            | (59.9)         | 344           | (59.8)      |
| Female                                                              | 116            | (40.3)         | 115            | (40.1)         | 231           | (40.2)      |
| Age (Years)                                                         |                |                |                |                |               |             |
| <18                                                                 | 3              | (1.0)          | 2              | (0.7)          | 5             | (0.9)       |
| 18 to 64                                                            | 200            | (69.4)         | 210            | (73.2)         | 410           | (71.3)      |
| ≥65                                                                 | 85             | (29.5)         | 75             | (26.1)         | 160           | (27.8)      |
| Mean                                                                | 53.5           |                | 53.0           |                | 53.3          |             |
| SD                                                                  | 16.7           |                | 15.9           |                | 16.3          |             |
| Median                                                              | 56.5           |                | 57.0           |                | 57.0          |             |
| Range                                                               | 14 to 85       |                | 15 to 91       |                | 14 to 91      |             |
| Race                                                                |                |                |                |                |               |             |
| AmericanIndianOrAlaska Native                                       | 4              | (1.4)          | 6              | (2.1)          | 10            | (1.7)       |
| Asian                                                               | 62             | (21.5)         | 60             | (20.9)         | 122           | (21.2)      |
| Black Or African American                                           | 3              | (1.0)          | 4              | (1.4)          | 7             | (1.2)       |
| Multiple                                                            | 25             | (8.7)          | 25             | (8.7)          | 50            | (8.7)       |
| AmericanIndianOrAlaska Native,Black OrAfican                        | 11             | (3.8)          | 8              | (2.8)          | 19            | (3.3)       |
| American AmericanIndian Or Alaska Native,Native Hawaiian            | 1              | (0.3)          | 3              | (1.0)          | 4             | (0.7)       |
| Or OtherPacificIslander AmericanIndian Or Alaska Native, White      | 10             | (3.5)          | 11             | (3.8)          | 21            | (3.7)       |
| Black Or African American, White White, Asian                       | 1 2            | (0.3) (0.7)    | 2 1            | (0.7) (0.3)    | 3 3           | (0.5) (0.5) |
| White                                                               | 194            | (67.4)         | 192            | (66.9)         | 386           | (67.1)      |
| Ethnicity                                                           |                |                |                |                |               |             |
| Hispanic Or Latino                                                  | 48             | (16.7)         | 57             | (19.9)         | 105           | (18.3)      |
| Not Hispanic Or Latino                                              | 220            | (76.4)         | 219            | (76.3)         | 439           | (76.3)      |
| Not Reported                                                        | 16             | (5.6)          | 9              | (3.1)          | 25            | (4.3)       |
| Unknown                                                             | 4              | (1.4)          | 2              | (0.7)          | 6             | (1.0)       |
| Weight (kg)                                                         |                |                |                |                |               |             |
| <40                                                                 | 2              | (0.7)          | 0              | (0.0)          | 2             | (0.3)       |
| 40 -<50                                                             | 31             | (10.8)         | 22             | (7.7)          | 53            | (9.2)       |
| 50 -<60                                                             | 58             | (20.1)         | 62             | (21.6)         | 120           | (20.9)      |
| 60 -<75                                                             | 105            | (36.5)         | 119            | (41.5)         | 224           | (39.0)      |
| 75 -<120                                                            | 90             | (31.3)         | 80             | (27.9)         | 170           | (29.6)      |
| ≥120                                                                | 2              | (0.7)          | 4              | (1.4)          | 6             | (1.0)       |
| Subjects with data                                                  | 288            |                | 287            |                | 575           |             |
| Mean                                                                | 68.6           |                | 68.1           |                | 68.4          |             |
| SD                                                                  | 16.1           |                | 15.4           |                | 15.7          |             |
| Median                                                              | 68.0           |                | 65.6           |                | 66.4          |             |
| Range                                                               | 39.6 to 125.0  |                | 40.2 to 132.0  |                | 39.6 to 132.0 |             |
| RiskStatus asclassifiedbyInvestigator High Risk                     | 113 175        | (39.2)         | 113 (60.6)     | (39.4)         | 226           | (39.3)      |
| Proven                                                              | 26             | (9.0)          | 15             | (5.2)          | 41            | (7.1)       |
| Probable                                                            | 137            | (47.6)         | 156            | (54.4)         | 293           | (51.0)      |
| Possible                                                            | 81             | (28.1)         | 79             | (27.5)         | 160           | (27.8)      |
| Cannot be determined                                                | 44             | (15.3)         | 37             | (12.9)         | 81            | (14.1)      |
| Neutropenic Status (10^9/L)                                         |                |                |                |                |               |             |
| S'0>                                                                | 132            | (45.8)         | 137            | (47.7)         | 269           | (46.8)      |
| ≥0.5                                                                | 142            | (49.3)         | 138            | (48.1)         | 280           | (48.7)      |
| Unknown Aspergillus classification is per adjudicator's assessment. | 14             | (4.9)          | 12             | (4.2)          | 26            | (4.5)       |

<div style=\"page-break-after: always\"></div>

The baseline disease characteristics were indicative of a critically ill study population, with 39.3% of subjects in the ITT population considered to be high risk for IA. In the ITT population, the POS and VOR treatment groups were comparably balanced for most baseline characteristics, including investigators' classification of risk status and laboratory determined presence of neutropenia

A majority of subjects were male (59.8%) and white (67.1%). Two subjects had a baseline weight &lt;40 kg, while 6 had a baseline weight ≥120 kg. The median age was 57 years, with 27.8% of subjects overall aged ≥65 years; 5 subjects we re adolescents, of whom 3 were treated with POS and 2 with VOR.

IA was classified by independent adjudicators blinded to study treatment assignment as proven or probable in 58.1% of subjects overall. More POS-treated subjects were classified as having proven IA (9.0%) compared with VOR-treated subjects (5.2%), while fewer POS treated subjects were classified as having probable IA compared with VOR-treated subjects (47.6% and 54.4%, respectively). Subjects with proven or probable IA constituted the FAS population (n=334).

Approximately 14% of subjects in the ITT population did not have an IA classification assigned; the primary reasons for this were insufficient information available to the adjudicators and/or comorbidities that confounded the classification diagnosis.

The proportions of subjects with specific medical history conditions and with conditions in each SOC were generally comparable in the POS and VOR treatment groups.

Almost all subjects (99.0%) reported use of prior medications, including antimycotics for systemic use (82.3% overall). Prior antimycotics included the study treatments POS (5.6% overall) and VOR (44.0% overall), with reported use balanced across the treatment groups.

Nearly all subjects in each treatment group (ITT population) were compliant (ie, received &gt;80% of assigned study therapy) with their treatment regimen (mean compliance &gt;98% of assigned days of study treatment). Compliance was similarly high in the FAS population.

Mean duration of exposure to study treatment in the ITT population was comparable in the POS and VOR treatment groups (67 days for POS and 64 days for VOR). Approximately 40% of subjects in each treatment group received study treatment for the planned duration of 84 days.

Baseline data of identified germs consists in a total of 140 subjects who had a positive mold fungal culture identified by either the local or central laboratory. A majority (n=116) of these had a culture positive for Aspergillus only (≥1 species) with the remainder having a posi tive culture for nonAspergillus mold species only (n=17) or for Aspergillus plus non-Aspergillus mold species (n=7). For those with Aspergillus only, the most commonly identified species were A. fumigatus (in 71 subjects), A. flavus (22 subjects), A. niger (14 subjects), and A. terreus (8 subjects). The proportions of subjects infected with organisms from each of these categories were comparable between the treatment groups.

<div style=\"page-break-after: always\"></div>

## Summary of Subjects with Culture by Fungal Type Intention to Treat Population

| Fungal Species                                                     | Posaconazole n (%)                                                 | Voriconazole n (%)                                                 | Total n (%)                                                        |
|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
| Number of subjects in population                                   | 288                                                                | 287                                                                | 575                                                                |
| Number of subjects with reported fungal culture result             | 62 (21.5)                                                          | 78 (27.2)                                                          | 140 (24.3)                                                         |
| Subjects with Aspergillus Mold only                                | 52 (18.1)                                                          | 64 (22.3)                                                          | 116 (20.2)                                                         |
| Aspergillus                                                        | 9                                                                  | 13                                                                 | 22                                                                 |
| Aspergillus Flavus                                                 | 9                                                                  | 13                                                                 | 22                                                                 |
| Aspergillus Fumigatus                                              | 36                                                                 | 35                                                                 | 71                                                                 |
| Aspergillus Lentulus                                               | 1                                                                  | 2                                                                  | 3                                                                  |
| Aspergillus Nidulans                                               | 0                                                                  | 1                                                                  | 1                                                                  |
| Aspergillus Niger                                                  | 5                                                                  | 9                                                                  | 14                                                                 |
| Aspergillus Sydowii                                                | 0                                                                  | 1                                                                  | 1                                                                  |
| Aspergillus Tamarii                                                | 1                                                                  | 0                                                                  | 1                                                                  |
| Aspergillus Terreus                                                | 1                                                                  | 7                                                                  | 8                                                                  |
| Aspergillus Tubingensis                                            | 3                                                                  | 2                                                                  | 5                                                                  |
| Aspergillus Ustus                                                  | 1                                                                  | 0                                                                  | 1                                                                  |
| Aspergillus Versicolor                                             | 0                                                                  | 1                                                                  | 1                                                                  |
| Subjects with Non-Aspergillus Mold only                            | 7 (2.4)                                                            | 10 (3.5)                                                           | 17 (3.0)                                                           |
| Cladosporium                                                       | 1                                                                  | 0                                                                  | 1                                                                  |
| Cryptococcus                                                       | 0                                                                  | 1                                                                  | 1                                                                  |
| Fungi                                                              | 1                                                                  | 1                                                                  | 2                                                                  |
| Fusarium                                                           | 1                                                                  | 1                                                                  | 2                                                                  |
| Fusarium Incarnatum-Equiseti                                       | 1                                                                  | 0                                                                  | 1                                                                  |
| Fusarium Solani                                                    | 0                                                                  | 1                                                                  | 1                                                                  |
| Geotrichum                                                         | 1                                                                  | 0                                                                  | 1                                                                  |
| Mold                                                               | 0                                                                  | 1                                                                  | 1                                                                  |
| Penicillium                                                        | 2                                                                  | 2                                                                  | 4                                                                  |
| Pneumocystis Jirovecii                                             | 1                                                                  | 0                                                                  | 1                                                                  |
| Rhizomucor Pusillus                                                | 0                                                                  | 1                                                                  | 1                                                                  |
| Rhizopus                                                           | 0                                                                  | 1                                                                  | 1                                                                  |
| Rhizopus Oryzae                                                    |                                                                    | 1                                                                  | 1                                                                  |
| Subjects with Aspergillus + Non-Aspergillus Mold                   | 0 3 (1.0)                                                          | 4 (1.4)                                                            | 7 (1.2)                                                            |
| Absidia+Aspergillus Fumigatus                                      | 0                                                                  | 1                                                                  | 1                                                                  |
| Aspergillus Flavus+Paecilomyces+Penicillium                        | 0                                                                  | 1                                                                  | 1                                                                  |
| Aspergillus Fumigatus+Mucor+Mucor Circinelloides                   | 1                                                                  | 0                                                                  | 1                                                                  |
| Aspergillus Fumigatus+Rhizomucor+Rhizomucor Pusillus               | 1                                                                  | 0                                                                  | 1                                                                  |
| Aspergillus Niger+Aspergillus Terreus+Penicillium                  | 0                                                                  | 1                                                                  | 1                                                                  |
| Aspergillus Niger+Fungi+Unspeciated Epicoccum                      | 0                                                                  | 1                                                                  | 1                                                                  |
| Aspergillus Niger+Fungi+Unspeciated Lasiodiplodia                  | 1                                                                  | 0                                                                  | 1                                                                  |
| Subjects may have more than one kind of pathogen identified.       | Subjects may have more than one kind of pathogen identified.       | Subjects may have more than one kind of pathogen identified.       | Subjects may have more than one kind of pathogen identified.       |
| Percentages are based on the number of subjects in the population. | Percentages are based on the number of subjects in the population. | Percentages are based on the number of subjects in the population. | Percentages are based on the number of subjects in the population. |

The CHMP considered that, overall, all baseline characteristics were well balanced between both groups. The subjects included in this study were White or Asian adults (only 1% of Black/African American subjects and &lt;1% adolescents) with blood and lymphatic system disorders (82%), with a good representativeness of gender, risk status and neutropenic status. As the study protocol allowed a brief period of systemic antifungal therapy given for the current episode of IA (up to 96 hours) prior to initiation of study antifungal treatment, a large proportion of subjects (82%) had previously been treated with antimycotics treatments, mainly with fluconazole (45%) or voriconazole (44%).

<div style=\"page-break-after: always\"></div>

Therefore, efficacy results according to the previous use or not of antifungal treatment should be provided (LOQ).

This study has initially intended to enroll adolescent subjects, but finally included 99% of adults.

Therefore, this study could not support alone an adolescent extension of the indication in the treatment of IA. PK bridging between adolescents and adults in IA treatment is required.

Compliance and duration of treatment was also similar between both groups.

Only 58% of the baseline IA diagnosis was probable or proven, and a non-negligible proportion of IA diagnosis (14%) cannot be determined at baseline by the CAC, suggesting that an undetermined number of subjects did not actually have IA. Aspergillus is the fungal agent most represented, without imbalance between both groups. However, only 24% of subjects overall had fungal culture results reported. A subgroup efficacy analysis by fungal species was not considered relevant by the MAH, which is endorsed by the CHMP.

## Outcomes and estimation

## Primary efficacy endpoint

Based on all-cause mortality through Day 42 in the ITT population, POS was demonstrated to be noninferior to VOR: 15.3% of subjects in the POS group, 20.6% in the VOR group, after stratification for risk of mortality/poor outcome, with an estimated difference of -5.3% [95% CI: -11.6, 1.0%]. Noninferiority of POS was demonstrated by the upper bound of the 95% CI on the estimated treatment difference being &lt;10%, with a p-value of &lt;0.0001. No subject in the ITT population had a Day 42 mortality assessment that was missing or 'unable to determine', thus all subjects were included in the primary endpoint analysis. The difference in mortality between the POS and VOR treatment groups did not meet the criterion for superiority, as the upper limit of the 95% CI was not &lt;0.

## Analysis of All-Cause Mortality Through Day 42 Intention to Treat Population

|                                | Unadjusted Data Summary by TreatmentGroup   | Unadjusted Data Summary by TreatmentGroup   | Treatment Difference (Posaconazole -Voriconazole)i   | Treatment Difference (Posaconazole -Voriconazole)i   | Treatment Difference (Posaconazole -Voriconazole)i   |
|--------------------------------|---------------------------------------------|---------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| All Cause Mortality Assessment | Posaconazole n/N (%)                        | Voriconazole n/N (%)                        | Estimated Difference (%)                             | 95% CI                                               | p-Value                                              |
| Dead                           | 44/288 (15.3)                               | 59/287 (20.6)                               | -5.3                                                 | (-11.6, 1.0)                                         | <.0001                                               |
| Alive                          | 244/288 (84.7)                              | 228/287 (79.4)                              |                                                      |                                                      |                                                      |

↑ Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszelweightingscheme.The p-Value isbasedon the one-sided non-inferiority test.Non-inferiority of posaconazole vs. voriconazole is established if the upper limit of the 95% confidence interval is less than 10%. If non-inferiority is established, it can befurther concluded that posaconazole is superior tovoriconazole if the upper limit of the 95%confidence intervalislessthanzero.

Missing or'unable to determine'responses are considered as failures(dead)

## Secondary efficacy endpoints

All-cause mortality through Day 42, FAS Population

These results support the primary endpoint result. In the FAS population, the incidence of all-cause mortality through Day 42 was 19.0% for the POS group and 18.7% for the VOR group with an estimated difference of 0.3% [95% CI: -8.2%, 8.8%].

<div style=\"page-break-after: always\"></div>

## Analysis of All-Cause Mortality Through Day 42 Full Analysis Set Population

|                                                                                                                                                                            | Unadjusted Data Summary by Treatment Group                                                                                                                                 | Unadjusted Data Summary by Treatment Group                                                                                                                                 | Treatment Difference (Posaconazole - Voriconazole)f                                                                                                                        | Treatment Difference (Posaconazole - Voriconazole)f                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| All Cause Mortality Assessment                                                                                                                                             | Posaconazole n/N (%)                                                                                                                                                       | Voriconazole n/N (%)                                                                                                                                                       | Estimated Difference (%)                                                                                                                                                   | 95% CI                                                                                                                                                                     |
| Dead Alive                                                                                                                                                                 | 31/163 (19.0) 132/163 (81.0)                                                                                                                                               | 32/171 (18.7) 139/171 (81.3)                                                                                                                                               | 0.3                                                                                                                                                                        | (-8.2, 8.8)                                                                                                                                                                |
| ↑ Based on Miettinen and Nurminens method stratified by the nisk for mortality/poor outcome (high risk, not high nisk) and using Cochran-Mantel-Haenszel weighting scheme. | ↑ Based on Miettinen and Nurminens method stratified by the nisk for mortality/poor outcome (high risk, not high nisk) and using Cochran-Mantel-Haenszel weighting scheme. | ↑ Based on Miettinen and Nurminens method stratified by the nisk for mortality/poor outcome (high risk, not high nisk) and using Cochran-Mantel-Haenszel weighting scheme. | ↑ Based on Miettinen and Nurminens method stratified by the nisk for mortality/poor outcome (high risk, not high nisk) and using Cochran-Mantel-Haenszel weighting scheme. | ↑ Based on Miettinen and Nurminens method stratified by the nisk for mortality/poor outcome (high risk, not high nisk) and using Cochran-Mantel-Haenszel weighting scheme. |

## All-cause mortality through Day 84, ITT and FAS Populations

In the ITT population, 3 subjects, all in the VOR treatment group, had unknown or missing mortality status at Day 84 and were therefore counted as dead at that time point as was specified in the protocol.

## Analysis of All-Cause Mortality Through Day 84 Intention to Treat Population

|                                                                                                                                                                                                                                                           | Unadjusted Data Summary by Treatment Group                                                                                                                                                                                                                | Unadjusted Data Summary by Treatment Group                                                                                                                                                                                                                | TreatmentDifference (Posaconazole - Voriconazole)t                                                                                                                                                                                                        | TreatmentDifference (Posaconazole - Voriconazole)t                                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| All Cause Mortality Assessment                                                                                                                                                                                                                            | Posaconazole n/N (%)                                                                                                                                                                                                                                      | Voriconazole n/N (%)                                                                                                                                                                                                                                      | Estimated Difference (%)                                                                                                                                                                                                                                  | ID %S6                                                                                                                                                                                                                                                    |
| Dead Alive                                                                                                                                                                                                                                                | 81/288 (28.1) 207/288 (71.9)                                                                                                                                                                                                                              | 88/287 (30.7) 199/287 (69.3)                                                                                                                                                                                                                              | -2.5                                                                                                                                                                                                                                                      | (-9.9, 4.9)                                                                                                                                                                                                                                               |
| I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead)) | I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead)) | I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead)) | I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead)) | I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead)) |

## Analysis of All-Cause Mortality Through Day 84 Full Analysis Set Population

|                                                                                                                                                                                                                                                           | Unadjusted Data Summary by Treatment Group                                                                                                                                                                                                                | Unadjusted Data Summary by Treatment Group                                                                                                                                                                                                                | Treatment Difference (Posaconazole - Voriconazole)t                                                                                                                                                                                                       | Treatment Difference (Posaconazole - Voriconazole)t                                                                                                                                                                                                       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| All Cause Mortality Assessment                                                                                                                                                                                                                            | Posaconazole n/N (%)                                                                                                                                                                                                                                      | Voriconazole n/N (%)                                                                                                                                                                                                                                      | Estimated Difference (%)                                                                                                                                                                                                                                  | IN %S6                                                                                                                                                                                                                                                    |
| Dead Alive                                                                                                                                                                                                                                                | 56/163 (34.4) 107/163 (65.6)                                                                                                                                                                                                                              | 53/171 (31.0) 118/171 (69.0)                                                                                                                                                                                                                              | 3.1                                                                                                                                                                                                                                                       | (-6.9, 13.1)                                                                                                                                                                                                                                              |
| I Based on Miettinen and Nurminen’s method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead). | I Based on Miettinen and Nurminen’s method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead). | I Based on Miettinen and Nurminen’s method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead). | I Based on Miettinen and Nurminen’s method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead). | I Based on Miettinen and Nurminen’s method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures (dead). |

The CHMP considered that the three subjects with unknown status counted as dead in the ITT population do not change the results. The rates of all-cause mortality at day 84 between VOR and POS are comparable and consistent with the non-inferiority of POS vs VOR observed with the primary endpoint.

## Time to death (all causes) in the FAS population

The cumulative all-cause mortality rates throughout the study period (i.e., through Day 114) in the ITT and FAS populations were comparable in the POS and VOR treatment groups.

<div style=\"page-break-after: always\"></div>

CumulativeAll-CauseMortlityRate(%)

Kaplan-MeierPlotforCumulativeAll-CauseMortalityRateThroughDay114 Intention to Treat Population

Number of Subjects

Nunber of Events

28

80

60

40

20

D

0

14

42

Number of subjects at risk.

POS

VOR

288

268

288

POS

92

Log-Rank p=0.7652

VOR

POS

56

Days

254

244

230

219

8

207

287

VOR

93

98

202

114

196

287

267

240

230

215

204

199

195

192

POS=Posaconazole; VOR=Voriconazole

Source: [P069MK5592: adam-adite]

Kaplan-Meier Plot for Cumulative All-Cause Mortality Rate Through Day 114 Full Analysis Set Population

<!-- image -->

## Mortality due to IA through Day 42 and Day 84 in the FAS population

The treatment-group comparison for attribution of death by the independent Clinical Adjudication Committee (CAC) to IA, to invasive fungal disease other than IA, or to another cause was limited by the high proportions of deaths adjudicated to an 'indeterminate' cause in the FAS population. This was particularly noteworthy for VOR-treated subjects, among whom 50% to 56% of deaths had an indeterminate attribution, compared with 36% to 41% of POS-treated subjects, depending on the time point.

Among deaths for which the CAC was able to assign an attribution, at Week 6 (Day 42), 16 of 20 (80.0 %) deaths in the POS group were attributed to IA compared with 10 of 14 (71.4%) deaths in the VOR group. At Week 12 (Day 84), 22 of 33 (66.7%) deaths in the POS group were attributed to IA compared with 14 of 22 (63.6%) in the VOR group.

<div style=\"page-break-after: always\"></div>

## Analysis of Adjudicator's Primary Attribution of Death Full Analysis Set Population

|                                                                                  | Posaconazole   | Voriconazole   | Difference in % Posaconazole vs Voriconazole   |
|----------------------------------------------------------------------------------|----------------|----------------|------------------------------------------------|
|                                                                                  | n(%)t          | n (%)t         | Estimate (95% C1)f                             |
| Number of subjects in population                                                 | 163            | 171            |                                                |
| Number of subjects who died through Day 42                                       | 31             | 32             |                                                |
| Death Armibuted to Invasive Aspergillosis                                        | 16 (51.0)      | 10 (31.3)      | 20.4(-4.1, 42.7)                               |
| Death Armibuted to Invasive Fumgal Disease Other Than Invasive Aspergillosis     | 1(3.2)         | 0 (0.0)        | 3.2(-7.8, 16.3)                                |
| Death Not Attibutable to Invasive Aspergillosis or Other Invasive Fumgal Disease | 3 (9.7)        | 4(12.5)        | -2.8(-20.2, 14.6)                              |
| Indetenminate Atmibution of Death                                                | 11 (35.5)      | 18 (56.3)      | -20.8(-43.1, 4.0)                              |
| Number of subjects who died through Day 84                                       | 56             | 50             |                                                |
| Death Atmibuted to Invasive Aspergillosis                                        | 22 (39.3)      | 14 (28.0)      | 11.3(-6.9, 28.6)                               |
| Death Armibuted to Invasive Fumgal Disease Other Than Invasive Aspergillosis     | 1(1.8)         | 0 (0.0)        | 1.8(-5.5, 9.5)                                 |
| Death Not Armibutable toInvasive Aspergillosis or Other Invasive Fumgal Disease  | 10 (17.9)      | 8 (16.0)       | 1.9(-13.2, 16.4)                               |
| Indetenminate Atmibution of Death!                                               | 23 (41.1)      | 28 (56.0)      | -14.9(-33.0, 4.2)                              |
| Number of subjects who died through Day 114                                      | 64             | 56             |                                                |
| Death Attibuted to Invasive Aspergillosis                                        | 23 (35.9)      | 17 (30.4)      | 5.6(-11.4, 22.1)                               |
| Death Aimibuted to Invasive Fumgal Disease Other ThanInvasive Aspergillosis      | 1 (1.6)        | 0 (0.0)        | 1.6(-5.0, 8.4)                                 |
| Death Not Atmibutable to Invasive Aspergillosis or Other Invasive Fumgal Disease | 14 (21.9)      | 11 (19.6)      | 2.2(-12.8, 16.8)                               |
| IndetemminateAtmibution of Death                                                 | 26 (40.6)      | 28 (50.0)      | -9.4(-26.7, 8.5)                               |

I Percentages are based on the mumber of subjects who died through Day 42/84/114 in the respective section.

I Based on Miettinen and Nuuminen's method.

I Death occured but umable to detemmine atmibution of invasive aspergillosis or other invasive fimgal disease and death. Mortality assessments are presented using Data as Observed.

Sowce:[P069MK5592: adam-adbase]

The CHMP noted that, when considering the mortality due to IA (according to the CAC), the results are not at the advantage of POS. At each time points (Day 42, Day 84 and Day 114), the mortality attributed to IA is more frequent in POS group compared to VOR group. However, a higher number of indeterminate attribution of death is present in VOR group, which could bias the estimation of the mortality due to IA. Indeed, it is expected that a significant proportion of these undetermined deaths were actually due to IA (probably combined with other pathologies or infections).

Without considering the indeterminate attributions of death, there is still a 10% difference of mortality between POS and VOR groups at day 42 (80% [16/20] vs 71% [10/14]), but the number of subject is too low to draw any conclusion. This difference was not retrieved at Day 84 (67% [22/33] vs 64% [14/22]) and Day 114 (61% [23/38] vs 61% [17/28]).

In conclusion, these results of deaths attributed to IA may be biased due to the imbalance of the number of indeterminate attribution of death by the CAC. Furthermore, these results are not consistent with the other efficacy endpoints, and they cannot alone challenge the non-inferiority of POS vs VOR. To be reassured, the CHMP requested that the MAH reassessed the mortality data of all subjects for whom no cause of death was attributed, and specify among them whether IA was suspected and the number of subjects with probable or proven IA in each groups.

<div style=\"page-break-after: always\"></div>

The MAH explained that independent adjudication of each subject was performed by a central adjudication committee (CAC). A listing of the subjects in the FAS population who died through Day 114 and had indeterminate attribution of death as classified by central adjudication is shown below. There were 26 posaconazole treated subjects and 28 voriconazole treated subjects who were classified as having an indeterminate cause of death during the study period (through Day 114). This listing displays the primary cause of death as provided by the study investigators who oversaw the study at a given site. Of the 26 posaconazole treated subjects with indeterminate cause of death by the CAC, no subject was identified as having death related to invasive aspergillosis or an invasive fungal infection. In comparison, of the 28 voriconazole treated subjects with indeterminate cause of death by the CAC, 3 subjects were identified as having death related to aspergillus infection, systemic mycoses, or fungal pneumonia.

The CHMP considered that the MAH satisfactorily clarified that none of the 26 POS treated subjects and three of the 28 VOR subjects with an indeterminate cause of death, were identified as having death caused by IA of other invasive fungal disease. With this reassessment, the proportion of deaths attributable to IA and IFD becomes more balanced: 24/64 for POS and 20/56 for VOR, though overall the number of deaths remains unfavourable to the POS group.

## Global Clinical Response at Weeks 6 and 12, FAS Population

Global response was assessed by the CAC as success (partial or complete) or failure (stable response, disease progression, or death). Approximately 10% of subjects in each treatment group, at both Week 6 and Week 12, were given an adjudicated response outcome of 'unable to determine' and were counted as 'failures' for the purpose of treatment comparison.

## Analysis of Global Clinical Response at Week 6 Full Analysis Set Population

|                                                                                                                                                                                                                                                | Unadjusted Data Summary by Treatment Group                                                                                                                                                                                                     | Unadjusted Data Summary by Treatment Group                                                                                                                                                                                                     | TreatmentDifference (Posaconazole - Voriconazole)t                                                                                                                                                                                             | TreatmentDifference (Posaconazole - Voriconazole)t                                                                                                                                                                                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Outcome                                                                                                                                                                                                                                        | Posaconazole n/N (%)                                                                                                                                                                                                                           | Voriconazole n/N (%)                                                                                                                                                                                                                           | Estimated Difference (%)                                                                                                                                                                                                                       | ID %S6                                                                                                                                                                                                                                         |
| Success Failure                                                                                                                                                                                                                                | 73/163 (44.8) 90/163 (55.2)                                                                                                                                                                                                                    | 78/171 (45.6) 93/171 (54.4)                                                                                                                                                                                                                    | -0.6                                                                                                                                                                                                                                           | (-11.2, 10.1)                                                                                                                                                                                                                                  |
| ↑ Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or'unable todetermine'responses are considered asfailures. | ↑ Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or'unable todetermine'responses are considered asfailures. | ↑ Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or'unable todetermine'responses are considered asfailures. | ↑ Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or'unable todetermine'responses are considered asfailures. | ↑ Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or'unable todetermine'responses are considered asfailures. |

## Analysis of Global Clinical Response at Week 12 Full Analysis Set Population

|                                                                                                                                                                                                                                                    | Unadjusted Data Summary by Treatment Group                                                                                                                                                                                                         | Unadjusted Data Summary by Treatment Group                                                                                                                                                                                                         | TreatmentDifference (Posaconazole - Voriconazole)t                                                                                                                                                                                                 | TreatmentDifference (Posaconazole - Voriconazole)t                                                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Outcome                                                                                                                                                                                                                                            | Posaconazole n/N (%)                                                                                                                                                                                                                               | Voriconazole n/N (%)                                                                                                                                                                                                                               | Estimated Difference (%)                                                                                                                                                                                                                           | ID %S6                                                                                                                                                                                                                                             |
| Success Failure                                                                                                                                                                                                                                    | 69/163 (42.3) 94/163 (57.7)                                                                                                                                                                                                                        | 79/171 (46.2) 92/171 (53.8)                                                                                                                                                                                                                        | -3.4                                                                                                                                                                                                                                               | (-13.9, 7.1)                                                                                                                                                                                                                                       |
| I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures. | I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures. | I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures. | I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures. | I Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. Missing or 'unable to determine' responses are considered as failures. |

<div style=\"page-break-after: always\"></div>

## Summary of Adjudicated Global Clinical Response Full Analysis Set Population

| Adjudicated Global Clinical Response                                                                                                                                                                                                                                                                                        | Posaconazole n/N (%)                                                                            | Voriconazole n/N (%)                                                                                                    | Total n/N (%)                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| At Week6                                                                                                                                                                                                                                                                                                                    |                                                                                                 |                                                                                                                         |                                                                                                                                            |
| Success, Complete Response Success, Partial Response Failure, Stable Response Failure, Progression of Fungal Disease Failure,Death During the Period of Evaluation Unable to Assess At Week 12 Success, Complete Response Success, Partial Response Failure, Stable Response Unable to Assess                               | 11/163 (6.7) 62/163 (38.0) 12/163 (7.4) 27/163 (16.6) 34/163 (20.9) 17/163 (10.4) 20/163 (12.3) | 9/171 (5.3) 69/171 (40.4) 22/171 (12.9) 21/171 (12.3) 33/171 (19.3) 17/171 (9.9) 19/171 (11.1) 7/171 (4.1) 15/171 (8.8) | 20/334 (6.0) 131/334 (39.2) 34/334 (10.2) 48/334 (14.4) 67/334 (20.1) 34/334 (10.2) 39/334 (11.7) 109/334 (32.6) 16/334 (4.8) 32/334 (9.6) |
| Complete Response: Survival with Resolution of Fungal Disease Evidence                                                                                                                                                                                                                                                      |                                                                                                 |                                                                                                                         |                                                                                                                                            |
| Failure, Progression of Fungal Disease Failure,Death During thePeriod of Evaluation Partial Response: Survival and Improvement of Fungal Disease Evidence Stable Response: Survival and Minor or No Improvement of Fungal Disease Evidence Progression of Fungal Disease: Survival and Worsening of Fungal Disease Evidence | 49/163 (30.1) 9/163 (5.5) 13/163 (8.0) 56/163 (34.4) 16/163 (9.8)                               | 60/171 (35.1) 19/171 (11.1) 51/171 (29.8)                                                                               | 107/334 (32.0) 31/334 (9.3)                                                                                                                |

The CHMP pointed out that, according to the CHMP scientific advice on the change of primary endpoint, this endpoint 'global clinical response at week 6' should be maintained and considered as a co -primary endpoint.

The results are comparable for all types of response (successes and failures) between POS and VOR at week 6 and week 12, and support the non-inferiority conclusion of the primary endpoint. Of note, this FAS population contains only 334 subjects, which is inferior to the targeted 400 subjects to ensure a power &gt;85% for statistical analysis.

The MAH however explained that the sample size had a 80% power to show non-inferiority with a 10% margin. The study results show that non-inferiority as pre-defined in the protocol was met in both cases. The explanation indicates that after the endpoint switch the study retained a sufficient power and sample size to determine and meet pre-defined criteria for non-inferiority.

## Ancillary analyses

## Subgroup analyses

Overall, mortality was higher for older subjects and for subjects with extra-pulmonary site(s) of infection or with neutropenia at baseline or with proven IA. When evaluating mortality by treatment group, observed mortality rates were either comparable across treatment groups or lower (with a 95% CI that did not contain 0) in the POS group than in the VOR group. All-cause mortality rates were lower for POS compared with VOR for subjects in the following demographic and baseline disease subgroups: age (18 to 57 [median age]), sex (male), race (white), and baseline adjudication of possible IA. On the contrary, all-cause mortality rates were higher for POS compared with VOR for Asian subjects.

<div style=\"page-break-after: always\"></div>

## Analysis of All-Cause Mortality Through Day 42 by Subgroup Intention to Treat Population

|                                                                                                                                       | Unadjusted DataSummaryby                                                                                                              | Unadjusted DataSummaryby                                                                                                              | Treatment Difference (Posaconazole -Voriconazole)t                                                                                    | Treatment Difference (Posaconazole -Voriconazole)t                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Subgroup Criterion                                                                                                                    | Treatment Group Posaconazole n/N (%)                                                                                                  | Voriconazole n/N (%)                                                                                                                  | Estimated Difference (%)                                                                                                              | ID %S6                                                                                                                                |
| Age (Years)                                                                                                                           |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| <18                                                                                                                                   | 1/3 (33.3)                                                                                                                            | 0/2 (0.0)                                                                                                                             | 33.3                                                                                                                                  | (-51.9, 82.0)                                                                                                                         |
| 18 to 57                                                                                                                              | 14/151 (9.3)                                                                                                                          | 27/151 (17.9)                                                                                                                         | -8.6                                                                                                                                  | (-16.6,-0.9)                                                                                                                          |
| >57                                                                                                                                   | 29/134 (21.6)                                                                                                                         | 32/134 (23.9)                                                                                                                         | -2.2                                                                                                                                  | (-12.3, 7.9)                                                                                                                          |
| Sex                                                                                                                                   |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| Male                                                                                                                                  | 21/172 (12.2)                                                                                                                         | 38/172 (22.1)                                                                                                                         | -9.9                                                                                                                                  | (-17.9, -1.9)                                                                                                                         |
| Female                                                                                                                                | 23/116 (19.8)                                                                                                                         | 21/115 (18.3)                                                                                                                         | 1.6                                                                                                                                   | (-8.7, 11.8)                                                                                                                          |
| Region                                                                                                                                |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| US                                                                                                                                    | 3/21 (14.3)                                                                                                                           | 0/12 (0.0)                                                                                                                            | 14.3                                                                                                                                  | (-11.9, 35.0)                                                                                                                         |
| Ex-US                                                                                                                                 | 41/267 (15.4)                                                                                                                         | 59/275 (21.5)                                                                                                                         | -6.1                                                                                                                                  | (-12.6, 0.4)                                                                                                                          |
| Ethnicity                                                                                                                             |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| Hispanic or Latino                                                                                                                    | 7/48 (14.6)                                                                                                                           | 14/57 (24.6)                                                                                                                          | -10.0                                                                                                                                 | (-25.0, 5.8)                                                                                                                          |
| Not Hispanic or Latino                                                                                                                | 37/220 (16.8)                                                                                                                         | 43/219 (19.6)                                                                                                                         | -2.8                                                                                                                                  | (-10.1, 4.5)                                                                                                                          |
| Unknown                                                                                                                               | 0/20 (0.0)                                                                                                                            | 2/11 (18.2)                                                                                                                           | -18.2                                                                                                                                 | (-48.2, 0.3)                                                                                                                          |
| Race                                                                                                                                  |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| AmericanIndianorAlaskaNative                                                                                                          | 0/4 (0.0)                                                                                                                             | 4/6 (66.7)                                                                                                                            | -66.7                                                                                                                                 | (-90.9, -1.5)                                                                                                                         |
| Asian                                                                                                                                 | 10/62 (16.1)                                                                                                                          | 4/60 (6.7)                                                                                                                            | 9.5                                                                                                                                   | (-2.1, 21.6)                                                                                                                          |
| Black                                                                                                                                 | 0/3 (0.0)                                                                                                                             | 0/4 (0.0)                                                                                                                             | NA                                                                                                                                    | (-18.5, 26.4)                                                                                                                         |
| Multi-Racial                                                                                                                          | 5/25 (20.0)                                                                                                                           | 4/25 (16.0)                                                                                                                           | 4.0                                                                                                                                   |                                                                                                                                       |
| White                                                                                                                                 | 29/194 (14.9)                                                                                                                         | 47/192 (24.5)                                                                                                                         | -9.5                                                                                                                                  | (-17.5, -1.6)                                                                                                                         |
| Risk Status                                                                                                                           |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| High Risk                                                                                                                             | 20/113 (17.7)                                                                                                                         | 23/113 (20.4)                                                                                                                         | -2.7                                                                                                                                  | (-13.0, 7.7)                                                                                                                          |
| No High Risk                                                                                                                          | 24/175 (13.7)                                                                                                                         | 36/174 (20.7)                                                                                                                         | -7.0                                                                                                                                  | (-15.0, 1.0)                                                                                                                          |
| Iype of IA perAdjudicator's Assessment                                                                                                |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| Proven                                                                                                                                | 7/26 (26.9)                                                                                                                           | 4/15 (26.7)                                                                                                                           | 0.3                                                                                                                                   | (-29.6, 26.5)                                                                                                                         |
| Probable                                                                                                                              | 24/137 (17.5)                                                                                                                         | 28/156 (17.9)                                                                                                                         | -0.4                                                                                                                                  | (-9.2, 8.5)                                                                                                                           |
| Possible                                                                                                                              | 7/81 (8.6)                                                                                                                            | 18/79 (22.8)                                                                                                                          | -14.1                                                                                                                                 | (-25.7, -3.0)                                                                                                                         |
| Cannot be determined                                                                                                                  | 6/44 (13.6)                                                                                                                           | 9/37 (24.3)                                                                                                                           | -10.7                                                                                                                                 | (-28.7, 6.5)                                                                                                                          |
| Site of IA                                                                                                                            |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| Lung                                                                                                                                  | 31/230 (13.5)                                                                                                                         | 39/230 (17.0)                                                                                                                         | -3.5                                                                                                                                  | (-10.1, 3.1)                                                                                                                          |
| Multiple Sites                                                                                                                        | 12/48 (25.0)                                                                                                                          | 17/45 (37.8)                                                                                                                          | -12.8                                                                                                                                 | (-31.1, 6.2)                                                                                                                          |
| Sinus                                                                                                                                 | 1/3 (33.3)                                                                                                                            | 2/7 (28.6)                                                                                                                            | 4.8                                                                                                                                   | (-47.5, 62.1)                                                                                                                         |
| Other                                                                                                                                 | 0/2 (0.0)                                                                                                                             | 1/2 (50.0)                                                                                                                            | -50.0                                                                                                                                 | (-92.4, 46.8)                                                                                                                         |
| Missing                                                                                                                               | 0/5 (0.0)                                                                                                                             | 0/3 (0.0)                                                                                                                             | NA                                                                                                                                    |                                                                                                                                       |
| UnderlyingDisease                                                                                                                     |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| Recenthistoryofprolongedneutropenia temporallyrelatedtotheonsetoffungal disease                                                       | 30/179 (16.8)                                                                                                                         | 47/189 (24.9)                                                                                                                         | -8.1                                                                                                                                  | (-16.4, 0.2)                                                                                                                          |
| Receipt ofan allogeneic HSCT                                                                                                          | 14/65 (21.5)                                                                                                                          | 9/59 (15.3)                                                                                                                           | 6.3                                                                                                                                   | (-7.8, 20.1)                                                                                                                          |
| Treatment with other recognized T-cell immunesuppressants                                                                             | 20/126 (15.9)                                                                                                                         | 22/109 (20.2)                                                                                                                         | -4.3                                                                                                                                  | (-14.5, 5.5)                                                                                                                          |
| Prolongeduseofcorticosteroid                                                                                                          | 23/93 (24.7)                                                                                                                          | 18/89 (20.2)                                                                                                                          | 4.5                                                                                                                                   | (-7.8, 16.7)                                                                                                                          |
| Inherited severe immunodeficiency                                                                                                     | 0/2 (0.0)                                                                                                                             | 1/1 (100.0)                                                                                                                           | -100.0                                                                                                                                | (-100.0, 31.5)                                                                                                                        |
| None of the above                                                                                                                     | 3/17 (17.6)                                                                                                                           | 1/18 (5.6)                                                                                                                            | 12.1                                                                                                                                  | (-11.6, 37.0)                                                                                                                         |
| Neutropenic Status at Baseline (10^9/L)                                                                                               |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |                                                                                                                                       |
| <0.5                                                                                                                                  | 23/132 (17.4)                                                                                                                         | 34/137 (24.8)                                                                                                                         | -7.4                                                                                                                                  | (-17.1, 2.4)                                                                                                                          |
| ≥0.5                                                                                                                                  | 20/142 (14.1)                                                                                                                         | 21/138 (15.2)                                                                                                                         | -1.1                                                                                                                                  | (-9.6, 7.3)                                                                                                                           |
| Unknown                                                                                                                               | 1/14 (7.1)                                                                                                                            | 4/12 (33.3)                                                                                                                           | -26.2                                                                                                                                 | (-56.2, 5.4)                                                                                                                          |
| Based onMiettinen and Nurminen'smethod.                                                                                               | Based onMiettinen and Nurminen'smethod.                                                                                               | Based onMiettinen and Nurminen'smethod.                                                                                               | Based onMiettinen and Nurminen'smethod.                                                                                               | Based onMiettinen and Nurminen'smethod.                                                                                               |
| Missingor'unable todetermine'responses are consideredasfailures(dead).Site ofIA and UnderlyingDiseaseareper Adjudicator's Assessment. | Missingor'unable todetermine'responses are consideredasfailures(dead).Site ofIA and UnderlyingDiseaseareper Adjudicator's Assessment. | Missingor'unable todetermine'responses are consideredasfailures(dead).Site ofIA and UnderlyingDiseaseareper Adjudicator's Assessment. | Missingor'unable todetermine'responses are consideredasfailures(dead).Site ofIA and UnderlyingDiseaseareper Adjudicator's Assessment. | Missingor'unable todetermine'responses are consideredasfailures(dead).Site ofIA and UnderlyingDiseaseareper Adjudicator's Assessment. |

<div style=\"page-break-after: always\"></div>

In the FAS population, all-cause mortality rates through Day 42 were generally comparable between treatment groups.

The CHMP considered that, overall, subgroup efficacy analyses for the ITT population were supportive of the primary efficacy endpoint analysis, with non-inferiority of POS to VOR by subgroup variables.

However, the mortality in the Asian population was higher in the POS group (16%, 10/62) than the VOR group (6.7%, 4/60). This higher mortality rate is also observed within the FAS population (POS: 21% (9/43); VOR: 6.5% (3/46)). Based on PPK analysis, no subexposure is expected within the Asian population, with furthermore a lower POS clearance and thus an increase of POS Cavg by 33% in Chinese patients. This increase was not considered clinically meaningful. Considering the low number of subjects in this subgroup, and the lack of efficacy concerns particularly observed in the Asian population with the current use of POS, these subgroups results are not considered relevant. Subgroup analysis including prior medication with antimycotics during the 3 days before starting the study treatment was requested.

The provided Subgroup analysis of study subjects that received prior antimycotic therapy showed that a large proportion (80%) of subjects in both groups (227/288 in the POS group and 229/287 in the VOR group) received prior antimycotics, which was allowed by the protocol. Overall, the use of antimycotics by class is balanced between the two treatment groups. The influence of prior treatment on the primary outcomes are rather inconclusive. However, as the proportion of pre-treated patients is very high, it drives the overall response results:

## All-cause mortality:

| All cause-mortality at D42 in ITT   | Pre-treated with antimycotics (% death)   | Not pre-treated with antimycotics   | Overall results   |
|-------------------------------------|-------------------------------------------|-------------------------------------|-------------------|
| POS                                 | 16.7%                                     | 9.8%                                | 15.3%             |
| VOR                                 | 21.8%                                     | 15.5%                               | 20.6%             |

## Global clinical response:

| Global clinical response at D42 in FAS   | Pre-treated with antimycotics (success)   | Not pre-treated with antimycotics   | Overall results   |
|------------------------------------------|-------------------------------------------|-------------------------------------|-------------------|
| POS                                      | 44.6%                                     | 45.5%                               | 44.8%             |
| VOR                                      | 48.5%                                     | 36.6%                               | 45.6%             |

As the proportion of pre-treated subjects as well as the primary outcomes are comparable between the two groups (POS and VOR), the CHMP considered that it could be assumed that there is no impact on the non-inferiority results.

The CHMP additionally noted that in the POS SmPC, the recommended treatment duration for IA is 612 weeks. It was also noted that approximately 40% of subjects have been treated with POS or VOR for less than 6 weeks, including 30-35% for less than 4 weeks.

The MAH was asked to provide efficacy outcomes according to treatment duration (&lt;6 weeks, 6 weeks to &lt;12 weeks, ≥12 weeks) and to justify the recommended treatment duration for IA.

<div style=\"page-break-after: always\"></div>

The MAH provided justification for the treatment duration: the study was designed for a 12 week treatment duration, and it was noted that failure rate in the sub-group treated for less than 42 days was more than 40% compared to the overall rate of 15% for the all-cause mortality and respectively more than 90% compared to the overall failure rate of 55% for the global clinical response. More importantly, the results are comparable between the POS and VOR treatments, regardless of the treatment duration and are consistent with the overall non-inferiority results.

Therefore, the data suggests a duration of treatment of more than 6 weeks. It seems that the overall success rate does not improve beyond 12 weeks of treatment. Therefore, the CHMP considered the proposed statement in the SmPC: ' Recommended total duration of therapy is 6-12 weeks ' to be supported.

## Exposure-Efficacy Relationship (see also PK/PD section)

For subjects with evaluable exposure data, there was no discernible trend across quartiles of POS trough plasma concentrations for the key efficacy endpoint of all-cause mortality through Day 42 in the ITT population. Same results are noted for the global clinical response at Week 6. These data suggest that POS exposures achieved in P069 with the IV and tablet formulations were on the plateau of the exposure-efficacy curve, where efficacy is relatively insensitive to changes in exposure.

However, it can be noted that subjects without evaluable POS exposure data had higher mortality rates than subjects with such data. The lower efficacy in these subjects may be a consequence of the fact that subjects who died or remained seriously ill were less likely to have evaluable exposure data, potentially introducing bias into the exposure-efficacy analysis.

All-CauseMortalityThroughDay42byQuartilesofWithin-SubjectMeanPosaconazole TroughPlasma Concentration(ITTpopulation)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Global ClinicalResponse atWeek6byQuartileofWithin-SubjectMeanPosaconazole TroughPlasmaConcentration(FASPopulation)

<!-- image -->

For VOR, subjects in the highest quartile of VOR trough plasma concentration and those without evaluable VOR exposure data had higher all-cause mortality through Day 42 than subjects in the lower 3 quartiles of VOR trough concentration in the ITT population. Same results for the global clinical response at Week 6.

All-Cause Mortality Through Day 42 by Quartiles of Within-Subject MeanVoriconazole TroughPlasma Concentration (ITT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

The CHMP considered that these data suggest a larger therapeutic margin with POS than with VOR, with higher rates of mortality and lower clinical response with the higher exposures of VOR, conversely to POS where higher exposures seem to not impact these endpoints.

The lower efficacy of POS or VOR treatment in the population without available exposition data may be subject to interpretations. As stated by the MAH, these data may reflect that subjects with higher advanced disease (and a poor prognosis) were less likely to have evaluable exposure data, potentially introducing bias into the exposure-efficacy analysis. These data may also suggest that a therapeutic drug monitoring of POS or VOR is associated to a better outcome.

## Summary of main study

The following table summarise the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 19: Summary of Efficacy for trial P069

| the Treatment of Study identifier   | Invasive Aspergillosis in Adults and Adolescents                                                                                                                                                                                                                                                                                                                                                                                            | Invasive Aspergillosis in Adults and Adolescents                                                                                                                                                                                                                                                                                                                                                                                            | Invasive Aspergillosis in Adults and Adolescents                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| the Treatment of Study identifier   | P069 Multicenter, parallel assignment (randomized 1:1), double blind, active comparator                                                                                                                                                                                                                                                                                                                                                     | P069 Multicenter, parallel assignment (randomized 1:1), double blind, active comparator                                                                                                                                                                                                                                                                                                                                                     | P069 Multicenter, parallel assignment (randomized 1:1), double blind, active comparator                                                                                                                                                                                                                                                                                                                                                     |
| Hypothesis                          | Duration of main phase: 12 weeks Demonstrate that POS is non-inferior to VOR in first line therapy of IA Primary hypothesis: The all-cause mortality rate through Day 42 in the POS treatment group is non-inferior to that in the VOR treatment group. Secondary hypothesis (as EMA request): The global clinical response for POS at Week 6 in the FAS population is non inferior to that in the VOR treatment group.                     | Duration of main phase: 12 weeks Demonstrate that POS is non-inferior to VOR in first line therapy of IA Primary hypothesis: The all-cause mortality rate through Day 42 in the POS treatment group is non-inferior to that in the VOR treatment group. Secondary hypothesis (as EMA request): The global clinical response for POS at Week 6 in the FAS population is non inferior to that in the VOR treatment group.                     | Duration of main phase: 12 weeks Demonstrate that POS is non-inferior to VOR in first line therapy of IA Primary hypothesis: The all-cause mortality rate through Day 42 in the POS treatment group is non-inferior to that in the VOR treatment group. Secondary hypothesis (as EMA request): The global clinical response for POS at Week 6 in the FAS population is non inferior to that in the VOR treatment group.                     |
| Treatments groups                   | Posaconazole (IV or tablets)                                                                                                                                                                                                                                                                                                                                                                                                                | Posaconazole (IV or tablets)                                                                                                                                                                                                                                                                                                                                                                                                                | 300 mg BID (IV or tablets) at Day 1, then 300 mg QD (IV or tablets) + placebo QD (to ensure double-blind) for 12 weeks. 293 subjects randomised, 288 subjects treated                                                                                                                                                                                                                                                                       |
| Treatments groups                   | Voriconazole (IV or capsules)                                                                                                                                                                                                                                                                                                                                                                                                               | Voriconazole (IV or capsules)                                                                                                                                                                                                                                                                                                                                                                                                               | IV: 6 mg/kg BID at Day 1, then 4 mg/kg BID for 12 weeks. OR capsules: 300 mg BID at Day 1, then 200 mg BID for 12 weeks. 292 subjects randomised, 287 subjects treated                                                                                                                                                                                                                                                                      |
| Endpoints and definitions           | Primary efficacy endpoint                                                                                                                                                                                                                                                                                                                                                                                                                   | All-cause mortality                                                                                                                                                                                                                                                                                                                                                                                                                         | To compare all-cause mortality for POS with that of VOR in the first-line treatment of IA through Day 42 in all randomized subjects who received at least one dose of study treatment (in the ITT population)                                                                                                                                                                                                                               |
| Endpoints and definitions           | Co-primary efficacy endpoint (as request by EMA)                                                                                                                                                                                                                                                                                                                                                                                            | Global clinical response                                                                                                                                                                                                                                                                                                                                                                                                                    | To evaluate the global clinical response for POS vs. VOR at Week 6 in the FAS population                                                                                                                                                                                                                                                                                                                                                    |
| Database lock                       | 10 sept 2019 (last patient last visit)                                                                                                                                                                                                                                                                                                                                                                                                      | 10 sept 2019 (last patient last visit)                                                                                                                                                                                                                                                                                                                                                                                                      | 10 sept 2019 (last patient last visit)                                                                                                                                                                                                                                                                                                                                                                                                      |
| Results and Analysis                | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Analysis description                | Primary Analysis All-cause mortality at day 42: Statistical methodology: The primary endpoint was assessed using a non- inferiority margin of 10%; if the upper limit of the 95% CI, adjusted for stratification factors for the difference in success rates, was less than 10%, non-inferiority was to be declared. If non-inferiority was declared, superiority of POS over VOR was to be assessed and declared if the upper limit of the | Primary Analysis All-cause mortality at day 42: Statistical methodology: The primary endpoint was assessed using a non- inferiority margin of 10%; if the upper limit of the 95% CI, adjusted for stratification factors for the difference in success rates, was less than 10%, non-inferiority was to be declared. If non-inferiority was declared, superiority of POS over VOR was to be assessed and declared if the upper limit of the | Primary Analysis All-cause mortality at day 42: Statistical methodology: The primary endpoint was assessed using a non- inferiority margin of 10%; if the upper limit of the 95% CI, adjusted for stratification factors for the difference in success rates, was less than 10%, non-inferiority was to be declared. If non-inferiority was declared, superiority of POS over VOR was to be assessed and declared if the upper limit of the |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description   | Intent to treat (ITT) population: All randomized subjects who received at least 1 dose of study drug                                                                                                                                                                                                                                                                                                                         | Intent to treat (ITT) population: All randomized subjects who received at least 1 dose of study drug                                                                                                                                                                                                                                                                                                                         | Intent to treat (ITT) population: All randomized subjects who received at least 1 dose of study drug                                                                                                                                                                                                                                                                                                                         |
|--------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                              | Posaconazole (POS)                                                                                                                                                                                                                                                                                                                                                                                                           | Voriconazole (VOR)                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability  | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                           | 288                                                                                                                                                                                                                                                                                                                                                                                                                          | 287                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability  | Mortality rate at day 42                                                                                                                                                                                                                                                                                                                                                                                                     | 44/288 (15.3%)                                                                                                                                                                                                                                                                                                                                                                                                               | 59/287 (20.6%)                                                                                                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability  | Estimated difference 95% confidence interval P value                                                                                                                                                                                                                                                                                                                                                                         | -5.3% [-11.6 ; 1.0%] <0.0001                                                                                                                                                                                                                                                                                                                                                                                                 | -5.3% [-11.6 ; 1.0%] <0.0001                                                                                                                                                                                                                                                                                                                                                                                                 |
| Conclusion                                       | POS is non-inferior to VOR in the treatment of IA with regard to all-cause                                                                                                                                                                                                                                                                                                                                                   | POS is non-inferior to VOR in the treatment of IA with regard to all-cause                                                                                                                                                                                                                                                                                                                                                   | POS is non-inferior to VOR in the treatment of IA with regard to all-cause                                                                                                                                                                                                                                                                                                                                                   |
| Analysis description                             | mortality through Day 42. Co-primary Analysis Global clinical response at week 6: Methodology: A subject was considered to have a successful global clinical response if the subject was FAS-evaluable and judged by the Clinical Adjudication Committee (CAC) to be alive and to have had a complete or partial response at the time point of interest. The CAC also adjudicated IFI- attributable mortality through Day 42 | mortality through Day 42. Co-primary Analysis Global clinical response at week 6: Methodology: A subject was considered to have a successful global clinical response if the subject was FAS-evaluable and judged by the Clinical Adjudication Committee (CAC) to be alive and to have had a complete or partial response at the time point of interest. The CAC also adjudicated IFI- attributable mortality through Day 42 | mortality through Day 42. Co-primary Analysis Global clinical response at week 6: Methodology: A subject was considered to have a successful global clinical response if the subject was FAS-evaluable and judged by the Clinical Adjudication Committee (CAC) to be alive and to have had a complete or partial response at the time point of interest. The CAC also adjudicated IFI- attributable mortality through Day 42 |
| Analysis population and time point description   | Full analysis set (FAS): All randomized subjects who were classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 EORTC/MSG definitions), and received at least 1 dose of study drug.                                                                                                                                                                             | Full analysis set (FAS): All randomized subjects who were classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 EORTC/MSG definitions), and received at least 1 dose of study drug.                                                                                                                                                                             | Full analysis set (FAS): All randomized subjects who were classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 EORTC/MSG definitions), and received at least 1 dose of study drug.                                                                                                                                                                             |
| Descriptive statistics and estimate variability  | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                              | Posaconazole (POS)                                                                                                                                                                                                                                                                                                                                                                                                           | Voriconazole (VOR)                                                                                                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability  | Number of subject                                                                                                                                                                                                                                                                                                                                                                                                            | 163                                                                                                                                                                                                                                                                                                                                                                                                                          | 171                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability  | Proportion of complete or partial response (=success) Estimated difference 95% confidence interval                                                                                                                                                                                                                                                                                                                           | 73/163 (44.8%) 78/171 -0.6% [11.2% ; 10.1%]                                                                                                                                                                                                                                                                                                                                                                                  | (45.6%)                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Conclusion                                       | While there was no formal statistical evaluation of global clinical response in the FAS population, it was noted that the proportions of observed global clinical responses were similar in the POS and VOR treatment groups at Week                                                                                                                                                                                         | While there was no formal statistical evaluation of global clinical response in the FAS population, it was noted that the proportions of observed global clinical responses were similar in the POS and VOR treatment groups at Week                                                                                                                                                                                         | While there was no formal statistical evaluation of global clinical response in the FAS population, it was noted that the proportions of observed global clinical responses were similar in the POS and VOR treatment groups at Week                                                                                                                                                                                         |
| Notes                                            | 6. Approximately 10% in each group were unable to assess and not counted as                                                                                                                                                                                                                                                                                                                                                  | 6. Approximately 10% in each group were unable to assess and not counted as                                                                                                                                                                                                                                                                                                                                                  | 6. Approximately 10% in each group were unable to assess and not counted as                                                                                                                                                                                                                                                                                                                                                  |

## Additional clinical data

The MAH has performed a systematic literature review to understand the efficacy/effectiveness of POS as monotherapy or combination therapy in the treatment of IFIs other than IA, consisting of the following: chromoblastomycoses (caused by Fonsecea , Phialophora , Cladosporium , Exophilia , or Chromoblastomycosis not specified), fungal mycetoma (caused by Eumycetoma , mycotic mycetoma, and fungal mycetoma not specified), hyalohyphomycosis/phaeohyphomycosis (caused by Fusarium ,

<div style=\"page-break-after: always\"></div>

Scedosporium , Pseudoallescheria , Talaromyces , and Penicillium spp.), and mucormycosis (caused by Rhizopus , Mucor , Cunnighamella , Apophysomyces , Lictheimia ( Absidia ), Saksenaea , Rhizomucor , Mucormycetes not specified, and Zygomycosis not specified).

Over the past 14 years, 351 articles have been published describing the efficacy of POS in the treatment of these rare IFIs (chromoblastomycosis, fungal mycetoma, hyalohyphomycosis/phaeohyphomycosis and mucormycosis). The literature-based evidence consists of observational evidence (mostly case reports). The majority of evidence was found in mucormycosis followed by hyalohyphomycosis/ phaeohyphomycosis, and chromoblastomycosis. Positive clinical outcomes with POS therapy were observed in 66.7% (564/845) of mucormycosis cases, 53.3% (49/92) of hyalohyphomycosis/ phaeohyphomycosis cases, and 73.9% (17/23) of chromoblastomycosis cases. Very sparse evidence was found for fungal mycetoma (2 positive cases).

## 2.4.1. Discussion on clinical efficacy

Posaconazole (IV and tablet forms) is currently indicated in the treatment and prophylaxis of the following IFI in adults: Invasive aspergillosis (in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products); fusariosis (in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B); chromoblastomycosis and mycetoma (in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole); coccidioidomycosis (in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products).

In current practice, voriconazole is used as first line therapy in IA. Isavuconazole showed non inferiority to voriconazole in CL-104 study and has also the indication in IA since 2015.

Regarding difficulties to treat IA and the known adverse events and DDI of voriconazole and isavuconazole, there is a need a need for additional therapies with at least similar levels of efficacy.

## Design and conduct of clinical studies

This extension of indication is based on the non-inferiority study P069 performed in patients with possible, probable or proven IA. Subjects with baseline possible IA have additional diagnostic to confirm the IA. In the event that possible IA was not confirmed, the patients may continue to be treated if clinician deems appropriate. Subjects should not have history of chronic, recurrent or refractory IA, consistency with the claimed first line treatment of IA, but an antifungal therapy started since 3 days maximum is tolerated. All patients were randomized 1:1 to receive POS or VOR with IV or oral formulation, according to the clinical status of the patient. POS oral suspension was not used, this extension of indication did not concern this formulation due to the differences between tablets and oral suspension in frequency of dosing, administration with food and plasma drug concentration achieved.

Two populations were studied:

- -ITT population: all randomized subjects who received at least 1 dose of study drug
- -FAS population: all randomized subjects who were classified as having proven or probable IA (based upon independent adjudication assessment by the CAC), and received at least 1 dose of study drug.

To assess the non-inferiority of POS vs VOR, the primary endpoint was changed during study and was defined as the all-cause mortality through day 42 in the ITT population, similarly than the noninferiority study CL-104 (ISA vs VOR). However, in accordance to the EMA scientific advice, the initial

<div style=\"page-break-after: always\"></div>

primary endpoint - global clinical response at week 6 in the FAS population - must be also considered as a co-primary endpoint for the non-inferiority assessment of POS vs VOR. The 10% non-inferiority margin is endorsed.

## Efficacy data and additional analyses

Overall, 575 subjects were part of the ITT population and randomized in a 1:1 ratio (POS = 288, VOR = 287). 26 countries in the Asia/Pacific region, Europe and North and South America were represented. Baseline data are similar between POS and VOR groups. A majority of subjects were male (59.8%) and white (67.1%), with a median age at 57 years. Only 5 subjects were adolescents &lt;18 years old, although this study has initially intended to enrol both adolescent and adult subjects. Therefore, this study could not support alone an adolescent extension of the indication in the treatment of IA. Only 1% of subjects were black/African American, but the known PK data of POS suggest the lack of significant effect of race on POS exposure for the tablets and IV formulations.

Only 58% of the baseline IA diagnosis was probable or proven, but a non-negligible proportion of IA diagnosis (14%) cannot be determined at baseline by the CAC. Aspergillus (and especially A. fumigatus ) is the fungal agent most represented, without imbalance between both groups. However, only 24% of subjects had fungal culture results reported.

The non-inferiority of POS vs VOR in the first-line treatment of IA was demonstrated. In the ITT population, the mortality rate at Day 42 was 15.3% in the POS group and 20.6% in the VOR group, after stratification for risk of mortality/poor outcome (difference: -5.3% [95% CI: -11.6, 1.0%]). In the FAS population, the global clinical response at 6 week (considered as a co-primary endpoint) also demonstrate a non-inferiority of POS vs VOR. Proportion of success were 44.8% for POS and 45.6% for VOR, with comparable proportion in complete and partial success (difference: -0.6% [95% CI: 11.01, 10.1]).

Other secondary endpoints support the non-inferiority of POS vs VOR, excepted the secondary endpoint 'mortality due to IA (according to the CAC)', with higher rates at each time points in the POS group than in the VOR group (Day 42: 51.6% vs 31.3% ; Day 84: 39.3% vs 28.0% ; Day 114: 35.9% vs 30.4%). However, approximately half of the deaths have an indeterminate relationship with IA or other IFI, with a higher proportion in the VOR group, which could bias the estimation of the mortality due to IA. Indeed, it is expected that a significant proportion of these undetermined deaths were actually due to IA (probably combined with other pathologies or infections). Upon request by the CHMP, the MAH reassessed the mortality data of all subjects for whom no cause of death was attributed, and specified among them whether IA was suspected and the number of subjects with probable or proven IA in each groups. The MAH satisfactorily clarified that none of the 26 POS treated subjects and three of the 28 VOR subjects with an indeterminate cause of death, were identified as having death caused by IA of other invasive fungal disease. With this reassessment, the proportion of deaths attributable to IA and IFD becomes more balanced: 24/64 for POS and 20/56 for VOR, though overall the number of deaths remains unfavourable to the POS group.

Subgroup analysis are supportive to the non-inferiority results. Considering that prior medication with antimycotics was authorized for 3 days maximum before to start study treatment, which potentially may influence the outcome, a subgroup analysis by prior medication with antimycotics should be added.

<div style=\"page-break-after: always\"></div>

## Assessment of paediatric data on clinical efficacy

An indication of POS for the first-line treatment of IA in paediatric patients is not claimed at this stage. The efficacy in IA was not demonstrated for paediatric patients in P069 study, with only 5 adolescents enrolled.

## 2.4.2. Conclusions on the clinical efficacy

In conclusion, POS is non-inferior to VOR for the first-line treatment of adults with probable, possible or proven IA, based on the all-cause mortality rate and global clinical response at 6 weeks.

## 2.5. Clinical safety

## Introduction

Safety analyses in P069 were based on the APaT population, consisting of all randomized subjects who received ≥1 dose of study treatment. The ITT population, consisting of all randomized subjects who received ≥1 dose of study drug, was used for the primary efficacy analysis (all-cause mortality through Day 42). The APaT and ITT populations were identical.

The overall adverse event (AE) profile in P069 was reflective of the known AE profile of POS IV and tablet, as described in product labeling, and was consistent with a critically ill study population. Furthermore, the types and incidences of AEs, drug-related AEs, and serious adverse events (SAEs) in the POS treatment group in P069 were similar to those reported in previous clinical studies of POS IV and tablet despite P069 having a longer duration of treatment (average therapy duration of &gt;60 days for the treatment of IA) compared with previous studies of POS IV and tablet (average therapy durations of &lt;30 days in a prophylaxis setting).

The proportion of subjects with a drug-related AE was lower in the POS treatment group (29.9%) than in the VOR treatment group (40.1%).  Treatment was discontinued due to a drug-related AE in 6.3% of POS-treated subjects compared with 9.8% of VOR-treated subjects.  No POS-treated subject died due to a drug-related SAE compared with 3 VOR-treated subjects. The incidences of AEs, SAEs, deaths, and discontinuations due to AEs were similar for subjects in the POS and VOR treatment groups.

## Patient exposure

In study P069, 288 subjects were randomized and treated with POS IV or tablet at a dose of 300 mg QD (300 mg BID on Day 1) compared with 287 subjects randomized and treated with VOR 4 mg/kg IV BID (6 mg/kg IV BID on Day 1) or 200 mg oral BID (300 mg oral BID on Day 1).  The median duration of exposure in the ITT population was 67 days in the POS group and 64 days in the VOR group. Approximately 40% of subjects in each treatment group received study treatment for the planned duration of 84 days (maximum allowed duration of 98 days).

Approximately 55% to 60% of subjects started treatment with the IV formulation of either POS or VOR.

## Adverse events

Overall, the AE profile was reflective of a critically ill study population. Nearly all subjects in both treatment groups experienced 1 or more AEs during the treatment period or within 30 days following the last dose. The proportion of subjects with drug-related AEs was lower in the POS treatment group

<div style=\"page-break-after: always\"></div>

than in the VOR treatment group; the incidences of AEs, SAEs, deaths, and discontinuations due to AEs were similar for subjects in the POS and VOR treatment groups.

The overall proportions of subjects with AEs in a given SOC were comparable between the 2 treatment groups; AEs categorized within the SOCs of Infections and Infestations and Gastrointestinal disorders were the most frequently reported.

In this critically ill population, the most frequently reported AEs were hypokalaemia, pyrexia, nausea, vomiting, diarrhoea, ALT increased, and febrile neutropenia in the POS group; and pyrexia, diarrhoea, nausea, and hypokalaemia in the VOR group. The frequencies and types of AEs were generally comparable across both treatment groups, although the AE of hypokalaemia was reported more frequently for POS-treated subjects (28.5%) than for VOR-treated subjects (17.1%).

The proportion of subjects with AEs that were considered by the investigator(s) to be related to study drug (i.e. drug-related) was lower in the POS group compared with the VOR group (-10.2%; 95% CI: -17.9, -2.4). The only drug-related AEs reported for &gt;5% of subjects (in either treatment group) were ALT increased, AST increased, and blood alkaline phosphatase increased.

When analyzed by drugrelated AEs occurring in ≥4 subjects in either treatment group (ie, Tier-2 events, as prespecified in the protocol, a lower proportion of POS-treated subjects than VOR-treated subjects reported drug-related AEs applicable to the SOCs of Eye disorders (-8.0%; 95% CI: -12.2, -4.5) and Psychiatric disorders. These differences were driven by between-group differences in the AEs of dyschromatopsia, vision blurred, visual impairment, and hallucination, each of which was reported at a lower incidence for POS-treated subjects compared with VOR-treated. A higher proportion of subjects with drug-related AEs in the Metabolism and Nutrition disorders SOC was noted for the POS treatment group compared with the VOR group (estimate: 3.8%; 95% CI: 0.5, 7.5), with the AE of hypokalaemia being the basis for this treatment difference.

Table 20 Analysis of Subjects with DrugRelated Adverse Events (Incidence ≥ 4 Subjects in One or More Treatment Groups) - All Subjects as Treated

-10.2 (-17.9, -2.4)

-1.4 (-3.9, 0.7)

-0.7 (-2.9, 1.3)

0.7 (-1.3, 2.9)

0.3 (-3.1, 3.8)

1.4 (-1.3, 4.3)

|                                           | Posaconazole   | Posaconazole   | Voriconazole   | Voriconazole   | Difference in %vs Voriconazole   |
|-------------------------------------------|----------------|----------------|----------------|----------------|----------------------------------|
|                                           | n              | (%)            | n              | (%)            | Estimate (95% CI) †              |
| Subjects in population                    | 288            |                | 287            |                |                                  |
| with one or more adverse events           | 86             | (29.9)         | 115            | (40.1)         | -10.2 (-17.9, -2.4)              |
| with no adverse events                    | 202            | (70.1)         | 172            | (59.9)         | 10.2 (2.4, 17.9)                 |
| Blood and lymphatic system disorders      | 2              | (0.7)          | 6              | (2.1)          | -1.4 (-3.9, 0.7)                 |
| Eye disorders                             | 5              | (1.7)          | 28             | (9.8)          | -8.0 (-12.2, -4.5)               |
| Dyschromatopsia                           | 0              | (0.0)          | 6              | (2.1)          | -2.1 (-4.5, -0.8)                |
| Photopsia                                 | 2              | (0.7)          | 6              | (2.1)          | -1.4 (-3.9, 0.7)                 |
| Vision blurred                            | 3              | (1.0)          | 10             | (3.5)          | -2.4 (-5.4, -0.0)                |
| Visual impairment                         | 0              | (0.0)          | 6              | (2.1)          | -2.1 (-4.5, -0.8)                |
| Gastrointestinal disorders                | 23             | (8.0)          | 25             | (8.7)          | -0.7 (-5.4, 3.9)                 |
| Abdominal pain                            | 2              | (0.7)          | 4              | (1.4)          | -0.7 (-2.9, 1.3)                 |
| Diarrhoea                                 | 4              | (1.4)          | 2              | (0.7)          | 0.7 (-1.3, 2.9)                  |
| Nausea                                    | 12             | (4.2)          | 11             | (3.8)          | 0.3 (-3.1, 3.8)                  |
| Vomiting                                  | 9              | (3.1)          | 5              | (1.7)          | 1.4 (-1.3, 4.3)                  |
| General disorders and administration site | 7              | (2.4)          | 8              | (2.8)          | -0.4 (-3.3, 2.5)                 |

<div style=\"page-break-after: always\"></div>

0.3 (-2.0, 2.8)

1.4 (-2.9, 5.7)

0.7 (-3.3, 4.7)

-3.1 (-6.7, 0.1)

1.0 (-1.6, 3.9)

0.3 (-1.8, 2.6)

-2.1 (-5.2, 0.7)

1.0 (-0.7, 3.2)

-1.4 (-3.7, 0.4)

| conditions                                  |    |        |    |        |                   |
|---------------------------------------------|----|--------|----|--------|-------------------|
| Hepatic function abnormal                   | 5  | (1.7)  | 4  | (1.4)  | 0.3 (-2.0, 2.8)   |
| Investigations                              | 43 | (14.9) | 35 | (12.2) | 2.7 (-2.9, 8.4)   |
| Alanine aminotransferase increased          | 22 | (7.6)  | 18 | (6.3)  | 1.4 (-2.9, 5.7)   |
| Aspartate aminotransferase increased        | 18 | (6.3)  | 16 | (5.6)  | 0.7 (-3.3, 4.7)   |
| Blood alkaline phosphatase increased        | 7  | (2.4)  | 16 | (5.6)  | -3.1 (-6.7, 0.1)  |
| Blood bilirubin increased                   | 8  | (2.8)  | 5  | (1.7)  | 1.0 (-1.6, 3.9)   |
| Blood lactate dehydrogenase increased       | 4  | (1.4)  | 3  | (1.0)  | 0.3 (-1.8, 2.6)   |
| Gamma-glutamyltransferase increased         | 5  | (1.7)  | 11 | (3.8)  | -2.1 (-5.2, 0.7)  |
| Total bile acids increased                  | 0  | (0.0)  | 4  | (1.4)  | -1.4 (-3.5, -0.1) |
| Metabolism and nutrition disorders          | 18 | (6.3)  | 7  | (2.4)  | 3.8 (0.5, 7.5)    |
| Decreased appetite                          | 4  | (1.4)  | 1  | (0.3)  | 1.0 (-0.7, 3.2)   |
| Metabolism and nutrition disorders          | 18 | (6.3)  | 7  | (2.4)  | 3.8 (0.5, 7.5)    |
| Hypokalaemia                                | 11 | (3.8)  | 1  | (0.3)  | 3.5 (1.4, 6.4)    |
| Nervous system disorders                    | 9  | (3.1)  | 14 | (4.9)  | -1.8 (-5.3, 1.6)  |
| Psychiatric disorders                       | 6  | (2.1)  | 22 | (7.7)  | -5.6 (-9.5, -2.2) |
| Hallucination                               | 4  | (1.4)  | 12 | (4.2)  | -2.8 (-5.9, -0.1) |
| Hallucination, visual                       | 1  | (0.3)  | 5  | (1.7)  | -1.4 (-3.7, 0.4)  |
| Renal and urinary disorders                 | 4  | (1.4)  | 3  | (1.0)  | 0.3 (-1.8, 2.6)   |
| Respiratory, thoracic mediastinal disorders | 5  | (1.7)  | 3  | (1.0)  | 0.7 (-1.5, 3.1)   |
| and                                         |    |        |    |        |                   |
| Skin and subcutaneous tissue disorders      | 5  | (1.7)  | 12 | (4.2)  | -2.4 (-5.6, 0.4)  |

† Based on Miettinen &amp; Nurminen method.

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title.

Estimated differences and confidence intervals are provided in accordance with the statistical analysis plan.

Adverse events are reported from the first dose of study treatment through 30 days after the last dose.

The CHMP considered that, in this study, the safety profile for POS was well established. Adverse events incidence was high in all groups, which was expected in this critically ill population.

In this critically ill population, the most frequently reported AEs were hypokalaemia, pyrexia, nausea, vomiting, diarrhoea, ALT increased, and febrile neutropenia in the POS group

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Death

A total of 173 (30.1%) subjects died during the full study period, through Day 114. In the POS group, no subject had a drug-related AE that resulted in death. In the VOR group, 3 subjects had drug-related AEs (pancreatitis, cerebral disorder, encephalopathy) that resulted in death.

## Other Serious Adverse Events

The proportions of subjects with SAEs were generally comparable across both groups, as were the proportions of subjects with drug-related SAEs, discontinuations due to SAEs, and discontinuations due to drug-related SAEs.

The frequencies and types of SAEs were generally comparable in both treatment groups, with the exception of SAEs of hypokalaemia and haemoptysis, which were reported more frequently in the POS group (n=4 each SAE) than in the VOR group (n=0 each SAE).

The overall proportion of subjects with drug-related SAEs was  7.0% in each group. The most commonly reported drug-related SAEs were ALT increased (n=3) in the POS treatment group and encephalopathy (n=3) in the VOR treatment group.

## Adverse Events of Special Interest -Analysis of Adverse Events by Organ System or Syndrome

## Hepatic Safety Events

Tier1 hepatic safety events comprised AST or ALT laboratory values ≥ 3xULN together with both an elevated total bilirubin value ≥ 2xULN and an alkaline phosphatase value &lt; 2xULN.

Comparable rates of Tier-1 hepatic safety events were noted for subjects in POS (3.8%) and VOR (3.5%) treatment groups.

## Central Nervous System and Visual Safety Events

Approximately one-third of subjects in each treatment group experienced an AE in the CNS and visual safety cat. A lower proportion of subjects in the POS group (6.6%) reported AEs in the SOC of Eye disorders compared with the VOR group (12.5%).

Treatment differences were not observed in the incidence of Tier-1 AEs associated with the SOCs of Nervous System disorders (POS: 20.8%; VOR: 18.5%) or Psychiatric disorders (POS: 12.2%; VOR: 16.4%). Within the Psychiatric disorders SOC, the most commonly reported Tier-1 AEs were confusional state (3.5% in the POS group, 5.6% in the VOR group) and hallucination (2.1% and 5.2%, respectively); the between-group treatment difference (-3.1%; 95% CI: -6.6, -0.1) in the incidence of hallucination favored POS.

## Treatment-related Central Nervous System and Visual Safety Events

The overall proportion of subjects with drug-related AEs reported in the CNS and visual safety category was lower in the POS group (5.6%) compared with the VOR group (16.4%).

The incidence of drug-related Tier-1 AEs classified within the SOC of Eye disorders was lower in POS-treated subjects (1.7%) than in VOR-treated subjects (9.4%) (-7.7%; 95% CI: -11.8, -4.2). Specifically, drug-related AEs of dyschromatopsia, vision blurred, and vision impairment occurred less frequently in the POS group than in the VOR group.

There were no notable between-group differences in drug-related Tier-1 AEs associated with the SOC of Nervous System disorders.

<div style=\"page-break-after: always\"></div>

A difference in the incidence of drug-related Tier-1 AEs for the SOC of Psychiatric disorders was observed, with a lower proportion of POS-treated subjects (2.1%) experiencing AEs classified for the Psychiatric disorder SOC compared with VOR-treated subjects (6.6%) (-4.5%; 95% CI: -8.3, -1.3). In particular, it was noted that the incidence of drug-related hallucination was lower in POS-treated subjects (1.4%) than in VOR-treated subjects (4.2%).

The most frequently reported (incidence ≥1%) drug -related CNS and visual safety AEs were as follows:

- POS treatment group: hallucination (1.4%) and vision blurred (1.0%)
- VOR treatment group: hallucination (4.2%), vision blurred (3.5%), dyschromatopsia (2.1%), photopsia (2.1%), visual impairment (2.1%), visual hallucination (1.7%), dizziness (1.0%), and encephalopathy (1.0%).

## Serious Central Nervous System and Visual Safety Events

The overall proportion of subjects with SAEs in the Nervous System or Eye Disorder SOC was low in the POS (3.8%) and VOR (5.6%) treatment groups. There were no meaningful treatment differences in the incidences of SAEs categorized within the SOCs of Eye disorders, Nervous System disorders, or Psychiatric disorders, and there were no meaningful differences in SAEs within these SOCs leading to treatment discontinuations.

## Dermatologic Events

The incidences of subjects who had a Tier-1 AE in the dermatologic reactions category (i.e., prespecified PTs in the SOCs of Immune System disorders and Skin and Subcutaneous Tissue disorders were comparable in the POS (16.3%) and VOR (19.2%) treatment groups. The most frequently reported AE in the dermatologic reactions category was rash (approximately 7% in each treatment group).

There were no drug-related AEs within the SOC of Immune System disorders. The incidence of drugrelated AEs categorized as Skin and Subcutaneous Tissue disorders was low in both treatment groups.

## Events Related to Adrenal Steroidogenesis or Hypotension

Comparable incidences of AEs in the Adrenal Steroidogenesis category (i.e., prespecified PTs in the SOCs of Endocrine disorders and Vascular disorders) were reported for subjects in the POS (8.0%) and VOR (7.0%) treatment groups. Hypotension was reported by approximately 7% of subjects in each group.

Two subjects, both in the POS group, had drug-related AEs in either the Endocrine disorder SOC or Vascular disorder SOC. One subject had drug-related adrenal insufficiency, and 1 subject had drugrelated hypotension.

## Most Frequently Reported Adverse Events by Posaconazole Plasma Concentration Quartile

Exposure-safety relationships of POS by quartile of exposure were evaluated for all AEs as well as treatment-related AEs. Exposure Cmin quartiles were: 244 to 1046 ng/mL (Q1); 1046 to 1625 ng/mL (Q2); 1625 to 2274 ng/mL (Q3); and 2274 to 5550 ng/mL (Q4). The range of POS trough concentrations was consistent with the known exposure profile of POS IV and POS tablet.

In the evaluation of exposure-safety relationships of POS by quartile of exposure, there were no meaningful differences in the AE incidence overall or for any given SOC across quartile exposure ranges. Additionally there were analyses (bimodal) for specific AEs of interest that did not suggest a trend of exposure with the occurrence of these AEs.

<div style=\"page-break-after: always\"></div>

Of those AEs reported by ≥10% of subjects, the incidence of any given AE or of all AEs within a given SOC category was not notably different across the exposure quartiles, or did not follow any overall pattern with respect to increasing exposure, with few exceptions, including ALT increased. The AEs of pyrexia, AST increased, hypomagnesemia, fatigue, and asthenia were reported more frequently for subjects in Q4 relative to those in Q1. The reverse was true for subjects in Q1 who generally had a higher prevalence of diarrhea, dyspnea, bacteremia, and neutropenia than did subjects in Q4. Given this critically-ill population, and the variability of AE incidence across the quartile ranges of exposure, these findings are not considered clinically meaningful.

## Adverse Events Related to Study Treatment by Posaconazole Plasma Concentration Quartile

Among subjects with available trough plasma POS concentrations, there was a trend toward a higher incidence of drug-related AEs in the highest quartile of POS exposure relative to lower-exposure quartiles 1. Specifically, a higher incidence of drug-related ALT increased, nausea, and vomiting were noted with higher POS exposures relative to lower trough plasma concentrations. While there is a trend of a higher incidence of drug-related AEs in quartile 4 compared with quartile 1 or 2, it is a modest one, and its non-monotonic increase with exposures is not suggestive of a strong PK relationship.

Figure 11 Proportion of Subjects with Treatment-Related AEs by Quartile of Within-Subjects Mean Posaconazole Trough Concentration

<!-- image -->

This observation is in contrast to that reported for earlier studies of POS IV (Study P05520; MK-5592-059) and POS tablet (Study P05615; MK-5592-065) in which the same dosing regimen was used (300 mg/day after BID dosing on Day 1 with QD dosing thereafter) given as antifungal prophylaxis to patients at high risk for an IFI. Exposure-safety quartile relationships for these 2 earlier studies were evaluated across a similar range of exposures.

For the earlier POS tablet study described above, a quartile analysis (n= 205) found no discernible correlation between POS plasma exposures and safety in terms of AEs or drug-related AEs, including no correlation between higher POS exposure and an increase in hepatic or cardiac AEs. Specifically, the

<div style=\"page-break-after: always\"></div>

incidence of drug-related AEs was lower for the fourth highest quartile of exposure when compared with the first lowest quartile of exposure (38% versus 57%).

Exposure-safety findings for the POS IV study P05520 were similar. Overall, the safety profiles in P05520 and P05616 for those subjects who achieved high POS exposures following administration of POS IV and POS tablet, respectively, are consistent with the safety profiles for those subjects who achieve normal/low POS exposures. In these 2 studies, no new safety signals were identified in subjects with high POS exposures, and specific AEs expected to be seen with POS were not more commonly seen in the high-exposure group.

The CHMP noted that, in the POS group, no subject had a drug-related AE that resulted in death

The frequencies and types of SAEs were generally comparable in both treatment groups, with the exception of SAEs of hypokalaemia and haemoptysis, which were reported more frequently in the POS group. Therefore, the Committee asked the MAH to explain this difference and also discuss if these events were the drug-related.

The MAH reviewed the reports of serious adverse events of hypokalaemia and hemoptysis (4 each) in P069. In line with the investigators' assessment , the MAH considered none of this SAEs drugrelated. This was endorsed by the CHMP.

The CHMP considered that treatment differences were not observed in the incidence of Tier-1 AEs associated with the SOCs of Nervous System disorders or Psychiatric disorders (POS: 12.2%; VOR: 16.4%). Within the Psychiatric disorders SOC, the most commonly reported Tier-1 AEs were confusional state and hallucination.

The most frequently reported AE in the dermatologic reactions category was rash (approximately 7% in each treatment group).

There were no drug-related AEs within the SOC of Immune System disorders. The incidence of drugrelated AEs categorized as Skin and Subcutaneous Tissue disorders was low in both treatment groups.

Comparable incidences of AEs in the Adrenal Steroidogenesis category (i.e. prespecified PTs in the SOCs of Endocrine disorders and Vascular disorders) were reported for subjects in the POS and VOR treatment groups. Hypotension was reported by approximately 7% of subjects in each group.

Two subjects, both in the POS group, had drug-related AEs in either the Endocrine disorder SOC or Vascular disorder SOC. One subject had drug-related adrenal insufficiency, and 1 subject had drugrelated hypotension.

The CHMP considered that, in this study, the safety profile of POS was well established.

Among subjects with available trough plasma POS concentrations, there was a trend toward a higher incidence of drug-related AEs in the highest quartile of POS exposure relative to lower-exposure quartiles 1. Specifically, a higher incidence of drug-related ALT increased, nausea, and vomiting were noted with higher POS exposures relative to lower trough plasma concentrations. While there is a trend of a higher incidence of drug-related AEs in quartile 4 compared with quartile 1 or 2 . This observation is in contrast to that reported for earlier studies of POS IV (Study P05520; MK-5592-059) and POS tablet (Study P05615; MK-5592-065). According to the MAH, this difference may be attributed, at least in part, to differences in bioavailability between formulations (tablet bioavailability 54% under fasting conditions). It may also reflect that subjects who remained on IV

<div style=\"page-break-after: always\"></div>

were more seriously ill and unable to transition to an oral formulation since a similar trend (higher IV concentration) was observed for VOR, which has high oral bioavailability (96%). With regard to an evaluation of the effect of food on POS tablet absorption, the modest (15% to 39%, depending on time point) increase in POS exposure when POS tablets were administered with a meal versus fasting is not considered to be clinically meaningful. A detailed comparison of POS exposure across studies based on a population PK analysis was reported separately.

## Laboratory findings

There were comparable rates of hepatic function elevations for the 2 treatment groups. In particular, with regards to the incidence of prespecified Tier1 hepatic safety event (AT ≥3  ULN and BILI ≥2  ULN and ALP &lt;2  ULN), there was no evidence of an increase in Tier-1 hepatic events for POS compared with VOR (3.9% vs 3.5%, respectively).

## Electrocardiogram findings

ECG data were collected in accordance with the protocol, which included stipulation that subjects on IV therapy have their Week 1 ECG performed at the completion of the 90-minute infusion to coincide with the time of anticipated Cmax and plasma sample collection. No clinically meaningful ECG findings were noted at the time of Cmax in subjects on IV therapy; therefore, an exposure-ECG-response analysis was not conducted.

For ECG findings meeting predetermined criteria, POS-treated subjects, relative to VOR-treated subjects, had a lower incidence of QTc &gt;500 msec, QTc increases from baseline &gt;60 msec, and any change in prespecified QTc parameters.

## Discontinuation due to adverse events

AEs leading to treatment discontinuation were reported for 33.9% of subjects.

Drug-related AEs leading to treatment discontinuation were reported for 8.0% of subjects. Fewer POStreated subjects (6.3%) discontinued treatment for a drug-related AE compared with VOR-treated subjects (9.8%). In both groups, drug-related AEs leading to treatment discontinuation were most commonly classified within the SOCs of Investigations, Nervous System disorders, and Psychiatric disorders. The most commonly reported drug-related AE leading to treatment discontinuation in both groups was hallucination (n=3 in each group).

SAEs leading to treatment discontinuation were reported for 27.5% of subjects. The most frequently reported SAEs leading to treatment discontinuation were septic shock (2.8%) and respiratory failure (2.4%) in the POS group, and septic shock (2.8%) and acute myeloid leukaemia (2.8%) in the VOR group.

The CHMP noted that fewer POS-treated subjects (6.3%) discontinued treatment for a drug-related AE compared with VOR-treated subjects (9.8%). The most commonly reported drug-related AE leading to treatment discontinuation in both groups was hallucination (n=3 in each group).

## Post marketing experience

POS has been registered and approved in more than 70 countries since its first approval on 25-Oct-2005. Currently there are 3 marketed formulations of POS: oral suspension, delayed-release tablet, and concentrate for solution for IV infusion. There are no records of any registration being revoked or withdrawn for safety reasons. The benefit-risk information on POS received by the MAH 's

<div style=\"page-break-after: always\"></div>

AE reporting and review system has been summarized in the PSUR and is currently conducted on a 3-year cycle in the EU.

Cumulative post-marketing exposure for POS was calculated from information provided by IMS Health, the MAH 's internal distribution data from the Worldwide Financial Reporting System, and the Financial Sharing Area databases. Total cumulative patient exposure for POS through 25-Oct-2019 was approximately 107,572 patient-years of treatment (46,987 for the OS; 59,590 for tablets; and 995 for the IV formulation).

As of 25-Oct-2019, there were 6240 AE reports containing 13,091 events (7725 nonserious, 5366 serious) from spontaneous and noninterventional postmarketing study reports in the Company's global safety database. There were no new safety signals identified in the most recent PSUR for POS.

A cumulative analysis of post-marketing AEs, as of 25-Oct-2019, did not identify new safety issues for POS. The safety profile revealed by the current analysis is consistent with those presented in PSURs submitted to date and those in the product label. The overall benefit-risk balance for POS continues to be positive for use in the approved indications. The MAH will continue to monitor the safety of POS through established routine pharmacovigilance processes.

A cumulative analysis of post-marketing AEs, as of 25-Oct-2019, did not identify new safety issues for POS. The overall benefit-risk balance for POS continues to be positive for use in the approved indications. The MAH will continue to monitor the safety of POS through established routine pharmacovigilance processes.

## 2.5.1. Discussion on clinical safety

The safety findings of this study were consistent with those reported for prior clinical studies of POS in prophylaxis and secondary invasive fungal infection treatment. POS was well tolerated and, while almost all subjects had one or more reported AEs, most frequently these were AEs representing the underlying disease conditions of immunosuppression and hematologic malignancy requiring treatment. The high frequency of co-morbid conditions impedes the ability to identify drug-associated toxicity when considering the overall AE profile. Therefore, an evaluation of drug-related AEs is useful in identifying and comparing drug-associated toxicities between the study treatment.

Overall, drug-related AEs were less frequently reported with POS treatment than with VOR treatment (29.9% vs 40.1% respectively). With regard to specific categories of drug-related AEs, visual and psychiatric disorders were more common with VOR treatment, while hypokalaemia was more common with POS treatment. Comparable rates of gastrointestinal disorders and hepatic disorders were reported across the treatment groups. In addition to the higher rates of drug-related visual and psychiatric AEs among VOR-treated subjects, there was also a higher rate of discontinuation of VORtreated than POS-treated subjects due to drug-related AEs overall. The lack of tolerance to VOR has been previously reported to limit the ability to complete a necessary course of antifungal therapy, which is of concern when treating a life-threatening infection such as IA. The safety findings for P069 are similar to those reported in the prior comparative study of ISA vs. VOR where VOR-treated subjects had higher rates of drug-related visual and psychiatric AEs, with a rate similar to those reported in this study.

Overall, POS exposure in this study, as measured by trough plasma concentration, was within the range observed in prior clinical trials of POS IV and tablet. In a prior study of POS IV 300 mg QD (BID on Day 1), POS IV administration resulted in a mean trough concentration of 1320 ng/mL at steady state. In a similar study, POS tablet 300 mg QD (BID on Day 1) resulted in a mean trough concentration of 1720 ng/mL at steady state. In the current study, POS plasma trough concentrations were higher throughout the course of study treatment in subjects who received POS exclusively via IV

<div style=\"page-break-after: always\"></div>

administration. This difference may be attributed, at least in part, to differences in bioavailability between formulations (tablet bioavailability 54% under fasting conditions. It may also reflect that subjects who remained on IV were more seriously ill and unable to transition to an oral formulation since a similar trend (higher IV concentration) was observed for VOR, which has high oral bioavailability (96%). With regard to an evaluation of the effect of food on POS tablet absorption, the modest (15% to 39%, depending on time point) increase in POS exposure when POS tablets were administered with a meal versus fasting is not considered to be clinically meaningful. A detailed comparison of POS exposure across studies based on a population PK analysis will be reported separately.

Exposure-safety relationships of POS by quartile of exposure were evaluated for all AEs as well as for drug-related AEs. While there was no relationship between exposure and the incidence of reported AEs overall (regardless of investigator-reported relationship), an association was seen between higher exposure (top quartile of exposure) and the incidence of drug-related AEs. This association has not been noted in prior studies of POS IV or tablet in which similar or higher exposures have been achieved. Similarly, with POS oral suspension, no exposure-safety adverse relationship has been noted, although exposures with the oral suspension are generally lower than those achieved with the IV or tablet formulations. A potential contributing factor to the observed association in the current study is that a larger proportion of subjects who were more seriously ill were likely to have been receiving the IV formulation rather than the tablet formulation, and thus would likely have had higher exposures. Furthermore, the severity of their illness would have led to a higher incidence of AEs. No association between POS exposure and Tier 1 AEs, and no relevant effect on QTc at the time of Cmax, was seen. Overall, the safety profile of POS IV and tablet in P069 was similar to that reported in POS product labelling of POS IV, tablet, and oral suspension.

## 2.5.2. Conclusions on clinical safety

POS is generally well tolerated, with fewer drug-related AEs in POS-treated than in VOR-treated subjects. The overall AE profile of POS-treated subjects in P069 is consistent with the safety profile established in current product labelling of POS IV and tablet and periodic safety reporting for POS IV and tablet.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 3. Risk management plan

The MAH submitted an RMP version (16.2, data lock point 01 February 2020, dated 10 September 2020) with this application to support the use of posaconazole for the treatment of invasive aspergillosis in adults, and the update to the safety concerns (important identified risks, important potential risks and missing information) for posaconazole following the completion of the Post Authorisation Efficacy Study in adults (PN069). The summary of significant changes in this RMP are:

<div style=\"page-break-after: always\"></div>

| RMP Part/Module                                                                                                                                                                                              | Major change(s)                                                                                                                      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| PART I Product Overview                                                                                                                                                                                      | Added 'treatment of invasive aspergillosis' as new indication                                                                        |
| PART II Safety Specification Module SII Non-clinical part of the safety specification Module SIII Clinical trial exposure                                                                                    | Updated the clinical implication of safety pharmacology findings in Table SII.1 Updated overall exposure and demographic information |
| Module SIV Populations not studied in trials                                                                                                                                                                 |                                                                                                                                      |
| clinical                                                                                                                                                                                                     | Updated to include exposure from PN069                                                                                               |
| Module SVII.2 New Safety Concerns and Reclassification with a Submission of an Updated RMP                                                                                                                   | Removed 6 Important Identified Risks, 7 Important Potential Risks, 1 Missing Information                                             |
| Module SVII.3.2 Presentation of the Missing Information                                                                                                                                                      | Removed Use in patients with hepatic impairment Summary                                                                              |
| Module SVIII Summary of safety concerns                                                                                                                                                                      | Updated safety concerns table                                                                                                        |
| PART III Pharmacovigilance Plan (including Post Authorisation Safety Studies) Module III.1 Routine Pharmacovigilance Activities                                                                              | Removed PN069 as another form of routine pharmacovigilance activities                                                                |
| PART IV Plans for Post Authorisation Efficacy Studies                                                                                                                                                        | Updated to reflect completion of PN069                                                                                               |
| PART V Risk Minimisation Measures (including evaluation of the effectiveness of risk minimisation activities) Module V.1 Routine Risk Minimization Measures Module V.3 Summary of Risk Minimization Measures | Updated according to revised safety concerns Updated according to revised safety concerns                                            |
| PART VI Summary of the Risk Management Plan by Product                                                                                                                                                       | Updated indications and safety concerns                                                                                              |

The (main) proposed RMP changes were the following:

## PART II SAFETY SPECIFICATION

## Module SVII Identified and potential risks

## SVII.2. New safety concerns and reclassification with a submission of an updated RMP

The MAH proposes to remove the important identified risks 'Elevated liver enzymes', 'Hepatotoxicity', 'Hepatic failure', 'Hepatitis', 'Thrombotic thrombocytopenia purpura', 'Hemolytic uremic syndrome', 'Torsade de Pointes/QTc prolongation', 'Drug interaction', 'Adrenal Insufficiency' and 'Hypokalaemia' as identified risks that are not considered important for i nclusion in the RMP, in accordance with GVP Module V (Rev 2), and therefore to remove from the list of safety concerns. The

<div style=\"page-break-after: always\"></div>

rationales (summarized) for the proposed changes to the list of safety concerns are briefly presented below.

The MAH proposes to reclassify the important potential risks 'Heart failure', 'Myocardial infarction', 'Convulsion', 'Pulmonary haemorrhage', 'Hypertension', 'Venous thrombosis', 'Photopsia', 'Visual brightness' and 'Visual disturbances' as potential risks that are not considere d important for inclusion in the RMP, therefore to remove from the list of safety concerns. The rationales (summarized) for the proposed changes to the list of safety concerns are briefly presented below.

The MAH proposes to remove the Missing Information 'Use in patients with hepatic impairment' based on the completion of Study PN069. The rationales (summarized) for the proposed changes to the list of safety concerns are briefly presented below.

## Important Identified Risks removed from the List of Safety Concerns

## Elevated liver enzymes; Hepatotoxicity, Hepatic failure, Hepatitis

Elevated liver enzymes, hepatotoxicity, hepatic failure and hepatitis have been removed from the list of Important Identified Risks. No new safety concerns related to elevated liver enzymes, hepatotoxicity, hepatic failure and hepatitis have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative postmarketing data through 01-Feb-2020. No additional PV activities are ongoing or planned as the risk has been well-characterised and the risk is mitigated by routine risk minimization measures provided in the Product Information including the recommendation for liver function monitoring in the Special warnings and precautions of the SmPC and as an adverse reaction seen in clinical trials and/or post-marketing use under Undesirable effects in the SmPC.

Since routine PV activities and routine risk minimization measures are considered to be sufficient to support a favourable benefit-risk profile, no new clinical studies will be performed to further characterise this identified risk. Therefore, elevated liver enzymes, hepatotoxicity, hepatic failure and hepatitis have been removed from the list of Important Identified Risks. The MAH will continue to monitor elevated liver enzymes, hepatotoxicity, hepatic failure and hepatitis through routine PV.

## Thrombotic Thrombocytopenic Purpura and Haemolytic Uremic Syndrome

Thrombotic thrombocytopenic purpura and haemolytic uremic syndrome have been removed from the list of Important Identified Risks. No new safety concerns related to thrombotic thrombocytopenic purpura and haemolytic uremic syndrome have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative postmarketing data through 01-Feb-2020. No additional PV activities are ongoing or planned as the risk has been well-characterised and routine PV activities support a favourable risk-benefit profile. The risk is mitigated by routine risk minimization activities that are provided in the Product Information, which lists thrombotic thrombocytopenic purpura and haemolytic uremic syndrome as rare adverse reactions reported in clinical trials and/or post-marketing use in the Undesirable effects section of the SmPC. No additional risk minimization activities are planned as these routine measures are considered to be sufficient. No further clinical trials or non-interventional studies will be performed to further characterise this identified risk. Therefore, thrombotic thrombocytopenic purpura and haemolytic uremic syndrome have been removed from the list of Important Identified Risks. The MAH will continue to monitor thrombotic thrombocytopenic purpura and haemolytic uremic syndrome through routine PV.

## Torsade de Pointes and QTc prolongation

Torsade de Pointes and QTc prolongation have been removed from the list of Important Identified Risks.  No new safety concerns related to torsade de pointes and QTc prolongation have been identified

<div style=\"page-break-after: always\"></div>

in the recently completed IA treatment study (PN069), and a review of the cumulative postmarketing data through 01-Feb-2020.  No additional PV activities are ongoing or planned as the risk has been well-characterised and routine PV activities support a favourable risk-benefit profile. The risk is mitigated by routine risk minimization activities that are provided in the Product Information, including medications that should not be co-administered with posaconazole due to increased risk of QTc prolongation or torsades de pointes in the Contraindications section of the SmPC, the recommendation to use with caution in patients with pro-arrhythmic conditions in the Special warnings and precautions for use section of the SmPC, and torsade de pointes and QTc prolongation as uncommon adverse reactions seen in clinical trials and/or post-marketing use under Undesirable effects in the SmPC.

No additional risk minimization activities are planned as these routine measures are considered to be sufficient. No further clinical trials or non-interventional studies will be performed to further characterise this identified risk. Therefore, torsade de pointes and QTc prolongation have been removed from the list of Important Identified Risks. The MAH will continue to monitor torsade de pointes and QTc prolongation through routine PV.

## Drug Interaction

Drug interaction has been removed from the list of Important Identified Risks. No new safety concerns related to drug interaction have been identified in the recently completed IA treatment study (PN069) and the review of cumulative postmarketing data through 01-Feb-2020. No additional PV activities are ongoing or planned as the risk has been well-characterised and routine PV activities support a favourable risk-benefit profile. The risk of drug interactions pertaining to CYP3A inhibition in particular is mitigated by routine risk minimization activities that are provided in the Product Information including information regarding medications that are contraindicated for coadministration with posaconazole in the Contraindications section of the SmPC and information regarding use with other medications metabolized by CYP3A4 under Special warnings and precautions for use in the SmPC.

No additional risk minimization activities are planned as these routine measures are considered to be sufficient. No further clinical trials or non-interventional studies will be performed to further characterise this identified risk. Therefore, drug interaction has been removed from the list of Important Identified Risks. The MAH will continue to monitor drug interaction through routine PV.

## Adrenal Insufficiency

Adrenal insufficiency has been removed from the list of Important Identified Risks.  No new safety concerns related to adrenal insufficiency have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative post-marketing data through 01-Feb-2020. No additional PV activities are planned as the risk has been well-characterised and routine PV activities support a favorable risk-benefit profile. The risk is mitigated by routine risk minimization activities that are provided in the Product Information, which lists adrenal insufficiency as an adverse reaction reported in clinical trials and/or post-marketing use under the Undesirable effects section of the SmPC. No additional risk minimization activities are planned as these routine measures are considered to be sufficient. No further clinical trials or non-interventional studies will be performed to further characterize this identified risk. Therefore, adrenal insufficiency has been removed from the list of Important Identified Risks. The MAH will continue to monitor adrenal insufficiency through routine PV.

## Hypokalaemia

Hypokalaemia has been removed from the list of Important Identified Risks.  No new safety concerns related to hypokalaemia have been identified in the recently completed IA treatment study (PN069), and a review of cumulative post-marketing data through 01-Feb-2020. No additional PV activities are planned as the risk has been well-characterised and routine PV activities support a favourable risk-

<div style=\"page-break-after: always\"></div>

benefit profile. The risk is mitigated by routine risk minimization activities that are provided in the Product Information, which lists hypokalaemia as a common adverse reaction reported in clinical trials and/or post-marketing use under the Undesirable effects section of the SmPC. No additional risk minimization activities are planned as these routine measures are considered to be sufficient. No further clinical trials or non-interventional studies will be performed to further characterise this identified risk. Therefore, hypokalaemia has been removed from the list of Important Identified Risks. The MAH will continue to monitor hypokalaemia through routine PV.

## Important Potential Risks removed from the List of Safety Concerns

## Heart failure

Heart failure has been removed from the list of Important Potential Risks. No new safety concerns related to heart failure have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative postmarketing data through 01-Feb-2020. No additional PV activities are planned as the risk has been well-characterised and routine PV activities support a favourable riskbenefit profile. The risk is mitigated by routine risk minimization activities that are provided in the Product Information, which lists heart failure as a rare adverse reaction reported in clinical trials and/or post-marketing use under the Undesirable effects section of the SmPC. No additional risk minimization activities are planned as routine measures are considered to be sufficient. No further clinical trials or non-interventional studies will be performed to further characterise this potential risk. Therefore, heart failure has been removed from the list of Important Potential Risks. The MAH will continue to monitor heart failure through routine PV.

## Myocardial Infarction

Myocardial Infarction has been removed from the list of Important Potential Risks. No new safety concerns related to myocardial infarction have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative post-marketing data through 01-Feb-2020. No additional PV activities are planned as the risk has been well-characterised and routine PV activities support a favourable risk-benefit profile. The risk is mitigated by routine risk minimization activities that are provided in the Product Information, which lists myocardial infarction as a rare adverse reaction reported in clinical trials and/or post-marketing use under the Undesirable effects section of the SmPC. No additional risk minimization activities are planned as routine measures are considered to be sufficient. No clinical trials or non-interventional studies will be performed to further characterize this potential risk. Therefore, myocardial infarction has been removed from the list of Important Potential Risks. The MAH will continue to monitor myocardial infarction through routine PV.

## Convulsion

Convulsion has been removed from the list of Important Potential Risks. No new safety concerns related to convulsion have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative post-marketing data through 01-Feb-2020. No additional PV activities are ongoing or planned as the risk has been well-characterised and routine PV activities support a favourable risk-benefit profile. The risk is mitigated by routine risk minimization activities that are provided in the Product Information, which lists convulsion as an uncommon adverse reaction reported in clinical trials and/or post-marketing use under the Undesirable effects section of the SmPC. No additional risk minimization activities are planned as routine measures are considered to be sufficient. No clinical trials or non-interventional studies will be performed to further characterise this potential risk. Therefore, convulsion has been removed from the list of Important Potential Risks. The MAH will continue to monitor convulsion through routine PV.

<div style=\"page-break-after: always\"></div>

## Pulmonary Haemorrhage

Pulmonary Haemorrhage has been removed from the list of Important Potential Risks. A review of safety data from the recently completed IA treatment study (PN069) and the cumulative postmarketing data through 01-Feb-2020 did not support the initial supposition of potential association between pulmonary haemorrhage and use of posaconazole. The underlying medical conditions such as pulmonary fungal infection and coagulopathy appear to be the more probable causes of pulmonary haemorrhage in patients with haematological malignancy treated with posaconazole. The MAH will continue to monitor reports of pulmonary haemorrhage through routine PV.

## Hypertension

Hypertension has been removed from the list of Important Potential Risks. No new safety concerns related to hypertension have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative post-marketing data through 01-Feb-2020. No additional PV activities are ongoing or planned as the risk has been well-characterised and routine PV activities support a favourable risk-benefit profile. The risk is mitigated by routine risk minimization activities that are provided in the Product Information, which lists hypertension as a common adverse reaction reported in clinical trials and/or post-marketing use under the Undesirable effects section of the SmPC. No additional risk minimization activities are planned as routine measures are considered to be sufficient. No clinical trials or non-interventional studies will be performed to further characterise this potential risk. Therefore, hypertension has been removed from the list of Important Potential Risks. The MAH will continue to monitor hypertension through routine PV.

## Venous Thrombosis

Venous Thrombosis has been removed from the list of Important Potential Risks. No new safety concerns related to venous thrombosis have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative post-marketing data through 01-Feb-2020. No additional PV activities are ongoing or planned as the risk has been well-characterised and routine PV activities support a favourable risk-benefit profile. The risk is mitigated by routine risk minimization activities provided in the Product Information, which lists venous thrombosis as a rare adverse reaction reported in clinical trials and/or post-marketing use under the Undesirable effects section of the SmPC. No additional risk minimization activities are planned as routine measures are considered to be sufficient. No clinical trials or non-interventional studies will be performed to further characterise this potential risk. Therefore, venous thrombosis has been removed from the list of Important Potential Risks. The MAH will continue to monitor venous thrombosis through routine PV.

## Photopsia, Visual Brightness and Visual Disturbances

Photopsia, Visual Brightness, and Visual Disturbances has been removed from the list of Important Potential Risks. No new safety concerns related to photopsia, visual brightness, and visual disturbances have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative post-marketing data through 01-Feb-2020. No additional PV activities are ongoing or planned as the risk has been well-characterised and routine PV activities support a favourable riskbenefit profile. The risk is mitigated by routine risk minimization activities that are provided in the Product Information, which lists eye disorders under adverse reactions reported in clinical trials and/or post-marketing use under the Undesirable effects section of the SmPC. No additional risk minimization activities are planned as routine measures are considered to be sufficient. No further clinical trials or non-interventional studies will be performed to further characterise this potential risk. Therefore, photopsia, visual brightness, and visual disturbances has been removed from the list of Important Potential Risks. The MAH will continue to monitor Photopsia, Visual Brightness, and Visual Disturbances through routine PV.

<div style=\"page-break-after: always\"></div>

The MAH's proposal to remove the important identified risks 'Elevated liver enzymes', 'Hepatotoxicity', 'Hepatic failure', 'Hepatitis', 'Thrombotic thrombocytopenia purpura', ' Haemolytic uremic syndrome', 'Torsade de Pointes/QTc prolongation', 'Drug interaction', 'Adrenal Insufficiency' and 'Hypokalaemia' from the summary of safety concerns as well as the rationales for the proposed changes was endorsed. Routine risk minimisation measures are in place to sufficiently address the risks of ''Elevated liver enzymes', 'Hepatotoxicity', 'Hepatic failure', 'Hepatitis', 'Thrombotic thrombocytopenia purpura', ' Haemolytic uremic syndrome', 'Torsade de Pointes/QTc prolongation', 'Drug interaction', 'Adrenal Insufficiency' and 'Hypokalaemia' is included as an adverse drug reaction in SmPC section 4.3, 4.4, 4.5 and 4.8. In addition, routine pharmacovigilance is sufficient to further characterise these risks. Moreover, according to the revised GVP Module V, risks that do not need further evaluation as part of pharmacovigilance plan or additional risk minimisation activities are recommended to be removed from the list of safety concerns.

The MAH's proposal to remove the important potential risks 'Heart failure', 'Myocardial infarction', 'Convulsion', 'Pulmonary haemorrhage', 'Hypertension', 'Venous thrombosis', 'Photopsia', 'Visual brightness' and 'Visual disturbances' from the summary of safety concerns was also endorsed. Routine pharmacovigilance is sufficient to characterise these risks. No new safety concerns have been identified in the recently completed IA treatment study (PN069), and a review of the cumulative postmarketing data through 01-Feb-2020. Moreover, according to the revised GVP Module V, risks that do not need further evaluation as part of pharmacovigilance plan or additional risk minimisation activities are recommended to be removed from the list of safety concerns.

## Missing information removed from the List of Safety Concerns

## Use in patients with hepatic impairment

Use in patients with hepatic impairment has been removed from the list of Missing Information. No new safety concerns related to use in patients with hepatic impairment have been identified in the recently completed IA treatment study (PN069), as well as a review of post-marketing data through 01-Feb-2020. The safety concern is mitigated by routine risk minimization activities that are provided in the Product Information including the recommendation to exercise caution when posaconazole is used in patients with hepatic impairment in the Posology and method of administration, Special warnings and precautions for use and Pharmacokinetic properties sections of the SmPC.

No additional PV and risk minimization activities are ongoing or planned as routine measures are considered to be sufficient. No new clinical studies will be performed in patients with hepatic impairment to further address this missing information. Therefore, use in patients with hepatic impairment has been removed from the list of Missing Information. The MAH will continue to monitor use in patients with hepatic impairment through routine PV.

The MAH's proposal to remove 'Use in patients with hepatic impairment' classified as missing information was endorsed. No new safety concerns related to use in patients with hepatic impairment have been identified in the recently completed IA treatment study (PN069), as well as a review of post-marketing data through 01-Feb-2020. No additional PV and risk minimization activities are ongoing or planned as routine measures are considered to be sufficient. No new clinical studies will be performed in patients with hepatic impairment to further address this missing information. Moreover, according to the revised GVP Module V, risks that do not need further evaluation as part of pharmacovigilance plan or additional risk minimisation activities are recommended to be removed from the list of safety concerns.

<div style=\"page-break-after: always\"></div>

## Module SVIII Summary of the Safety Concerns

Table SVIII.1 Summary of the Safety Concerns (MAH proposal, removed in red font and strike through)

| Summary of Safety Concerns   | Summary of Safety Concerns                                                                                                                                                                                                                                                                    |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Hepatic : Elevated liver enzymes; Hepatotoxicity; Hepatic failure; Hepatitis Blood : Thrombotic thrombocytopenia purpura; Hemolytic uremic syndrome Cardiac : Torsade de Pointes/QTc prolongation General : Drug interaction Endocrine : Adrenal Insufficiency Metabolism :Hypokalaemia None* |
| Important potential risks    | Cardiac : Heart failure; Myocardial infarction CNS : Convulsion Respiratory : Pulmonary haemorrhage Vascular : Hypertension; Venous thrombosis Visual : Photopsia; Visual brightness; Visual disturbances None*                                                                               |
| Missing information          | Use in patients with hepatic impairment Experience in children                                                                                                                                                                                                                                |

* The important identified or potential risks included in prior versions of the RMP have been removed based the review of accumulating clinical data and the guidance in GVP module 5 (Rev 2), as per routine updates of the RMP during the life cycle of the product.

## PART III PHARMACOVIGILANCE PLAN

There are no ongoing and planned category 1-2 and 3 studies for Noxafil. As part of the routine pharmacovigilance activities, the Company uses event-specific questionnaires to obtain structured information about the following events: hepatic disease, cardiac arrhythmia, QT prolongation, adrenal insufficiency, seizure/convulsion, venous thromboembolism, myocardial infarction, neutropenia/agranulocytosis, cerebrovascular accident, and drug adverse experience.

The PRAC considered that routine pharmacovigilance is sufficient to identify and characterise the risks of the product.

The MAH removed the PN069 study from the Other Forms of Routine Pharmacovigilance Activities for Safety Concerns. This is endorsed.

<div style=\"page-break-after: always\"></div>

## PART IV PLANS FOR POST-AUTHORISATION EFFICACY STUDIES

There are no ongoing or proposed post-authorization efficacy studies (PAES) for posaconazole. This was accepted by the PRAC.

## PART V RISK MINIMISATION MEASURES (INCLUDING EVALUATION OF THE EFFECTIVENESS OF RISK MINIMISATION ACTIVITIES)

The MAH states that routine risk minimisation activities are sufficient to manage the safety concerns of Noxafil. No additional risk minimisation measures are proposed.

The PRAC considered that the proposed routine risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication.

## 3.1. Overall conclusion on the RMP

The changes to the RMP are acceptable.

## 4. Changes to the Product Information

As a result of this variation, sections 4.1, 4.2, 4.8, 5.1 and 5.2, 6.2 and 6.6 of the SmPC were updated. The Package Leaflet (PL) is updated accordingly.

Some editorial PI adjustments were carried out to the suspension SmPC:

The  statement  ' Treatment  should  be  initiated  by  a  physician  experienced  in  the  management  of  fungal infections or in the supportive care in the high-risk patients for which posaconazole is indicated as prophylaxis ' was moved in the oral formulation SmPCs so to appear at the beginning of Section 4.2, as it does in the IV SmPC. The following grammatical amendment to the sentence was also carried out:

Treatment should be initiated by a physician experienced in the management of fungal infections or in the supportive care of in the high-risk patients for which posaconazole is indicated as prophylaxis .

As a result of QRD comments, 'dextrose' (not a standard term in the EU pharmacopoeia) was changed into 'glucose' to comply with the compilation of QRD decisions on use of terms , impacting Sections 6.2 and 6.6 of the SmPC and the relevant section of the PL for the IV formulation.

Additionally, the opportunity was taken to update to the clinical breakpoint of Candida dubliniensis in the Noxafil PI according to the published EUCAST clinical breakpoints.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 5. Benefit-Risk Balance

## 5.1. Therapeutic Context

## 5.1.1. Disease or condition

IA is a serious, life-threatening disease among patients with prolonged and/or severe impairment of the immune system. Without the initiation of antifungal therapy, the acute mortality rate has been shown to exceed 85%. Aspergillus fumigatus is the most common cause of IA.

<div style=\"page-break-after: always\"></div>

## 5.1.2. Available therapies and unmet medical need

Current guidelines for the primary treatment of IA recommend early initiation of antifungal therapy while definitive diagnostic evaluation is in progress. Guidelines recommend VOR and/or ISA for the primary treatment of IA, with liposomal amphotericin B being the first alternative and POS, as well as echinocandins, mainly recommended for salvage treatment. Given the side effects and DDI of VOR and ISA, and the high underlying mortality of IA, a need exists for additional therapies that can overcome the limitations of currently approved IA therapies.

## 5.1.3. Main clinical studies

POS is currently indicated for refractory IA or for patients with intolerance to 1 st  line therapy of IA. The extension of indication of POS for the first-line treatment of IA is based on the non-inferiority study P069. This study was performed in subjects with possible, probable or proven IA, and compare POS vs the first-line treatment VOR.

## 5.2. Favourable effects

POS is non-inferior to VOR for the first-line treatment of adults with IA, based on the rate of all-cause mortality in the ITT population and the global clinical response in the FAS population (i.e. subjects with probable or proven IA) after 6 weeks of treatment. Likewise, non-inferiority was also observed at Week 12. Subgroups analysis support this non-inferiority.

In vitro data from study P069 and surveillance studies show that POS has comparable activity to VOR, ISA, and ITR against Aspergillus spp.

## 5.3. Uncertainties and limitations about favourable effects

There is no relevant efficacy data in paediatric subjects, with only 5 adolescents included in this study.

Only 58% of the baseline IA diagnosis was probable or proven, and a non-negligible proportion of IA diagnosis (14%) cannot be determined at baseline by the CAC. This suggest that an undetermined number of subjects in this study did not actually have IA.

When considering the mortality due to IA (according to the CAC), the results are not at the advantage of POS. At each time points (Day 42, Day 84 and Day 114), the mortality attributed to IA is more frequent in POS group (51.6%, 39.3% and 35.9%, respectively) compared to VOR group (31.3%, 28% and 30.4%, respectively). However, a higher number of indeterminate attributions of death is present in VOR group (56.3% vs 35.5% at Day 42), which could bias the estimation of the mortality due to IA.

The mortality in Asian population is higher in POS group (16%, 10/62) than VOR group (6.7%, 4/60). This higher mortality rate is also observed within the FAS population (POS: 21% (9/43); VOR: 6.5% (3/46)).

Surveillance studies show that NWT strains of A. fumigatus have increased in Europe since 10 years, reaching 4.5% of strains resistant to VOR and POS in 2018.

## 5.4. Unfavourable effects

Overall, drug-related AEs were less frequently reported with POS treatment than with VOR treatment (29.9% vs 40.1% respectively). With regard to specific categories of drug-related AEs, visual and psychiatric disorders were more common with VOR treatment, while hypokalaemia was more common with POS treatment.

<div style=\"page-break-after: always\"></div>

Comparable rates of gastrointestinal disorders and hepatic disorders were reported across the treatment groups. In addition to the higher rates of drug-related visual and psychiatric AEs among VOR-treated subjects, there was also a higher rate of discontinuation of VOR-treated than POS-treated subjects due to drug-related AEs overall.

## 5.5. Uncertainties and limitations about unfavourable effects

Exposure-safety relationships of POS by quartile of exposure were evaluated for all AEs as well as for drug-related AEs. While there was no relationship between exposure and the incidence of reported AEs overall (regardless of investigator-reported relationship), an association was seen between higher exposure (top quartile of exposure) and the incidence of drug-related AEs. This association has not been noted in prior studies of POS IV or tablet in which similar or higher exposures have been achieved. Similarly, with POS oral suspension, no exposure-safety adverse relationship has been noted, although exposures with the oral suspension are generally lower than those achieved with the IV or tablet formulations. A potential contributing factor to the observed association in the current study is that a larger proportion of subjects who were more seriously ill were likely to have been receiving the IV formulation rather than the tablet formulation, and thus would likely have had higher exposures.

## 5.6. Effects Table

Table 21: Effects Table for Noxafil in the first-line treatment of IA

| Effect                                                             | Short description                                     | Unit                                                                     | Treatment            | Control              | Uncertainties / Strength of evidence                                                                                                              | References           |
|--------------------------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------------------------|----------------------|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| Favourable Effects                                                 | Favourable Effects                                    | Favourable Effects                                                       | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                                                                                | Favourable Effects   |
| Clinical improvement and decrease of mortality in subjects with IA | All-cause mortality                                   | %of all-cause mortality at Day 42 (ITT population)                       | POS IV or tablets    | VOR IV or tablets    | POS: 15.3% VOR: 20.6% Difference: -5.3% 95%CI: -11.6, 1.0                                                                                         | Study P069           |
| Clinical improvement and decrease of mortality in subjects with IA | Global clinical response according to independent CAC | %of treatment success at Week 6 (FAS population = probable or proven IA) | POS IV or tablets    | VOR IV or tablets    | POS: 44.8% VOR: 45.6% Difference: -0.6% 95%CI: -11.2, 10.1                                                                                        | Study P069           |
| Decrease of mortality due to IA?                                   | Death attributed to IA by the CAC                     | %of deaths attributed to IA at Day 42 (FAS population)                   | POS IV or tablets    | VOR IV or tablets    | POS: 51.6% VOR: 31.3% Difference: 20.4% 95%CI: -4.1, 42.7 Probable bias due to the high number of indeterminate attribution of death (POS: 35.5%, | Study P069           |
| Unfavourable Effects                                               | Unfavourable Effects                                  | Unfavourable Effects                                                     | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                                                              | Unfavourable Effects |
| Hepatic Safety Events                                              | ASAT increased ALAT increased                         | %                                                                        | POS IV or tablets    | VOR IV or tablets    | POS (3.8%) VOR (3.5%)                                                                                                                             | Study P069           |
| Central Nervous System Event - Visual Safety Events                | Hallucination Vision blurred                          | %                                                                        | POS IV or tablets    | VOR IV or tablets    | POS (1.4%) VOR (4.2%) POS (1.0%) VOR (3.5%)                                                                                                       | Study P069           |

<div style=\"page-break-after: always\"></div>

## 5.7. Benefit-risk assessment and discussion

## 5.7.1. Importance of favourable and unfavourable effects

IA is a severe disease with high level of mortality (over 85% without antifungal therapy). Study P069 has demonstrated that POS is non-inferior to the reference VOR for the first-line treatment of IA in adults, with similar mortality rate (15-20%) and treatment success (45%) at 6 weeks after the beginning of treatment.

The overall adverse event (AE) profile in P069 was reflective of the known AE profile of POS IV and tablet, as described in product labeling, and was consistent with a critically ill study population. Furthermore, the types and incidences of AEs, drug-related AEs, and serious adverse events (SAEs) in the POS treatment group in P069 were similar to those reported in previous clinical studies of POS IV and tablet despite P069 having a longer duration of treatment (average therapy duration of &gt;60 days for the treatment of IA) compared with previous studies of POS IV and tablet (average therapy durations of &lt;30 days in a prophylaxis setting).

## 5.7.2. Balance of benefits and risks

POS and VOR are both azole antifungals effective on the majority of strains of Aspergillus . No relevant efficacy difference between these treatments has been demonstrated. Safety and DDI considerations should be taken into account for the choice of first-line treatment of Invasive Aspergillosis.

Considering the limited available therapeutic options and the high mortality rate of such infection, the benefit-risk balance for this extension of indication of POS in the first-line treatment of Invasive Aspergillosis in adults is considered positive.

## 5.8. Conclusions

The overall B/R of Noxafil is positive.

## 6. Recommendations

## Outcome

Based on the review of the submitted data, this application regarding the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include primary treatment of invasive aspergillosis in adults for Noxafil gastroresistant tablet and concentrate for solution for infusion as result of conclusion of Study P069 (a Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 6.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 16.2 of the RMP was approved with this procedure.

is recommended for approval.

<div style=\"page-break-after: always\"></div>

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.